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G6Pase                       Glucose-6-phosphatase 
GR   Glucocorticoid receptor 
GRE   Glucocorticoid response element 
HPA   Hypothalamic-pituitary-adrenal 
Hsp   Heat shock protein 
IκB   Inhibitory κB 
IL-2/8/10  Interleukins 2/8/10 
kb   Kilobase 
LBD   Ligand binding domain 
LIF                              Leukimia Inhibitory Factor 
LPS                             Lipopolysaccharide 
MMTV (LTR)  Mouse mammary tumour virus (long terminal repeat) 
MOPS   3-(N-Morpholino) propanesulfonic acid 
mRNA   Messenger RNA 
MR   Mineralocorticoid receptor 
NF-κB   Nuclear factor κB 
NLS                            Nuclear Localization Signal 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PEPCK  Phosphoenolpyruvate carboxykinase 
PNMT   Phenyethanolamine-N-methyl-transferase 
POMC   Pro-pionomelanocortin 
PVN                            Paraventricular nucleus of the hypothalamus 
RA                              Retinoic Acid 
RAAS                         Renin-angiotensin-aldosterone system 
RNA   Ribonucleic acid 
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PRA                            Plasma Renin Activity 
PRC                            Plasma Renin Concentration 
RT-PCR  Reverse transcription PCR 
SAT                             Subcutaneous adipose tissue area 
SBP                             Systolic Blood Pressure 
SCCE                          Side chain cleavage enzyme 
SDS   Sodium dodecyl sulfate 
SEM   Standard error of the mean 
SSC   Saline sodium citrate 
STAT   Signal transducer and activator of transcription 
TAT   Tyrosine aminotransferase 
TBE   TRIS boric acid EDTA 
TBP   TATA binding protein 
TCR   T cell receptor 
TEMED  N,N,N’,N’-Tetramethyl-1-,2-diaminomethane 
TG                               Triglycerides 
TNF-α                         Tumour necrosis factor α 
VAT                            Visceral adipose tissue area 
X-gal                           5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside     
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Abstract  
The primary determinants of tissue glucocorticoid action are glucocorticoid receptor 
(GR) density and intracellular levels of ligand, the latter determined both by activity 
of the hypothalamic-pituitary-adrenal (HPA) axis and cellular activity of 11β-
hydroxysteroid dehydrogenase (11β-HSD) enzymes that interconvert active 11-
hydroxy (corticosterone, cortisol) and inactive 11-keto (11-dehydrocorticosterone, 
cortisone) glucocorticoids. Here, the contribution of GR density and ligand levels in 
determining body composition and metabolic phenotype have been investigated in 
mice and in humans. 
 
Genetic evidence in humans implicates variations in the GR gene in the regulation of 
the HPA axis as well as the control of body fat distribution, metabolic parameters 
and blood pressure. Although GR deficient mouse models have been previously 
generated (with homozygous nulls dying at birth), the effects of altered GR density 
upon fat distribution and blood pressure have not been described. This study 
addresses the relationship between GR density and metabolic parameters, including 
body fat distribution, insulin resistance and hypertension. A novel line of mice 
harbouring a null mutation in the GR gene (GR+/-) was generated from an ES cell line 
in which a β-galactosidase-neomycin phosphotransferase (βgeo) reporter cassette 
was fused with GR. The resulting fusion protein lacks part of the DNA binding 
domain and the entire ligand binding domain and is transcriptionally inactive. In 
addition, the β-galactosidase enzyme activity “reports” activity of the GR gene 
promoter. GR-/- mice are present in a normal Mendelian ratio before birth. 
Intriguingly, 1 (of 36/146 expected if null allele not lethal) survived to adulthood 
suggesting this might be a hypomorphic rather than a null allele. Heterozygous 
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(GR+/-) mice showed 40-45% reductions in GR mRNA levels in the hippocampus, 
paraventricular nucleus of the hypothalamus, pituitary gland and adipose tissue, 30% 
in liver, 56% in muscle and 67% in adrenals. X-gal staining of GR+/- brain sections 
showed that GR-βgal is present throughout, mirroring GR mRNA expression.  Adult 
GR+/- mice had larger adrenals, higher evening plasma corticosterone levels and 
greater corticosterone responses following 10 minute restraint suggesting a 
hyperactive HPA axis. Compared to GR+/+ littermates, GR+/- mice had similar body 
weight gain on normal chow or high fat diet, with unaltered fat depot (inguinal, 
epididymal, mesenteric) weights and similar glucose and insulin tolerance. However, 
GR+/ - mice had higher (10%) systolic blood pressure, associated with activation of 
the renin-angiotensin system. Thus GR haploinsufficiency in mice causes increased 
blood pressure and accords with data associating GR polymorphisms with 
hypertension in humans.   
 
The role of altered GC sensitivity was also investigated in a mouse model of HPA 
axis hypoactivity pro-opiomelanocortin null (POMC) mice. POMC-null mice are 
obese due to central melanocortin deficiency. In contrast to most rodent models of 
obesity, POMC-null mice are also glucocorticoid deficient due to ACTH deficiency. 
Previous data have shown that glucocorticoid replacement in POMC-null mice 
exaggerated hyperphagia, obesity and insulin resistance and caused hypertension. 
Here, the contribution of peripheral glucocorticoid sensitivity was investigated. 
POMC-null mice have increased liver and retroperitoneal fat GR mRNA levels but, 
specifically in adipose tissue, decreased levels of mRNA encoding 11β-HSD1, a 
reductase which regenerates active glucocorticoids, thus amplifying their action. 
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Adipose tissue expression of 11β-HSD1 mRNA and other glucocorticoid target 
genes (e.g. lipoprotein lipase) was increased following glucocorticoid replacement in 
POMC-null mice, possibly contributing to increased fat accumulation and 
exacerbated metabolic abnormalities.  
 
Finally, the relationship between intra-adipose glucocorticoid action and obesity in 
humans was explored, specifically comparing intra-abdominal and subcutaneous 
depots. 11β-HSD1 mRNA expression in omental (visceral) fat was positively 
associated with body mass index, visceral adiposity, fat cell size and plasma 
triglyceride levels. In contrast, GR mRNA levels were negatively correlated with 
these parameters. The novel correlation of 11β-HSD1 with omental fat cell size 
independently of obesity suggests that intracellular GC regeneration is a stronger 
predictor of adipocyte hypertrophy than GR levels in the omentum in these 
individuals.  
 
In conclusion, altered tissue GC sensitivity, mediated through altered GR density, 
altered ligand availability or 11β-HSD1-mediated ligand regeneration, can 
differentially result in a variety of phenotypic changes. These may not lead to a 
disease state per se but may explain, in part, an individual’s susceptibility to a 



























1. Glucocorticoids  
 
Glucocorticoids (GCs) are multi-tasking steroid hormones secreted from the adrenal 
glands. Cortisol and corticosterone are the principal active glucocorticoids produced 
by most mammalian species and probably have analogous roles. Cortisol is the major 
active glucocorticoid produced by humans and most mammals, whereas rodents 
synthesize corticosterone. Corticosterone is also a minor glucocorticoid (10-15%) in 
humans. GCs have pleiotropic and profound physiological effects that are essential 
for the maintenance of homeostasis and adaptation under physical and emotional 
stress. They are key regulators of the development and maturation of tissues/organs. 
They exert crucial modulatory effects on intermediate metabolism, immune and 
inflammatory processes and the cardiovascular system. They have central (brain) 
effects on mood and behaviour and food intake. Dysregulation of GC production and 
secretion is involved in the pathogenesis of diseases. Hypersecretion of GCs, as in 
the Cushing’s Syndrome, leads to a plethora of pathological features such as 
redistribution of body fat (visceral obesity), protein catabolism (wasting of skeletal 
muscle), hyperglycaemia, insulin resistance, hypertension, increased serum lipids, 
salt and water retention, osteoporosis, impaired cognitive function, depression and 
reproductive abnormalities (reviewed in Buckingham 2006). In contrast, GC 
insufficiency, as in Addison’s disease, is characterised by weight loss, 
hypoglycaemia, hypotension, weakness/generalised fatigue and mood abnormalities 
(reviewed in Buckingham 2006). However, more subtle alterations in GC action are 
also implicated in the pathogenesis of common diseases, such as the Metabolic 
Syndrome (a cluster of related conditions including visceral obesity, hypertension, 
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insulin resistance, hyper/dyslipidaemia and atheromatous cardiovascular diseases), 
autoimmune disorders, depression and reproductive abnormalities (reviewed in 
Reaven, 2006, Seckl, 2004; De Kloet et al., 1998).   
 
GCs act on target cells via intracellular receptors, which belong to the superfamily of 
ligand-activated nuclear receptors (Manglesdorf et al., 1995).   GCs bind to and 
interact with 2 receptors; the glucocorticoid (GR) and mineralocorticoid (MR) 
receptor. GR has a lower affinity (cortisol/corticosterone kd~5nM) and is 
glucocorticoid selective, whereas MR has a higher affinity (kd~0.5nM) and binds to 
cortisol, corticosterone and the mineralocorticoid, aldosterone (Arriza et al., 1987; 
Rupprecht et al., 1993) with high and roughly equal affinity. Both receptors regulate 
the transcription of a number of target genes when activated (reviewed in Beato et 
al., 1996 and also see sections 1.5.1.5 & 1.5.1.6). 
 
The main focus of this Thesis was to investigate the effects of altered GC sensitivity 
on metabolism and HPA axis function.  Thus, in this chapter (a) the biosynthesis and 
physiological functions of GC (b) the mechanisms that regulate GC secretion, (c) the 
mechanisms of GC action, with main emphasis given to the GR and (d) the 
modulation of  GC sensitivity and downstream physiological consequences are 
discussed.  
 
1.1 Production and secretion 
The zona fasiculata and reticularis of the adrenal cortex are the main sites of 
cortisol/corticosterone production. As with all steroid hormones, the precursor for 
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GC biosynthesis is cholesterol. The first step in the biosynthetic pathway, is the 
cleavage of the cholesterol side chain by the side chain cleavage (SCC) enzyme (also 
known as cytochrome P450, or CYP11A1) to produce pregnenolone (fig. 1.1). Next, 
a series of reactions occur to give rise to cortisol and corticosterone (fig. 1.1).  
Rodents do not produce cortisol due to a lack of the 17α-hydroxylase (CYP17) 
enzyme in the adrenal gland. When GCs are produced, they are immediately released 
into the circulation by diffusion (Orth et al., 1992). GCs release occurs in a pulsatile 
manner and follows a circadian rhythm with maximal levels in the morning and nadir 
levels (3-5 fold lower) early in the sleep phase, in humans. Conversely in rodents, 
peak levels of GC secretion are in the evening (active phase) and nadir levels in the 
morning. Furthermore, GCs are released in response to fasting, physical/emotional 
stress, and the magnitude of the response depends on the intensity and duration of the 
stimulus and the individual’s previous “exposure” to stress (reviewed in McEwen et 
al., 1997).  
 
1.2 Regulation of secretion  
GC secretion is under the tight control of the hypothalamus-pituitary-adrenal (HPA) 
axis (fig.1.2). The hypothalamus integrates a variety of neural and humoral signals, 
processessing the information received and responding by activating the synthesis of 
GCs. A forward drive of the HPA axis stimulates the release of corticotrophin-
releasing hormone (CRH) and arginine vasopressin (AVP) from parvocellular 
neurons of the hypothalamic paraventicular nucleus (PVN) into the hypophyseal 
portal blood vessels (reviewed in McEwen et al., 1997). CRH and AVP are thus 
delivered to the anterior pituitary gland where they bind to the corticotrophin-  
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Figure 1.1 Biosynthesis of glucocorticoids. 
Cortisol/corticosterone are synthesized in the zona fasciculata of the adrenal cortex 
from cholesterol. This schematic view illustrates the principal enzymes (in green) 
involved and the reactions they catalyze. The highlighted substituents on each 
molecular structure indicate the chemical change occurring in each reaction. SCCE; 




























































Figure 1.2 Regulation of glucocorticoid secretion by the HPA axis 
A simplified schematic view of the hypothalamus-pituitary-adrenal (HPA) axis 
showing principal loci involved in glucocorticoid feedback control. A forward drive 
stimulates (black thick arrows) the production and secretion of cortisol/corticosterone 
from the adrenal glands. Glucocorticoid secretion is auto-regulated by negative 
feedback (blunt red arrows) at the level of the pituitary (suppressing POMC 
expression and ACTH release) and the hypothalamus (suppressing CRH expression). 
The negative feedback depends on the levels of GR (red block arrow) in the pituitary, 
hypothalamus and hippocampus and MR (purple block arrow) levels in the 
hippocampus. CRH; corticotrophin releasing hormone, AVP;arginine vasopressin, 
POMC; proopiomelanocortin peptide, ACTH; adrenocorticotrophin, GR; 
















   GR 
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releasing hormone receptor 1 and vasopressin receptor 1, respectively (McEwen et 
al., 1997). This triggers the production of proopiomelanocortin (POMC), the 
precursor for adrenocorticocotrophic hormone (ACTH), which in turn is secreted by 
the corticotrophs into the circulation.  ACTH binds to melanocortin receptor type 2 
and stimulates the synthesis of cortisol/corticosterone from the adrenal cortex 
(McEwen et al., 1997). 
 
 
GC secretion is autoregulated by negative feedback acting principally at the level of 
the pituitary and hypothalamus, by suppressing the release of ACTH and CRH/AVP 
respectively (Keller-Wood and Dallman, 1984). This negative feedback system is 
sensitive to the rise of cortisol levels. There is a fast feedback, by which  ACTH 
suppression occurs within minutes to 2h, and a delayed feedback which happens in 
two phases; an early (2-4h of cortisol elevation) and a late (after 4h of cortisol 
increase) phase (Jones and Gilham, 1988). The feedback system is regulated by both 
MR and GR. MR mainly regulates the basal circadian secretion whereas GR is 
involved in the peak circadian and stressed-induced cortisol secretion (Reul and De 
Kloet, 1985; reviewed in de Kloet, 2004).   
 
GCs also exert rapid effects on the hippocampus, thus inhibiting the HPA axis.  
Paradoxically, the effects of GCs on the hippocampus are primarily excitatory, 
causing a rapid transcription-independent increase in the release of glutamate on 
CA1 neurons and thus inducing excitatory synaptic inputs to these cells (reviewed in 
Tasker et al., 2006). However, the hippocampal regulation of the HPA axis is mainly 
inhibitory. Excitatory hippocampal output is transformed to an inhibitory 
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hypothalamic input by hippocampal projections relaying through γ-aminobutiric acid 
(GABA)ergic inhibitory neurons in the PVN (Tasker et al., 2006). Thus, GCs induce 
a rapid increase in the hippocampal excitatory output to the hypothalamus which in 
turn inhibits hypothalamic neuroendocrine cells (CRH neurons) and results in a rapid 
GC feedback inhibition of the HPA axis (Tasker et al., 2006).  
 
1.3 Physiological functions of glucocorticoids 
1.3.1 Development 
 
Prenatally, GCs are essential for the structural development of organs and for the 
maturation of tissues. GCs regulate the growth and maturation of tissues especially at 
critical phases where proliferation and terminal differentiation occur. Adequate GC 
exposure in utero is essential for lung maturation (reviewed in Brown and Seckl, 
2005).  Clinically, in situations of premature birth, GCs are administered to the 
mother in late gestation to accelerate the maturation of the prenatal lungs and 
ameliorate respiratory distress (Halliday, 2004). GR is essential for foetal lung 
maturation as evidenced by GR hypomorphic (GRhypo/hypo) mice which die at birth 
from atelectasis of the lungs and cannot be rescued by GC treatment (Cole et al., 
1995; details on this model in section 1.6.1). Moreover, mice with low GC exposure 
in utero (CRH-/-) die at birth from respiratory distress but can be rescued by 
glucocorticoid replacement (Muglia et al., 1995). GCs affect a number of processes 
involved in lung maturation. They up-regulate respiratory epithelial sodium channels 
and genes involved in lung expansion (ie surfactant proteins, fatty acid synthase). 
They also reduce lung cellularity leaving larger and fewer alveoli, by reducing type 
II alveolar cell proliferation, promoting their terminal differentiation, increasing 
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apoptosis and reducing angiogenesis (reviewed in Brown and Seckl, 2005). GCs play 
a key role in triggering the differentiation of neural crest epithelial cells into 
chromaffin cells. The proposed mechanisms were that they do this, by (a) 
suppressing neuronal markers in the sympathoadrenal progenitors, shifting them into 
a chromaffin cell phenotype and (b) inducing the adrenaline-synthesizing enzyme, 
phenylethanolamine-N-methyl transferase (PNMT) in a subpopulation of chromaffin 
cells (Unsicker et al., 1978; Anderson, 1993). However, analyses of chromaffin cell 
development in GRhypo/hypo and GR-deficient mice (GRnull/null, details in section 1.6.1) 
mice showed that loss of GR-mediated signalling does not reduce or deplete adrenal 
chromaffin cell numbers (Finotto et al., 1999). On the other hand, PMNT 
immunoreactivity was undetectable in E18.5 GRnull/null or GRhypo/hypo adrenals (while 
in wild type mice PNMT immunoreactivity is clearly detectable at E15.5), and 




During fasting and exercise, when glucose and insulin levels are low, GCs are 
released into the circulation to antagonize the anabolic effects of insulin and promote 
hepatic glucose production. In contrast, after food intake, GCs induce energy storage 
in the form of glycogen by activating glycogen synthase (Orth et al., 1992).   In 
skeletal muscle, GCs modulate both protein and glucose metabolism. They suppress 
protein synthesis and promote protein degradation and amino acid export and inhibit 
glucose uptake and glycogen synthesis (reviewed in Vegiopoulos and Herzig, 2007). 
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 The central role of GCs to maintain glucose levels comes from evidence from 
Addison’s disease (GC deficient) patients that have low glucose levels while 
Cushing’s (GC excess) patients exhibit glucose intolerance  (reviewed in Andrews 
and Walker, 1999). Moreover, CRH knock out mice, that lack GCs, fail to counteract 
hypoglycaemia (Jacobson et al., 2006). The potential mechanisms involved in the 
maintenance of glucose by GCs can be summarized as follows: First, GCs can 
promote gluconeogenesis by inducing phosphoenolpyruvate (PEPCK) (reviewed in 
Hanson and Reshef, 1997) and glucose-6-phosphatase expression (G6Pase) (Garland, 
1986). The GC effects on hepatic glucose metabolism are mediated by the GR, since 
GR liver-specific ablation results in hypoglycaemia during fasting accompanied by 
down-regulation of gluconeogenic enzymes (Opherk et al., 2004; details in section 
1.6.1).  Second, GCs can decrease glucose transport by causing translocation of  
glucose transporter (GLUT4) from the cell membrane to an internal location and thus 
inhibit glucose transport in peripheral tissues (Horner et al., 1987). Third, GCs can 
prevent insulin production and secretion , as evident from mice over-expressing GR 
in pancreatic β-cells (Delaunay et al., 1997, details in section 1.6.1). However, 
whether this function occurs under normal GR levels with excess GCs still remains 
to be addressed. Fourth, GCs can induce the synthesis and promote liver and portal 
circulation accumulation of the sphingolipid, ceramide (Zierath, 2007; Holland et al., 
2007), which has been suggested to antagonise insulin stimulation of glucose uptake 
and glycogen synthesis by inhibiting phosphorylation and activation of Akt/protein 
kinase B signalling thus contributing to the development of insulin resistance 
(Summers et al., 1998; Hajduch at al., 2001; Powell et al., 2003; Stratford et al., 
2004). Recent data from Des1 (dihydroceramide desaturase; converts inactive 
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dihydroceramide to active ceramide) knock out mice showed that they were 
unresponsive to GC-induced insulin resistance (Holland et al., 2007). This is an 
interesting study linking GC-induced insulin resistance and ceramide, but will need 
further investigation, for example testing the ceramide synthesis/sectretion in tissue-
specific (liver, pancreas, adipose) GR transgenic models. In adipose tissue, GCs 
affect lipid metabolism. In peripheral (eg subcutaneous, gluteal and thigh) fat depots, 
they increase lipolysis by up-regulating hormone sensitive lipase (Slavin et al., 1994; 
and reviewed in Leung and Munk, 1975; Mattsson and Olsson, 2007), whereas in 
central (abdominal, visceral) fat depots they induce pre-adipocyte differentiation 
(Gaillard et al., 1991), lipogenic activity and hypertrophy (Samra et al., 1998; 
Masuzaki et al., 2001). Finally, in brown adipose tissue glucocorticoids reduce 
thermogenesis by down-regulating uncoupling protein 1 (UCP-1) (Soumano et al., 
2000). 
 
1.3.3 Immune system  
 
GCs are one of the most frequently prescribed drugs and are used to treat a range of 
immune/inflammatory disorders, mainly allergic and autoimmune disorders such as 
asthma, rheumatoid arthritis and also acute inflammation because of their potent 
immunosuppressive action. GCs modulate genes involved in the priming of the 
innate immune response, suppress T lymphocytes (or T cells) (of the Th (helper)1 
lineage) while they promote humoral (Th2 cells) immunity and tolerance (reviewed 
in Franchimont et al., 2002). Firstly, the role of GCs in innate immunity, has been 
demonstrated in adrenalectomised animals, which were more sensitive to the lethal 
effects of  LPS administration (Abernathy et al., 1957; Sambhi et al., 1964) and LPS-
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mediated poinflammatory (IL-1, TNF-α) cytokine secretion by macrophages (Bertini 
et al., 1988).  This highlighted the macrophage as a key cell type for GC-mediated 
increased survival after LPS challenge. Consistent with the increased mortality of 
adrenalectomized animals to LPS administration, macrophage-specific GR knock out 
mice (MGRKO) mice die when challenged with LPS (Bhattacharyya et al, 2007). 
Moreover, GR-deficient macrophages treated with dexamethasone (DEX; synthetic 
GC) fail to inhibit LPS-mediated induction of inflammatory genes (Bhattacharyya et 
al, 2007) suggesting an essential role of GR in mediating immunosuppression in 
macrophages. Secondly, with respect to adaptive immunity, GCs promote a Th2 
response by increasing IL-10 secretion by macrophages or Th2 cells (Ramirez et al., 
1996). Additionally, GCs may induce the development of regulatory T cells (Treg: 
produce high IL-10 levels), that in turn suppress immune responses, prevent self-
reactivity and promote immune tolerance (Barrat et al., 2002).   They can also block 
dendritic cell maturation, thus reducing the ability of the latter to present antigens to 
T lymphocytes and induce an immune response (Piemonti et al., 1999). Moreover, 
GCs can promote T cell survival or apoptosis depending on the type of T cell, the 
degree of activation and the timing of GC exposure (Ashwell et al., 2000).  It has 
been hypothesized that endogenous GCs are involved in thymocyte development and 
positive/negative selection (Godfrey et al., 2000). However, GR knockout mice 
display normal thymocyte development and selection (Purton et al., 2000) and this 
remains a controversial field.   The mechanisms by which GCs exert their anti-
inflammatory effects are beyond the scope of this thesis. Briefly, many of their 
effects are mediated though interference with the key inflammatory transcription 
factor, NF-kB (McEwen et al., 1997).   
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1.3.4 Cardiovascular system 
 
 The direct effects of GCs on the cardiovascular system are difficult to dissect since 
any changes in GC plasma levels have multiple central and systemic consequences. 
GC excess raises blood pressure (Whitworth et al., 1995; Ferrari, 2003; Baid and 
Nieman, 2004). They may do this either by altering tissue sensitivity to 
catecholamines or by exerting aldosterone-like actions modulating water and 
electrolyte balance through illicit activation of MR in kidney (Brilla and Weber, 
1992; Young et al., 1994; Young et al., 1995). Additionally, cortisol increases 
plasma erythropoietin levels, which in turn has direct vasoconstrictor effects, thus 
contributing to cortisol-induced hypertension (Kelly et al., 2000). GCs also increase 
the number of β-adrenergic receptors in vascular smooth muscle cells thus increasing 
vascular tone (reviewed in Magiakou et al., 2006). They reduce atrial natriuretic 
peptide (vasodilator), inhibit membrane transport of L-arginine and nitric oxide 
synthase (eNOS) synthesis which impairs peripheral vasodilation hence leading to 
blood pressure elevation (reviewed in Magiakou et al., 2006).  Observations in 
rodents suggest that GCs contribute to the maintenance of normal cardiac contraction 
by modulating membrane calcium transport and potassium channel activity 
(Penefsky and Kahn, 1971; Wang et al., 1999). Furthermore, in healthy volunteers 
short-term glucocorticoid treatment decreased resting heart rate suggesting that GCs 
may be involved in regulation of cardiac electrical activity (Brotman et al., 2005). 
Recently, selective overexpression of GR in cardiomyocytes resulted in enhanced 
cell contractility and increased heart rate, atrio-ventricular block and ion-channel 
remodelling, suggesting a direct role of GR in cardiac function (Sainte-Marie et al., 
 30
2007, also see section 1.6.1). However, the direct effects of GCs on the heart require 




Although GC production and secretion is strictly regulated by the HPA axis, 
impairment of the latter leads to abnormal GC levels that induce structural 
remodelling in the brain (reviewed in McEwen, 2005). GR is widely expressed in the 
brain (hypothalamus, thalamus, cerebellum, amygdala, cortex) with the highest 
expression observed in the hippocampus (Herman et al., 1989). MR is also expressed 
in the hippocampus where it acts as a glucocorticoid receptor because the tissue does 
not contain 11β-hydroxysteroid dehydrogenase type 2 (Holmes et al., 2003; for 
details refer to section 1.4), and therefore little cortisol is converted into cortisone 
(Arriza et al., 1988; De Kloet et al., 1998). The hippocampus is a key locus for 
learning, memory, reasoning, mood and behaviour (reviewed in McEwen, 1999). The 
hippocampus is also sensitive to GC alterations, and susceptible to stress (McEwen, 
1999). Chronic overexposure to GCs (as in Cushing’s disease) causes long-lasting 
deficits in memory, attention and depressive symptoms. Conversely, low GC levels 
are associated with chronic fatigue, antisocial personality disorder (aggressiveness), 
with the amygdala being a key target (reviewed in Kim and Haller, 2007).   
 
 
1.3.6 Stress response 
 
Physical or emotional stress leads to HPA axis activation and increased GC 
secretion. In the short term, the stress-protective effects of GCs promote survival by 
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ensuring energy availability and limiting potentially threatening processes such as 
inflammation. Following a stress response, homeostasis is restored by the negative 
feedback system of GCs through the HPA axis. This is an essential mechanism since 
long term exposure to excessive circulating GCs leads to pathological consequences 
(ie diabetes, hypertension, osteoporosis etc).   
 
1.4 Regulation of glucocorticoid action  
 
The primary determinants of GC action are the GR density and intracellular levels of 
ligand, the latter determined both by activity of the HPA axis (as described in section 
1.2) and cellular activity of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes 
(reviewed in Seckl et al., 2004). The GR-mediated GC action is extensively 
described in the following section (1.5). Tissue-specific GC availability is regulated 
by the intracellular enzymes, 11β-HSDs (fig. 1.3). 11β-HSD1 is predominantly a 
reductase in intact cells, regenerating cortisol/corticosterone (active GCs) from 
cortisone/11-dehydrocorticosterone (inactive GCs) (Low et al., 1994; Kotelevtsev et 
al., 1997; Jamieson et al., 2000; Hundertmark, 1995). It is highly expressed in liver, 
adipose tissue, lung and central nervous system, classical GR target tissues, where it 
amplifies local GC action (Cole, 1995; Krozowski et al., 1995a, b, c).  Conversely, 
11β-HSD2 limits cortisol/corticosterone availability and action in placenta and 
mineralocorticoid-target tissues such as kidney, colon and salivary glands by 
converting active to inactive GCs (reviewed in Seckl and Walker, 2001). Following 
interconversion of cortisol and cortisone, both steroids undergo A-ring reduction by 
5α- and 5β-reductases and the resulting dihydro-metabolites are then reduced further 












Figure1.3Interconversion of corticosterone/cortisol to 11β-hydrocorticosterone / 
cortisone  by 11β-hydroxysteroind dehydrogenases (11β-HSDs). 
The active 11-hydroxy glucocorticoids are converted to inactive 11-keto 
glucocorticoids by the high affinity 11β-HSD2 (nicotinamide adenine dinucleotide –
dependent dehydrogenase) enzyme. 11β-HSD2 is mainly expressed in 
mineralcorticoid target tissues like kidney, colon and salivary glands and also in the 
placenta.  The regeneration of active glucocorticoids is catalysed by the lower affinity 
11β-HSD1. In tissue homogenates 11β-HSD1 is a NADP(H)-dependent bidirectional 
enzyme while in intact cells and tissues it acts as a 11-ketoreductase. 11β-HSD1 is 
mainly expressed in tissues with high sensitivity to glucocorticoids (liver, adipose 
tissue, lung and brain). The catalytic moiety of 11β-HSD2 faces the cytoplasm while 
11β-HSD1 is directed into the endoplasmic reticulum (ER) lumen which is important 
for cofactor availability and bidirectionality of the enzyme (reviewed in Odermatt et 





























tetrahydrocortisol (THF), 5α-tetrahydrocortisol (allo-THF) and 5β-
tetrahydrocortisone (THE) (Andersson et al., 1991; Normington and Russell, 1992 
and reviewed in Hammer and Stewart, 2006). The activity of 11β-HSD in the body is 
classically reflected by the ratio of total urinary cortisol and cortisone metabolites: 
[THF + allo-THF]/THE (Hammer and Stewart, 2006), although this is a rather rough 
measure of net action of both isoenzyes in all tissues as well as A-ring reductases. 
 
Furhermore, corticosteroid binding globulin (CBG) modulates the availability of 
GCs (Dunn et al., 1981). In the circulation, approximately 90% of active GCs are 
bound to CBG, with the remainder either bound to albumin or found in a “free” form 
(Dunn et al., 1981). While CBG might act as a “sink” it has been suggested that GCs 
can only enter the cells by dissociating from CBG (Pardridge, 1987). Evidence to 
support the latter hypothesis comes from observations that receptors for CBG are 
present on target cell membranes and that serine protease- mediated cleavage of 
CBG results in the release of bound GC (Singer et al, 1988; Hammond, 1988). CBG 
knockout mice revealed a more active role of the protein than previously thought. 
Apart form a cargo transporter, CBG is important for bioavailability, local delivery, 
and/or cellular signal transduction of GCs (Petersen et al., 2006).  
 
1.5 The Glucocorticoid Receptor  
 
GR was the first mammalian transcription factor isolated and studied in great detail 
(Miesfeld et al., 1984) and it is highly conserved between species 
(http//www.NURSA.org). In humans, the gene encoding GR is located on 
chromosome 5 (Gehring et al., 1985) and comprises of 9 exons, spread over ~124kb 
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DNA.  GR, as for all nuclear receptors, has a three domain structure (fig. 1.4). The 
N-terminal domain consists of sequences required for target-gene activation (Giguere 
et al., 1986), the DNA binding domain (DBD), encodes 2 highly conserved Zn 
fingers absolutely essential for DNA binding and which are also required for 
dimerization of the receptor (Tsai et al., 1988), nuclear translocation (Picard and 
Yamamoto, 1987) and transactivation (Hollenberg et al., 1987; Lefstin et al., 1994).  
 
The third domain of GR is the C-terminal or ligand binding domain (LBD), which is 
responsible for hormonal binding (Giguere et al., 1986; Warriar et al., 1994) and 
nuclear translocation (Picard and Yamamoto, 1987). Additionally, the LBD is 
involved in heat shock protein binding (Dalman et al., 1991; Pratt, 1993), 
transactivation (Hollenberg and Evans, 1988; Webster et al., 1988), dimerization 
(Dahlman-Wright et al., 1992) and, in the absence of the hormone, silencing of the 
receptor (Godowski et al., 1987; Danielson, 1986).   
 
1.5.1 Mechanisms of GR action  
1.5.1.1 GR is activated when it binds to glucocorticoids 
 
In the absence of its ligand, GR is present in a multiprotein complex of several heat 
shock proteins (hsp) including hsp90, hsp70, hsp56 and hsp40, immunophilins 
(Cyp40, FKBP52) and molecular chaperones (eg hsp90) (Pratt, 1993; Hutchison et 
al., 1994a,b; Pratt, 1998) that  retains the unligated GR in the cytoplasm in an 
inactive (partly unfolded) state (Hutchison et al., 1993). The unliganded, hsp-
complexed GRs exist in a dynamic equilibrium between nucleus and cytoplasm and 
shuttle continuously across the nuclear membrane (Hache et al., 1999). 
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Figure 1.4 Human GR gene and protein structures.  
(A) Schematic representation of the hGR gene. (B) Alternative splicing results in two 
mRNA isoforms GRα and GRβ. Alternative translation starts, result in GR proteins 
differing at N-terminus; GR-A and GR-B protein isoforms. (C) Structure of the GRα 
protein, indicating the different domains and functions mapped to specific regions 
(amino acid numbers) of the protein. NTD; N-terminal domain (exons 1-2), DBD; 
DNA-binding domain (exons 3-4) with the 2 zing fingers (insert), LBD; ligand 
binding domain (exons 5-9); NL; nuclear localization signals; hsps; heat shock 




















































Recent evidence suggest that hsp90 appears to be an essential component of the 
multisubunit chaperone machine that functions in the nucleus to maintain the 
mobility of GR, therefore assisting in the assembly and disassembly of the 
macromolecular complexes that are recruited to GR-responsive promoters (Elbi et 
al., 2004). Additionally, hsp90 has been shown to be essential for steroid binding to 
GR (Pratt and Toft, 1997), and thus changes in hsp90 binding affinity for GR, and in 
hsp90 levels can alter the EC50 value (concentration of agonist for half maximal 
induction of gene expression) and the partial activity of the agonist (Kaul et al., 
2002). In the absence of ligand, GR is generally accepted to be located in the 
cytoplasm (Lukola et al., 1985; Cidlowski et al., 1990; Akner et al., 1994), although 
there are some contradictory reports that suggest a bidirectional shuttling between the 
cytoplasm and the nucleus (Madan and DeFranco, 1993; Pratt, 1993). For unliganded 
wild type (WT) receptors expressed at physiological levels, this equilibrium is 
normally expected to strongly favor cytoplasmic localization of the receptor (Hache 
et al., 1999), while overexpression of GR in some cells showed partial transfer of GR 
to the nucleus in the absence of ligand (Sanchez et al., 1990; Martins et al., 1991).  
 
Upon binding of the GC to the GR (GC/GR), conformational changes of the latter 
take place that lead to a) GC/GR dissociation from the hsp complex which is now 
unable to reassemble b) GR protein hyperphosphorylation and c) the nuclear 
localization sites (NLS) in the GR are unmasked and the GC/GR translocates into the 
nucleus, where it binds as a homodimer to glucocorticoid response elements (GREs) 
on target genes and regulates their transcription (reviewed in Bamberger et al., 1996).   
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1.5.1.2 Hormone binding, GR conformational change and dissociation 
from hsps  
 
The crystal structure of the LBD revealed that it contains 12 α-helices that are folded 
to generate a hydrophobic pocket for the ligand (Bledsoe et al., 2002). When the 
hormone binds the receptor, a conformational change of helix 12 occur (folds back 
trapping the ligand in its binding pocket) and consequently the pocket “shuts” 
(Bledsoe et al., 2002). Hormone binding affinity determines the potency of 
transcriptional activity. Point mutations in the LBD of GR lead to reduced or 
increased glucocorticoid binding affinity (Hurley et al., 1991; Warriar et al., 1994; 
Lind et al., 2000) or GC/GR complex stability (Ashraf and Thompson, 1993). These 
alterations are associated with clinical syndromes of GC hypo- or hyper-sensitivity 
(section 1.6). 
 
1.5.1.3 Phosphorylation of GR 
 
In the absence of the hormone, GR is partially phosphorylated (in the NTD), and 
after binding to an agonist and dissociation from the hsp complex becomes highly 
phosphorylated (Orti et al., 1992). GR phosphorylation does not seem to be essential 
for nuclear translocation since mouse GR that lacks all phosphorylation sites is able 
to translocate to the nucleus after hormone binding (Webster et al., 1997). 
Furthermore, it is still debatable if the GR phosphorylation state alters the receptor’s 
transcriptional activity since mutations of single, multiple or all phosporylation sites 
of mouse or human GR resulted in very subtle reductions of its transcriptional 
activity at least in transfected cells (Mason and Housley, 1993; Almlof et al., 1995).  
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1.5.1.4 Nuclear translocation, dimerization and GRE binding to target 
genes 
 
Following hormone binding, nuclear translocation occurs after a nuclear localization 
signal (NLS) is unmasked (Picard and Yamamoto, 1987; reviewed in Akner et al., 
1995). Two NLSs have been identified in the glucocorticoid receptor, the first (NL1) 
located in the DBD (exon 4) and the second (NL2) in the LBD, but its exact location 
is unknown (Picard and Yamamoto, 1987). In most in vitro experiments following 
agonist treatment, GR nuclear translocation and saturation (complete translocation) 
occurs within 10-20 min and 30-60min respectively (Ucker and Yamamoto, 1984; 
Picard and Yamamoto, 1987, Htun et al., 1996 and reviewed in Stahn et al., 2007). In 
the nucleus the activated GR interacts with the DNA/chromatin and subsequently 
with GREs on target genes. The “classical” model of this interaction is thought to be 
dependent on the GR DBD, where a GRE (consists of a pair of DNA half sites) binds 
GR as a homodimer (Luisi et al., 1991). Briefly, a GR monomer binds to the higher 
affinity half-site, followed by binding of the second monomer and its stabilization by 
protein-protein interaction within the second zinc finger of the DBD (Wrange et al., 
1989; Dahlman-Wright et al., 1991; Dahlman-Wright et al., 1993). However, there 
are a subset of GREs that do not require dimerization at least in a conventional 




Transactivation by GR is mediated via “positive” GREs and is thought to be 
responsible for many of the effects of GCs. Transactivation depends on the τ1 and τ2 
domains in GR. The former is located in the N-terminal region and is hormone-
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independent (Hollenberg and Evans, 1988), while the latter locates to the LBD (fig. 
1. 4) and requires hormone binding (Giguere et al., 1988). When GR binds to GREs, 
the transcription process is initiated by a complex mechanism. GR itself is capable of 
recruiting and stabilising the transcriptional pre-initiation complex (Freedman, 
1999), and also make contacts with numerous components of the transcriptional 
machinery in vitro (Robyr et al., 2000). Studies using the mouse mammary tumour 
virus long terminal repeat (MMTV LTR), which contains several GREs, showed  
that transcriptional activation by GR requires DNA binding, disruption of local 
chromatin structure and assembly of the initiation complex at a TATA box (Hebbar 
and Archer, 2003). The interaction between GR and  MMTV LTR  is  dynamic;   
after ligand activation, GR first binds to the chromatin, recruits remodelling activity 
and is then lost from the template (Hager et al., 2000).  
 
The GR transcriptional activity depends on co-activators that mediate the recruitment 
of the basic (eg RNA polymerase II, TATA-box binding protein) transcriptional 
machinery (Robyr et al., 2000) or chromatin remodelling (eg histone acetylation; 
Yao et al., 1996). Apart from the recruitment of co-activators of the basic 
transcriptional machinery, the transcriptional activity of GR is enhanced by other co-
activators, for example of the p160 family (Kurihara et al., 2000). The p160 family 
consists of steroid receptor activator SRC-1, SRC-2 and SRC-3 (Onate et al., 1995; 
Anzick et al., 1997; Hong et al., 1996), which could act as a docking platform for the 
recruitment of other associated co-regulators such as CBP (cAMP response element 
binding protein) or p300 and thus enhance GR-mediated gene expression (Wu et al., 
2007). P160 knock out experiments (using siRNA) showed that the effect of p160 in 
GR transactivation is promoter and cell type specific (Trousson et al., 2007). For 
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example, inhibition of SRC-1 expression induced a 40% and 50% inhibition in 
GRE2-TATA promoter activity in astrocytes and Schwann cells respectively, 
whereas SRC-2 or SRC-3 inhibition affected only one or the other cell type 
(Trousson et al., 2007). Regarding the MMTV promoter, SRC knock down gave 
similar results in both cell types, with siSRC-1 and siSRC-2 inhibiting (50%-60%) 
DEX activation while siSRC-3 did not affect GR signalling (Trousson et al., 2007). 
1.5.1.6 Transrepression 
 
The transcription of genes can be inhibited by GCs through direct interaction 
between the GR and negative GREs, such as in the pro-opiomelanocortin, α-
fetoprotein and prolactin gene (Sakai et al., 1988). However, more recent studies 
suggest that in the case of POMC and prolactin, repression occurs by tethering, in 
which positive transcriptional regulators bind DNA and are then targeted by GR in a 
process termed “transrepression” (Chandran et al., 1999). Transrepression refers to 
molecular mechanisms in which monomers of the GC/GR complex directly or 
indirectly interact with transcription factors, for example those that regulate the 
expression of pro-inflammatory genes (activator protein 1; AP1 and nuclear factor-
κB; NF-κB) (reviewed in Newton and Holden, 2007). Negative regulation by the GR 
receptor complexes results in reduced transcriptional activities of target genes and 
thus the inhibition of  inflammatory mediators such as  cytokines (eg IL1, IL2, TNF-
α, IFN-γ) and prostaglandin synthesis. Briefly, the following mechanisms are thought 
to mediate transrepression: (1) inhibition of a transcription factor binding to specific 
DNA sequences through direct protein–protein interaction (2) increased IκB 
synthesis (an inhibitor of NF-κB), by the GRE and the GC/GR complex interaction 
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and (3) competition for nuclear coactivators between the GC/GR complex and other 
transcription factors (reviewed in Stahn et al., 2007). 
 
1.5.1.7 Trans-repression by protein-protein Interactions 
 
A popular view is that transrepression by GR is through protein-protein interactions 
between monomers of activated GR and “pro-inflammatory” transcription factors, 
particularly NF-kB and AP-1. The “dissociation” of DNA-binding versus protein-
protein interactions have been studied in transgenic mice carrying a mutation in the 
D-loop of the second Zn finger (dimerization interface) in the DBD of GR (GRdim/dim 
mice; details in section 1.6.1 & Table 1.1) (Reichardt et al., 1998). The GR 
dimerization and DNA-binding to target genes was partially impaired in this model 
(Adam et al., 2003). Although exhibiting less than total impairment of dimerization, 
GRdim/dim mice showed a lack of responsiveness of TAT under GC exposure and thus 
impaired transactivation, while the protein-protein-dependent suppression of AP-1 
activity was unaffected (Reichardt et al., 1998). Interestingly, this model showed that 
HPA axis feedback depends on both DNA-binding and protein-protein interactions 
since CRH expression was unaffected (thus its suppression does not require DNA-
binding) whereas POMC expression was increased (requires GR DNA-binding 
activity) (Reichardt et al., 1998). This mechanism of transrepression apparently does 
not require DNA-binding by GR (Reichardt et al., 1998). The main line of evidence 
is from studies in transfected cells and from the GRdim/dim mice. However, caution 
should be exerted when interpreting these data. Firstly, many of these initial 
experiments were in transfected cells where GR was over-expressed in cell types that 
are not directly relevant to the inflammatory response (eg HEK293). Secondly, the 
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interpretation of the GRdim/dim phenotype has been called into question (Adams et al., 
2003) by experiments showing that activation of the PMNT gene is dependent upon 
non-classical GREs (not the conventional inverted repeat arrangement) and thirdly, 
by recent data, on macrophage-specific GR knockout mice (MGRKO), 
demonstrating the importance of p38-GR interaction for mediating GC 
immunosuppression, thus providing an alternative mechanism, based on gene 
induction for suppression of NF-kB (Bhattacharyya et al., 2007).  
1.5.2 Regulation of GR action 
1.5.2.1 GR splicing variants  
 
Cloning of the human GR gene revealed two splicing isoforms, designated GRα and 
GRβ (Hollenberg et al., 1985), with the first considered as the classical GR (fig. 1.4). 
The GRα protein consists of 777 amino acids and is the primary mediator of GC 
action (Hollenberg et al., 1985). GRβ is generated by alternative splicing of exon 9 
(Hollenberg et al., 1985). The GRα and GRβ proteins are identical  for  the first 727 
amino acids (fig. 1.4). They differ only at the C-terminal domain, where GRβ has a 
unique 15 amino acid sequence replacing the last 50 amino acids of GRα 
(Hollenberg et al., 1985; Encio and Detera-Wadleigh, 1991). GRβ cannot bind ligand 
and in several promoter/transactivation systems it has been shown that is 
transcriptionally inactive (Oakley et al., 1999; Yudt and Cidloowski et al., 2001). 
Another difference between GRα and GRβ isoforms is that the latter is located in the 
nucleus in the absence of the hormone (Oakly et al., 1999; Yudt and Cidlowski et al., 
2001). However, although GRβ mRNA is widely expressed in human tissues, levels 
are less than for GRα, and it has not been identified in mice (Bamberger et al., 1995; 
de Castro et al., 1996; Oakley et al., 1996; Oakley et al., 1997). There is controversy 
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regarding the functional significance of GRβ. It has been proposed that GRβ exerts a 
dominant-negative effect on GRα activity (Bamberger et al., 1995) by forming 
GRα/GRβ heterodimers (Bamberger et al., 1995; Oakley et al., 1996). Furthermore, 
in human neutrophils, which are less sensitive to GCs compared to T cells, GRβ 
expression is higher than that of GRα, and treatment with IL-8 increased only the 
expression of the former (Strickland et al., 2001). Transfection of GRβ into mouse 
neutrophils (do not express GRβ) resulted in reduction in cell death when cells were 
exposed to dexamethasone (Strickland et al., 2001). Thus, high expression of GRβ 
may be a potential mechanism by which neutrophils could escape GC-induced cell 
death and further IL-8-mediated GRβ induction may contribute to enhanced survival 
in the presence of GCs during inflammation (Stickland et al., 2001). 
 
Finally, a third spicing variant, GRγ, has been described (Rivers et al., 1999). This 
variant results from an additional codon between exons 3 and 4, coding for arginine. 
GRγ is widely expressed in different tissues but its function is still unknown (Rivers 
et al., 1999). 
 
1.5.2.2 GR translational variants 
 
Variants of GR are also generated through use of alternative translation starts (fig. 
1.4). GR-B lacks the 27 amino acids in the N-terminal domain compared to GR-A 
(major and longer protein product), due to translation starting from a second in frame 
ATG, 71bp downstream of the first ATG (Yudt and Cidlowski, 2001). Distribution 
of the GR-B in various tissues has not been investigated and its physiological role is 
still questionable. However, GR-B was shown to be an efficient GRE transactivator 
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and to have equal potency to GR-A in a transrepression assay with NF-kB (Yudt and 
Cidlowski, 2001). 
 
1.5.3 Regulation of GR levels 
 
GR is widely expressed (Ballard et al., 1974), but the expression levels vary in a 
tissue-specific manner with the greatest mRNA levels seen in the lung (Funder, 
1992) and thymus (Miller et al., 1990). In rat tissues, the GR mRNA expression 
levels are highest in lung (100%), with lower levels as follows: spleen (70%)>brain 
(55%)>liver (50%)>kidney (43%)>heart (35%)>adrenal (13%)>testis (8%) 
(Kalinyak et al., 1987).  Moreover, GR levels vary within a tissue, with the most well 
studied being the hippocampal subfields (Herman and Spencer, 1998). In the 
following sections (1.5.3.1 and 1.5.3.2) the regulation of GR levels by GCs and 
perinatal “programming” are discussed.   
 
1.5.3.1 Down-regulation of GR by glucocorticoids 
 
GCs seem to be the most potent regulators of GR levels. GCs down-regulate GR 
expression levels in the majority of cell lines and in human and animal tissues and 
cells (Burnstein et al., 1991). The physiological role of this negative regulation may 
be to protect the tissues from excessive GC levels (Burnstein et al., 1991; Silva et al., 
1994 and references therein). The proposed autoregulatory mechanisms include a) 
inhibition of GR mRNA by interfering with an AP-1 and/or AP-2 mediated 
transcriptional activation of the GR gene (Vig et al., 1994; Nobukuni et al., 1995; 
Freeman et al., 2005), b) reduction of GR mRNA stability and translation (Burnstein 
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et al., 1990; Burnstein et al., 1994) and c) reduction of the half-life of the GR protein 
(McIntyre and Samuels, 1985; Wallace and Cidlowski, 2001). Of these, the latter is 
still debatable since other groups showed no apparent effect (Rosewicz et al., 1988; 
Hoeck et al., 1989). 
 
The time of GC exposure seems to be an important parameter in the regulation of GR 
levels by its ligand. For example, in rat hepatoma cells treated with DEX, it has been 
observed that there is a small increase in the GR mRNA levels after 6h exposure, 
followed by a 50-90% decrease after 24h and a restoration of GR levels to basal after 
72h (Okret et al., 1986). However, the initial increase in GR levels after DEX-
treatment has not been confirmed in rat livers in vivo (Dong et al., 1988). Moreover, 
in a variety of rat tissues GCs caused a decrease in GR mRNA levels up to 72h, 
reaching a plateau thereafter (Kalinyak et al., 1987). 
 
While in most cells and tissues GCs down-regulate GR levels, in human T-
lymphoma and myeloma cell lines (Eisen et al., 1988; Denton et al., 1993; Gomi et 
al., 1990) and a mouse thymoma cell line (Gruol et al., 1989), as well as double 
positive thymocytes (Cole et al., 2001), they up-regulate GR expression. Since T 
cells are sensitive to GC-induced apoptosis, this up-regulating effect on GR levels 
might be a cell/tissue-specific response regulating T cell homeostasis (Pedersen et 
al., 2004).  
 
1.5.3.2 Perinatal programming of GR levels 
 
 46
Events that occur around the time of birth, pre-natally or post-natally, can 
permanently “set” or “programme” GR levels in a tissue-specific manner throughout 
the lifespan (reviewed in Seckl and Holmes 2006). An adverse maternal environment 
(either GC overexposure or poor nutritional status) leads to low birth weight 
offspring and  has been associated with the development of a range of pathologies 
later in life (Seckl and Holmes, 2006). This phenomenon is widely known as the 
foetal origins of disease. There is strong evidence that prenatal overexposure to GCs 
permanently “programmes” GR levels. When pregnant rats are exposed to DEX in 
the third week of gestation, their offspring have reduced birth weights and develop 
hyperglycaemia as adults. Hepatic GR and PEPCK levels (Nyrienda et al., 1998), as 
well as adipose tissue GR levels (Cleasby et al., 2003) are permanently elevated, 
whereas hippocampal GR levels are decreased (Holmes et al., 1997, Levitt et al., 
1996) indicating a tissue-specific regulation of GR levels. Events in the immediate 
post-natal period can also programme GR levels. Removal of pups for a short period, 
daily, for 7d, alters maternal care and permanently increases GR levels in the 
hippocampus resulting in a more efficient negative feedback of the HPA axis 
following stress (Stanton et al., 1988; Meaney et al., 1988). The mechanisms 
involved in GR “programming” may involve epigenetic alterations in the GR 
promoter but are beyond the scope of this Thesis, therefore are not discussed further.   
 
1.6 Altered glucocorticoid sensitivity and physiological consequences  
 
As described in previous sections, the regulation of GC secretion and metabolism is 
determined by the GR, the HPA axis and at the peripheral level by the 11β-HSD 
enzymes. In the following sections the effects on GC sensitivity and metabolic 
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parameters of modulating GR (section 1.6.1.1) or 11β-HSD1 levels (section 1.6.1.2) 
in mice are described. Furthermore, the effects of GR polymorphisms on GC 
sensitivity and associated pathologies in humans are reviewed.  
 
1.6.1 GR transgenic mice models elucidating the role of altered GR 
levels on a number of  systems involved in HPA axis regulation  & 
metabolism 
 
There are a number of GR mutant mice generated over the past 15 years. Table 1.1 
summarizes the GR transgenic mouse models published to date and their phenotype 
with respect to metabolic parameters and HPA axis function. Most of these models 
have been used to study the effects of altered GR levels on behaviour but this aspect 
is not discussed here. The main focus of this Thesis was to investigate the effects of 
altered GC sensitivity on metabolism and HPA axis function.   
 
The first transgenic GR mouse model was generated by expressing, under the control 
of the neurofilament promoter, antisense RNA to the 3-prime non-coding region of 
GR (Pepin et al., 1992). This led to a 40-60% reduction in GR levels, not only in 
neuronal tissue but also liver. The mice displayed HPA axis hyperactivity and late 
onset obesity (Pepin et al., 1992) with increased fat mass and plasma triglycerides 
(Richard et al., 1993). However, in this model, GR density is only partially reduced, 
the degree of down-regulation of the receptor varies with the tissues examined and 
levels have not been assessed in many tissues, thus limiting the utility of this model.  
Cole et al., (1995) used a gene targeting (insertion of neomycin phosphotransferase 
cassette into exon 2) approach with the aim of inactivating GR. This strategy resulted 
in incomplete inactivation (hypomorphic allele) of the GR gene (GRhypo/hypo) due to 
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expression of a truncated protein (39kD GR fragment) with residual activity (Cole et 
al., 2001).  10-20% of homozygous mice survived (Cole et al., 1995; 2001).  
GRhypo/hypo mice were profoundly GC resistant, displayed HPA axis hyperactivity, 
adrenal hypertrophy and reduced hepatic gluconeogenic enzyme expression (Cole et 
al., 1995; 2001). To ensure complete inactivation of GR function, another model was 
generated by deleting exon 3 (GRnull/null) (Finotto et al., 1999).  This resulted in 100% 
lethality shortly after birth due to atelectasis of the lungs (Finotto et al., 1999).  
GRnull/null mice exhibited a similar phenotype to GRhypo/hypo mice, with glucocorticoid 
resistance, an absent HPA axis negative feedback and impaired gluconeogenic 
enzyme expression (Tronche et al., 1998). Since GR is reported to affect 
transcription both by DNA binding-dependent and independent mechanisms, 
Reichardt et al., (1998) used gene targeting to create a  point mutation in the D-loop 
of the second zinc finger (GRdim/dim), which abolishes GR dimerization,  with the aim 
of separating these modes of action. The GRdim/dim mice are apparently unable  to 
transactivate gene transcription through  DNA binding of GR, but retain the 
repressing function of GR attributed to the action of GR monomers, independent of 
DNA binding (as discussed in section 1.5.1.7). Mice homozygous for this mutation 
survive, have normal lung and adrenal development but increased corticosterone 
(CORT) levels and upregulated POMC mRNA expression in the pituitary while CRH 
expression was unaltered (Reichardt et al., 1998). Oddly, PNMT, a classically GC 
up-regulated gene, was normally expressed in GRdim/dim mice (Reichardt et al., 1998). 
These data has been called into question by Adams et al., (2003) who reported that 
the mutation in the D-loop, whilst it abolishes transactivation through a conventional 
inverted repeat (or palindromic) GRE, still permits transactivation, via DNA binding-
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dependent manner from “non-classical” GREs such as present in the PNMT gene 
(Adams et al., 2003, also see section 1.5.1.7). It remains to be established whether 
the repressive effects of GR are mediated via DNA-independent mechanisms or 
through non-conventional GREs as in the PNMT gene.  
 
Heterozygous mice (GR+/-) with a 50% GR reduction, showed normal basal CORT 
levels, but CORT was increased after restraint stress indicating a disinhibited HPA 
axis (Ridder et al., 2005). Conversely, mice with a 2-fold increase in GR gene dosage 
(using a yeast artificial chromosome; YGR) displayed reduced expression of the 
main components of the HPA axis, 4-fold lower circulating CORT and enhanced 
HPA feedback regulation after immobilization stress (Reichardt et al., 2000; Ridder 
et al., 2005). 
 
Because complete inactivation of the GR gene is incompatible with survival, a 
number of conditional GR gene targeting models have been generated to dissect the 
role of GR in specific tissues (Table 1.1). A nervous-system-specific inactivation of 
GR gene was created by flanking exon 3 with loxP sites and crossing the line with 
nestin-Cre mice (Tronche et al., 1999). This trangene manipulation resulted in viable 
mice that lack GR in neurons and glial cells (GRNesCre). Loss of GR function in the 
nervous system resulted in plasma glucocorticoid excess, HPA axis hyperactivity, 
growth retardation, reduced size, fat redistribution (similar to Cushing’s disease) and 
osteoporosis (Tronche et al., 1999; Kellendonk et al., 2002). However, this model 
had a complex phenotype with different metabolic phenotypes during suckling, after 
weaning and in adulthood. Briefly, during suckling GRNesCre displayed a 60% 
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increase of percent body fat, associated with elevated plasma leptin and insulin levels 
but normal fat distribution and reduced lean mass (Kellendonk et al., 2002). After 
weaning, the lean mass was reduced further along with marked reduction in fat mass 
but persistent hyperleptineamia. Reaching adulthood the GRNesCre mice had reduced 
fat and lean mass but normalized leptin and insulin levels (Kellendonk et al., 2002). 
The reduced fat/lean mass in the GRNesCre was probably due to the catabolic signals 
of elevated hypothalamic CRH and plasma GC levels (Kellendonk et al., 2002).   
Another 2 models, with altered forebrain GR density have been generated. FBGRKO 
mice (loss of GR in forebrain) displayed elevated circulating CORT and ACTH 
levels, impaired negative feedback regulation of the HPA axis and glucocorticoid 
resistance (Boyle et al, 2005). This time-inducible (CaMKIIa promoter) disruption of 
GR in the forebrain was an elegant strategy showing that there is a threshold effect: 
that is, the HPA system and the susceptibility to depression-related disorders is not 
compromised until GR expression falls below a specific level (Boyle et al., 2005). 
Conversely, the GRov (increased GR) showed normal HPA axis activity basally and 
after a mild stress and unaltered expression of HPA axis components (Wei et al., 
2004). 
 
Less attention has been focused on the effects of peripheral alterations in GR density 
in metabolically relevant tissues/organs. To elucidate the role of GR in liver, a 
hepatocyte-specific GR knockout model was created by crossing GRloxP (exon3-
floxed) mice with albumin-α-fetoprotein- Cre mice (GRAlfpCre) in which the albumin 
enhancer and αFP promoter drive Cre expression in hepatocytes  (Opherk et al., 
2004). Half of the GRAlfpCre mice died shortly after birth due to hypoglycaemia 
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demonstrating that GR is essential to activate gluconeogenic genes neonatally. Under 
basal (normally fed) conditions adult transgenic mice had normal glucose levels 
indicating sufficient compensation by GC-independent mechanisms (ie an increase in 
glucagon and a decrease in insulin levels). However, GRAlfpCre mice developed 
hypoglycaemia after prolonged fasting, indicating that GR plays an essential role in 
liver glucose metabolism only during fasting (Opherk et al., 2004). Moreover, they 
developed milder hyperglycaemia after streptozotocin-induced diabetes due to 
impaired induction of gluconeogeneis, suggesting that liver-specific GC-antagonists 
might be beneficial for the treatment of hyperglycaemia in diabetic patients (Opherk 
et al., 2004). The role of GR in pancreatic β-cells has been explored in mice 
overexpressing GR in the β-cells (GRTG) under the rat insulin promoter (Delaunay 
et al., 1997; Davani et al., 2004). Young adult GRTG mice displayed impaired 
glucose tolerance and reduced insulin secretion, but unaltered fed or fasted plasma 
glucose levels (Delaunay et al., 1997). Aged GRTG mice had unaltered body weight, 
elevated blood glucose levels, reduced insulin secretion and reduced insulin 
responses to glucose treatment in the islets (Davani et al., 2004), clearly indicating 
that the elevated GR causes impaired insulin secretion in β-cells.  Finally, a 
transgenic model with conditional inducible cardiac-specific expression of the human 
GR (hGR) was generated by crossing tetracycline-inducible hGR mice (tetO-hGR) 
with αMHC-τTA transactivator (expression of the τTA transactivator under the 
control of cardiac-specific αMHC promoter) mouse line (double transgenic; DT) to 
evaluate the direct cardiovascular function of increased GR (Sainte-Marie et al., 
2007). DT mice had normal survival rates, circulating CORT levels and blood 
pressure (Sainte-Marie et al., 2007). Cardiac hGR overexpression led to  conduction 
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defects, reduced heart rate, atrio-ventricular block, altered calcium (Ca2+) 
homeostasis and in isolated cardiomyocytes, cardiac remodelling (Sainte-Marie et 
al., 2007). Despite the plethora of models of altered GR density, the effects of 
reduced/increased GR in adipose tissue function/metabolism have not been 
examined.  
In summary,   the model that is more relavent, with respect to altered GC sensitivity 
and the effects on metabolic parameters,  to the system I generated and presenting in 
the following chapters  are the GR+/null  mice. However, comparisons could not be 
performed with respect to metabolic effects of altered GR density between the 2 
models since data from GR+/null  mice are unavailable. The advantage of the model 
presented in the next chapters is that the LacZ reporter can provide a visual mean of 
monitoring the expression of the GR in cells, tissues or whole organs or  at  different 
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Table 1.1 GR transgenic mice and their phenotype with respect to metabolic parameters and HPA axis (continue) 
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Table 1.1 GR transgenic mice and their phenotype with respect to metabolic parameters and HPA axis (continue) 
 
 
BW; body weight, HC; hippocampus, PVN; paraventricular nucleus of the hypothalamus, TGs; triglycerides, PEPCK;    
phosphoenolpyrouvate carboxylase,TAT;, G6Pase; glucose-6-phosphatase, DEX; dexamethasone (synthetic glucocorticoid), AR; 
adrenergic receptor, IGF; insulin growth factor, YAC; yeast artificial chromosome, ND; not determined, w/o; without. Note that GR 
transgenic mice with phenotypes not directly relevant to HPA/metabolic (eg macrophage or Tcell specific GR knock out) are not 
included.  
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1.6.2 GR polymorphisms and associations with altered GC sensitivity 
and pathologies in humans. 
 
Data from GR transgenic mice have clearly shown that altered GR density results in 
altered glucocorticoid sensitivity and HPA axis dysregulation (where brain GR 
density is altered). In humans, GC sensitivity (measured by the DEX suppression 
test) varies between but not within individuals suggesting that there is a set-point for 
GC sensitivity which might be genetically determined (Huizenga et al., 1998). 
Impaired GC sensitivity has been associated with mutations/polymorphisms in the 
GR gene, and has been hypothesized to be the cause or a contributing factor to 
pathological conditions or subtle metabolic abnormalities  (reviewed in van Rossum 
and Lamberts, 2004). Rare mutations in the GR gene have been identified in a small 
number of patients diagnosed with general glucocorticoid resistance (or 
hyposensitivity) (van Rossum and Lamberts, 2006). These mutations are associated 
with elevated cortisol production, and impaired central negative feedback (van 
Rossum and Lamberts, 2004). Clinical features in these patients include hypertension 
(due to increased mineralocorticoid production), hypokalemic alkalosis, fatigue and, 
in females, hyperandrogenism (van Rossum and Lamberts, 2004). Severe generalized 
glucocorticoid resistance is not well studied since it is extremely rare. However, 2 
patients have been identified, with symptoms of Cushing’s syndrome despite low or 
normal plasma cortisol levels (Iida et al., 1990; Newfield et al., 2000). Lymphocytes 
from one of these patients, with normal cortisol levels, showed increased GR number 
per cell (but normal binding affinity), suggesting that  the presence of peripheral 
Cushingoid phenotype might be explained by differential GC sensitivity at the 
peripheral vs the hypothalamic-pituitary level either by tissue-specific differences in 
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GR numbers or by hypothalamic desensitization (Newfield et al., 2000). 
Additionally, in vitro experiments (lymphoid cell lines) showed that increasing the 
quantity of GR induces enhanced responses to glucocorticoids (Pfahl et al., 1978; 
Nieman et al., 1985). Common polymorphisms linked to or within the GR gene have 
been implicated in altered GC sensitivity (van Rossum and Lamberts, 2004).  
 
Figure 1.5 shows the location of polymorphisms in the GR gene identified to date 
that cause GC resistance or altered GC sensitivity. Here the discussion focuses on the 
3 most well studied GR polymorphisms which are associated with altered GC 
sensitivity and alterations in body composition and metabolic parameters.  
 
The ER22/23EK polymorphism in the GR gene is associated with relative 
glucocorticoid resistance (fig. 1.5). This polymorphism consists of 2 linked single 
nucleotide changes/substitutions in codons 22 and 23 (exon 2), with only the second 
substitution causing an amino acid change from arginine (R) to lysine (K) (Koper et 
al., 1997). A population-based study in elderly Dutch men showed that carriers of the 
ER22/23EK polymorphism had impaired cortisol suppression after a DEX 
suppression test, lower risk of dementia, lower fasting insulin levels, increased 
insulin sensitivity, lower total and low density cholesterol levels and lower C-
reactive protein that could protect them from cardiovascular abnormalities and 
increase their survival (van  Rossum et al., 2002; van Rossum et al, 2004a, b; Wust et 
al., 2004; Koeijvoets et al., 2006). When younger male and female (followed from 




Figure 1.5 Polymorphisms in the GR gene and their clinical associations   
A simplified view of the GR gene showing the locations of polymorphisms 
associated with altered glucocorticoid sensitivity and their effects on body 
composition and metabolic parameters. The 3 intensively studied and characterized 
polymorphisms are presented. ER22/23EK (highlighted in blue) carriers show 
reduced glucocorticoid sensitivity and have a healthy metabolic profile, while N363S 
or BclI (highlighted in red) carriers show increased glucocorticoid sensitivity and an 
unfavourable metabolic profile. Please note that the fourth polymorphism, TtIIII 
(oval arrow) in the GR promoter region is much less studied. However, it is believed 
to be non-functional itself and might be functionally relevant only in combination 
with the ER22/23EK, since it was found that all ER22/23EK carriers also carry the 
TtIIII polymorphism (van Rossum et al., 2004c). The dashed arrows indicate 
mutations in the GR gene that lead to the syndrome of cortisol resistance (adapted 
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carriers were studied, the male carriers were taller, had more lean body mass and 
increased muscle strength,  and the females had smaller waist circumference (used as 
a measure for visceral adiposity and a risk factor for the Metabolic Syndrome; 
reviewed in Reaven, 2005). In all carriers studied, this polymorphism was associated 
with a healthier metabolic/body composition profile, possibly attributable to 
glucocorticoid resistance in tissues such as adipose and liver (van Rossum and 
Lamberts, 2004). However, it has also been associated with a more aggressive 
multiple sclerosis phenotype (van Winsen et al., 2007), as well as increased risk of 
dementia (van Rossum 2006). The mechanisms involved in mediating the effects of 
ER22/23EK polymorphism have been recently elucidated. Transfection experiments 
showed a reduced capacity for GRE-luciferase activation, indicating decreased 
transactivation ability (Russcher et al., 2005a).  Dexamethasone treatment of 
peripheral blood mononuclear lymphocytes (PBMLs) from homozygous or 
heterozygous ER22/23EK carriers showed a dose-dependent reduction in the 
transcriptional activation of the GC-responsive gene, leukine Zipper protein (GILZ), 
but normal transrepression of NF-kB (Russcher et al., 2005a). Interestingly, overall 
GR expression levels in lymphocytes (measured by [3H]-DEX binding of PBMLs) 
did not differ between control, heterozygous or homozygous carriers (Russcher et al., 
2005a).   However, the ER22/23EK polymorphism resulted in a shift in favour of the 
GR-A translational variant over the GR-B (Russcher et al., 2005b; described in 




The N363S and BclI-restriction fragment polymorphisms (fig. 1.5) have been 
associated with increased GC sensitivity and a generally unfavourable metabolic 
profile (reviewed in van Rossum and Lamberts, 2004). The N363S polymorphism 
was first identified in an elderly Dutch population and is located in codon 363 of GR 
exon 2, resulting in an asparagine to serine amino acid change (Koper et al., 1997; 
Huizenga et al., 1998). The N363S polymorphism is present with allele frequencies 
ranging from 0.7% to 27% in South Asian (Dhawan et al., 1994; Syed et al., 2004) 
and Australian (Morris et al., 2003) subjects respectively, and 4-15% in European 
carriers (Bhopal et al., 1999). The findings regarding this polymorphism and 
associations with obesity and metabolic abnormalities are contradictory, with some 
reporting higher BMI (body mass index), increased waist-to -hip ratio (WHR), 
increased insulin responses to exogenous DEX, elevated plasma lipids and increased 
CAD risk (Lin et al., 1999; Di Blasio et al., 2003, van Rossum et al., 2003),  and 
others showing no associations with the above parameters in carriers (Rosmond et 
al., 2001; Dobson et al., 2001). The proposed molecular mechanism by which the 
N363S variant exerts its effects is by increasing the transactivating capacity of GR 
(Russcher et al., 2005) or by regulating different genes (Jewell and Cidlowski, 2007). 
However, recently a meta-analysis study (included 5,909 individuals), performed to 
evaluate the association between the polymorphism and obesity risk, showed that 
homo-/hererozygous carriers of the N363S allele did not have a higher risk of 
developing obesity compared to non-carriers, although they pointed out that there 
maybe certain genotypic effects that are population-specific (Marti et al., 2006).  
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The BclI polymorphism is an intronic restriction fragment length polymorphism of 
the GR gene in which a C to G nucleotide mutation has occurred 646 nucleotides 
downstream of exon 2 resulting in 2.2 kb and 3.9 kb fragments following a BclI 
digest (Murray et al., 1987; van Rossum et al., 2003). The C allele is the most 
frequently (65%) occurring (van Rossum and Lamberts, 2004).  This polymorphism 
has shown clear associations with increased GC sensitivity (Buemman et al., 1997, 
Rosmond et al., 2000; Fleury et al., 2003; van Rossum et al., 2003; Trembley et al., 
2003) but the data with respect to alterations in adiposity over time are contrasting. 
The controversy is probably due to different consequences of BclI-induced 
hypersensitivity to GCs during life (van Rossum and Lamberts, 2004). For example, 
it might be possible that early in life, fat mass (especially visceral) is predominately 
affected (G-allele carriers have more fat) while later in life (middle-age carriers), 
lean mass is more profoundly affected (G-allele carriers have less lean mass)( van 
Rossum and Lamberts, 2004). Interestingly, homozygosity of the G allele was more 
frequent in subjects with heritable hypertension (Watt et al., 1992). The molecular 
mechanisms by which the BclI polymorphism exerts its effects are unknown. Being 
in an intron limits the use of transfection experiments. One hypothesis proposed that 
this intronic polymorphism is linked to another polymorphism in the GR promoter 
region which could increase GR expression and in turn increase mRNA stability, but 
still waits to be confirmed (van Rossum and Lamberts, 2004). 
 
Finally, it should be noted that the phenotypic changes (especially with respect to 
metabolic parameters and body composition) and the severity of pathological 
consequences associated with polymorphisms in the GR gene are complicated and 
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vary, dependent upon the age, gender and general health status (obese, over- or 
normal weight) of the carrier, and are population-specific therefore here the review 
of the literature has been simplified.  
1.6.3 11β-hydroxysteroid dehydrogenase type 1 transgenic mice, 
altered GC sensitivity and the Metabolic Syndrome 
 
GCs that have diffused through the cell membrane must engage with the GR to exert 
their effects. As mentioned above, apart from the GR determining GC sensitivity, 
intracellular GC sensitivity is determined by the levels of 11β-HSD enzymes (section 
1.4). In this section the focus is on 11β-HSD type 1 since its manipulation is of 
greatest relevance to explain tissue-specific alterations in GC sensitivity and 
associations with the Metabolic Syndrome. Studies on adipose-specific 11β-HSD1 
over-expressing mice (ap2-11β-HSD1) showed increased corticosterone levels in 
adipose tissue and the portal system, but not in the peripheral circulation (Masuzaki 
et al., 2001). The mice developed visceral obesity, glucose intolerance, insulin 
resistance, dyslipideamia and hypertension (Masuzaki et al., 2001; Masuzaki et al., 
2003). Interestingly, GR levels were unaltered in adipose tissue (Masuzaki et al., 
2001), suggesting that 11β-HSD1-mediated amplification of GCs in adipose  does 
not affect the level of the receptor in fat in this model. Conversely, 11β-HSD1 
knockout mice (11β-HSD1-/-; unable to convert inactive to active GCs) showed an 
improved lipid profile and resisted obesity and glucose intolerance when challenged 
with high fat diet (Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004).  
With respect to circulating GC levels and HPA axis phenotype, 11β-HSD1-/- mice 
exhibited adrenal hypertrophy and elevated basal ACTH and CORT levels at their 
nadir and, in vitro, 11β-HSD1-/- adrenals were hyper-responsive to ACTH, indicating 
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a compensation for the lack of active GCs (Kotelevtsev et al., 1997; Harris et al., 
2001). However, CRH mRNA levels in the paraventricular nucleus (PVN) of the 
hypothalamus are unaltered suggesting maintenance of central drive (Harris et al., 
2001). Similar to ap2-11β-HSD1 mice, 11β-HSD1-/- mice had unchanged GR levels 
(Harris et al., 2001). However, the HPA phenotype appears to be strain-dependent. 
The original observations were made in a mixed background (129 and the outbred 
MF1). When the 11β-HSD1 disruption was backcrossed onto a C57BL/6J 
background, only the adrenal hypertrophy was maintained (Carter et al., submitted 
for publication). Additionally, GR was increased in the hippocampus and PVN, 
which possibly led to improved GC feedback, thus explaining the unaltered plasma 
corticosterone (CORT) and ACTH levels (Holmes and Seckl, 2006). Metabolic 
studies on a C57BL/6 background confirmed the insulin-sensitive phenotype of the 
11β-HSD1-/- mice. It seems that the phenotype (either metabolic or HPA axis) in 11β-
HSD1-/- mice is strongly affected by the genetic background in which the gene is 
deleted. However, it is clear that adipose-specific amplification of GCs, by increased 
11β-HSD1 activity, in mice causes obesity and all the adverse consequences widely 
known as the Metabolic Syndrome. What are the parallels with idiopathic obesity in 
humans?  
 
1.6.4 11β-HSD1 and human obesity 
Exposure to high circulating GC levels, as found in Cushing’s disease, causes a 
metabolic disease that resembles features of idiopathic metabolic syndrome including 
pronounced visceral obesity (reviewed in Seckl et al., 2004; Stewart, 2005). 
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However, idiopathic obesity is not associated with high circulating GC levels (Marin 
et al., 1992; Homma et al., 2001; reviewed in Bjorntorp, 2000). Rather, it appears 
that intra-cellular generation of active from inactive GCs by 11βHSD1 is aberrantly 
elevated in adipose tissue of obese individuals (reviewed in Seckl et al., 2004; 
Stewart, 2005). Thus, it has been extensively shown that 11β-HSD1 mRNA and 
activity are elevated in abdominal subcutaneous adipose tissue from obese compared 
with non-obese individuals (Rask et al., 2002; Paulmyer-Lacroix et al., 2002; 
Lindsay et al., 2003; Wake et al., 2003; Engeli et al., 2004; Kannisto et al., 2004). In 
vivo microdialysis confirmed increased regeneration of cortisol from cortisone in 
abdominal subcutaneous adipose from obese humans (Sandeep et al., 2005). Given 
the key association of intra-abdominal (visceral) adipose tissue with metabolic and 
cardiovascular disease risk, it has been hypothesized that increased 11βHSD1 in the 
visceral, rather than subcutaneous, adipose depot causes the adverse metabolic 
consequences of idiopathic obesity and the metabolic syndrome (Bujalska et al., 
1997).  However, Tomlinson et al. reported a negative association between 11β-
HSD1 activity and BMI in primary omental human adipocytes cultured in vitro, 
though there was no correlation in whole adipose biopsies (Tomlinson et al., 2002). 
A further study could not detect increased portal vein cortisol (Aldhahi et al., 2004) 
or increased splanchnic cortisol production rates (Basu et al., 2005) in obesity 
suggesting that if cortisol generation is indeed elevated in the visceral fat, it is further 
metabolised or is not released at higher rates from adipocytes. Together, these data 
have engendered some confusion as to whether visceral as well as subcutaneous 11β-
HSD1 is elevated in human obesity.   
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Finally, in contrast to the plethora of studies of 11β-HSD1 in adipose tissue and 
Metabolic Syndrome, curiously few studies have examined associations between 
tissue GR levels and metabolic parameters. As reviewed here, genetic studies 
strongly support a role for GR in determining body composition and fat distribution 
(section 1.6.2).  Higher levels of GR found in omental compared to subcutaneous fat 
(Rebuffe-Scrive et al., 1990) would further be expected to have a more pronounced 
effect on GC action in the omental depot. However, a previous study in this lab 
showed no correlation between adipose tissue GR mRNA in abdominal sc adipose 
tissue and obesity (Wake et al., 2003), whereas another group reported an inverse 
correlation between sc adipose GRα mRNA and BMI (Kannisto et al., 2004). 
Therefore, assessing the levels of GR in different adipose depots (central vs 
peripheral) and studying the GR associations with metabolic parameters as well as 
the relationship between GR and 11β-HSD1 levels is crucial to our understanding of 




1.7 Thesis Aims  
As described in this chapter GCs have a variety of physiological roles and cause a 
number of responses, primarily through the GR. One major concept, presented here 
is the sensitivity to the effects of GCs and downstream metabolic consequences. This 
is of great importance since GCs are used routinely for the treatment of many 
conditions. However in certain individuals they cause deleterious side effects.  
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Genetic studies in humans and studies following manipulation of GR in transgenic 
mice provided compelling evidence that the absolute level of GR protein expressed 
in a cell can have a dramatic impact on the cellular responsiveness to GCs with 
consequent downstream effects on a plethora of physiological processes. Therefore 
the aim of my PhD was to use mouse models of altered GC sensitivity to investigate 
the effects primarily on metabolism/susceptibility to metabolic disease  and HPA 
axis function, and crucially a human population study to investigate how 
mechanisms “dissected” from mouse models could be applied to humans. 
Specifically the aims of this Thesis were to:  
(1) investigate the effect of global reduction in GR density upon  tissue GC 
sensitivity, HPA axis regulation, susceptibility to dietary-induced obesity (DIO) and 
body fat distribution (chapters 3, 4 and 5). 
(2) investigate GC sensitivity and determine key parameters of GC action (GR and 
11βHSD1) in metabolically important tissues (liver and adipose) and their role in 
body fat distribution in POMC-deficient mice (chapter 6), an established model of 
HPA hypo-activity which also shows hyperphagic obesity (Challis et al., 2004;  Coll 
et al., 2004; Coll et al., 2005). 
(3) address if adipose (biopsies form 4 distinct adipose depots:omental, abdominal 
subcutaneous, gluteal and thigh) GR  levels are altered in obesity, and whether they 
associate with 11βHSD1 levels  and metabolic parameters in human obesity (chapter 
7).   
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 Chapter 2 


















2.1 Materials  
Except where stated otherwise, all chemicals were from Sigma (suppliers addresses 
can be found in Appendix D).  
2.1.1 General chemicals  
 
NICK columns 
Scintillation proximity assay reagent 
(anti-rabbit reagent) 
Hybond-C nitrocellulose membrane 
 
Amersham Pharmacia Biotech UK Ltd. 
Protein assay dye reagent 
concentrate 
Bio-Rad Laboratories Ltd. 
SeaKemTM LE agarose Cambrex Bio Science Wokingham Ltd. 
1 kb DNA ladder 
Superscript III cDNA synthesis kit 
Lyophilised desalted primers (1μg/μl 
stock) 
Invitrogen 
Formamide Loading Buffer 
Reverse Transcription System 




dNTPs (100mM stock) 
Promega Ltd. 
Lightcycler 480 Probes Master Mix Roche  
Kodak MS-1 autoradiographic film 
Dexamethasone 
20xSSC 
Oil Red O 
Sigma-Aldrich Company Ltd. 
ACTH ELISA Kit Biomerica  
DNeasy Tissue extraction kit  Qiagen 
RNA Matrix and wash Anachem 
RIA cups  Sarstedt 
Whatman 3MM paper 
1ml eppendorf tubes 
0.5ml eppendorf tubes 
Superfrost slides 









GeneQuant RNA/DNA Calculator 
Amersham Pharmacia Biotech UK Ltd. 
Lumat LB9501 Luminometer Berthold Technologies (U.K.) Ltd. 
Agarose gel electrophoresis equipment 
583 Gel Drier 
Bio-Rad Laboratories Ltd. 
Eppendorf Mastercycler Eppendorf AG. 
Ultra-turrax TD Homogeniser IKA Labortechnik 
Shimadzu spectrophotometer 160A Shimadzu Europa U.K. 
Techne Genius Thermocycler 
















[125I]-iodotyrosyl Angiotensin I 
(2000Ci/mmol or 74TBq/mmol) 








GE Healthcare  
 
 
2.1.4 Enzymes  
 
All enzymes were obtained from Promega Ltd., unless otherwise stated.  
 
DNase  Invitrogen 





2.1.5 ES cell tissue culture reagents & equipment 
 





Porcrine Gelatin  
MEM non essential amino acid 
Sodium Pyruvate 




T75 Vented Flasks 
Quadriperm 4x12 chambers 
Greiner Bio-One Ltd. 
2ml Cryotubes Nalgene Labware 
 
 










Chromosome paints Gambio 
Vectashield  Vector 
 
 
2.1.7 Solutions & buffers 
 
SOLUTIONS & BUFFERS RECIPE 
DEPC dH2O 0.5ml DEPC in 500ml ultrapure dH2O. Leave for 
1-24 h, autoclave. 
DNA Loading Buffer 40% v/v glycerol, 0.3% w/v Orange G 
1kb ladder buffer 1:2; 1kb ladder:loading buffer, make vol with 
dH2O  
Oil Red O  210ml ORO in 140ml dH2O 
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Borate buffer 8.25g boric acid, 2.7g NaOH, 5g BSA in 1lt dH2O, 
pH 7.4 
Phosphate buffer 13.8g NaH2PO4-1-hydrate, 42.6g Na2HPO4-
anhydrous, 0.93g EDTA in 500ml dH2O 
Tris (50mM, pH 7.4 @ 22°C) 
for angiotensinogen & renin 
assays 
Tris (12.14g) in 1l dH2O. Add 10ml 5M HCl, 3.5g 
neomycin sulphate, 1.75g  serum albumin 
(sprinkle). Adjust to pH 7.4, make up to 2l. 
Aliquot 10ml and store at -20°C. 
 
Charcoal for agiotensinogen and 
renin assays 
 
Tris (6.07g) in 500ml dH2O , add 5ml 5M HCl,  2g 
neomycin sulphate,1.85g EDTA, 5g BSA 
(sprinkle).Adjust pH to 7.4, make up to 1l; store 
100ml aliquots. 
Dissolve 0.062g dextran T70 in 5.0ml buffer (0.6g 
Norit charcoal + 95ml buffer + 5ml Dextran T70 
soln.).Store @ 5°C.  
 
10 x MOPS  200mM MOPS acid, 50mM C2H3O2Na, 10mM 
EDTA. pH adjusted to 7.2. 
1 x PBS  1 x PBS tablet (Sigma) dissolved in 200ml dH2O 
to give 10mM phosphate buffer, 2.7mM KCl, 
137mM NaCl 
Potassium Acetate (5M acetate, 
3M potassium) 
245.6g KC2H3O2 dissolved in 442.5ml dH2O, 
57.5ml glacial acetic acid. 
Prehybridisation Buffer 5 x SSC, 0.5% SDS, 5 x Denhardt’s Solution (50 x 
Denhardt’s Solution = 5g Ficoll, 5g 
polyvinylpyrrolidone, 5g BSA to 500ml with 
dH20). 
RNase -free Loading Buffer 2g Ficoll 400, 100mg SDS, 25mg bromophenol 
blue 25mg xylene xyanol in 10ml 0.1M EDTA pH 
8 (made with DEPC dH2O) 
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20 x SSC  3M NaCl, 0.3M sodium citrate. pH adjusted to 7.0 
with 10M NaOH. 
50 x TAE  121.1g Tris  dissolved in 421.5ml dH2O, 50ml 
0.5M EDTA, 28.6ml glacial acetic acid 
10 x TBE  0.9M Tris, 0.9M Boric Acid, 12.5mM EDTA 





2.2.1 Molecular Biology 
2.2.1.1 RNA methods 
2.2.1.1.1 RNA isolation by TRIzol extraction 
 
Total RNA was extracted from frozen tissues and cells using TRIzol reagent 
(Invitrogen). Tissues (50-100mg) were homogenised in 1ml of TRIzol in pre-chilled 
eppendorf tubes, using an Ultra-turrax homogenizer. Cells (from a confluent T25 
flask) were washed once in 1x PBS before 1ml TRIzol was added. Cells were 
scraped into an eppendorf tube and then 0.2 ml of chloroform was added per 1ml 
TRIzol. Tubes were vortexed for 20-30s, incubated for 3min at room temperature 
(RT) then for 15min on ice. Tubes were centrifuged at 12000g for 30min at 40C. The 
aqueous (top) layer was transferred to new pre-chilled eppendorfs. 20-30μl of RNA 
Matrix (RNaid Plus kit, BIO 101; Anachem, UK) per 500μl sample was added, and 
tubes were gently inverted for 5min at RT. Samples were then centrifuged at 14000g 
for 1min at 40C to pellet the matrix. 500μl of wash ethanol solution (Anachem) was 
added to the pellets which were gently re-suspended, then centrifuged for 1min at 
14000g at 40C. Another two rounds of washes were performed. Finally, RNA was 
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recovered from the matrix by re-suspending the final washed pellet in 20μl of 
diethylpyrocarbonate-treated water (DEPC H2O) containing 400 U/ml RNasin and 
10mmol/l dithiothreitol. A final centrifugation (14000g, 2min, 40C) to remove the 
matrix allowed the RNA in the supernatant to be transferred to fresh eppendorfs in 
3x6μl aliquots. RNA was quantified using a GeneQuant spectrophotometer 
(Amersham, Pharmacia Biotech, UK Ltd) and stored at -800C for further analysis.  
 
2.2.1.1.2 RNA gel electrophoresis   
 
For each RNA (5 μg)  sample, 2.5μl formaldehyde (37%), 2.5μl 10x MOPS buffer 
and 10μl of de-ionised formamide were added and mixed thoroughly. Samples were 
then heated to 65°C for 15 min in order to denature RNA secondary structure and the 
samples were rapidly chilled on ice. 1 μl of DEPC treated loading buffer was added. 
The samples were resolved on a denaturing 1% agarose 1xMOPS/18% formaldehyde 
gel. Brielfy, agarose was melted in a microwave, allowed to cool down and MOPS 
and formaldehyde were added. The gel was allowed to set for 1h and immersed in 1x 
MOPS buffer for at least 30 min before loading of samples. Samples were run for 3-4 
hr until the first band of bromophenol blue dye reach ¾ of the length of the gel. For 
analysis of transcripts of larger size (>4kb) 0.7% agarose gels were used. 
 
2.2.1.1.3 Northern blotting and hybridisation  
 
To allow RNA capillary transfer, a nylon membrane (Hybond N) and three pieces of 
Whatman No.3 filter paper of identical size to the gel were immersed in 20x SSC. A 
“wick” (similar width to the gel but longer length) was placed above an RNAse free 
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gel tray. The ends of the wick were immersed in the reservoir of 20x SSC which was 
used as the source of transfer buffer. On completion of electrophoresis, the gel was 
washed in 20x SSC, inverted, and placed onto the wick. The nylon membrane was 
placed on top of the gel surface. The assembly was then covered with saran wrap to 
isolate the buffer chamber, leaving a ‘window’ uncovered with the gel, membrane 
and wet Whatman papers at the centre so that capillary transfer would occur only 
through the gel and up into the membrane when dry paper towels were placed above 
it. Layers of filter paper were placed on top of the nylon membrane followed by a 
stack of dry paper towels. A glass plate (to maintain a flat, even transfer) was placed 
on top with extra weight on top to maximize capillary force. A small spirit level was 
used to maintain the balance of the transfer and thus even transfer of RNA to the 
membrane. Following transfer, the memebrane was washed in 2xSCC and then 
allowed to dry. The RNA was cross-linked to the membrane by UV transilluminator 
with an irradiation of 7x105 J.   
 
[α32P]-dCTP-labelled cDNA probes were synthesized by adding 15ng of denatured 
template to the RediVue kit (Amersham) and left incubating at 37°C for 30 minutes. 
cDNA probes for mouse 11β-HSD1, GR, angiotensinogen, phosphoenolpyruvate 
carboxykinase (PEPCK), lipoprotein lipase (LPL) and 18S were generated by PCR 
using gene and exon specific primers. Identities of all PCR products were verified by 
sequencing as previously described (Morton et al.,  2005). Probes were purified using 
Nick columns (Amersham) into 400μl of water and specific activity of the probe was 
estimated using a scintillation counter with 1μl of the probe in 1ml of scintillant 
(Pico-fluor 40). The probe’s labelling efficiency was measured by a β-counter, and 
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105 counts were added to the blot. The nylon membrane was soaked in 20x SSC for 
10 minutes and then pre-hybridised by placing it in a pre-warmed (55ºC) 
hybridisation bottle containing 12ml phosphate buffer and 6ml 20% SDS at 55°C. 
Sonicated Salmon Testis DNA (10mg/ml; 1ml) was denatured at 105° for 15 min, 
cooled on ice and added to the pre- hybridisation mixture at 65°C for at least 3-4 h 
prior to adding the probe. Following addition of the 32P-labelled probe, blots were 
hybridized at 65°C overnight, washed at 65°C to a stringency of 0.5x SSC, 0.1% 
SDS and  exposed to phosphoimager screen, and read with a phosphoimager (Fuji 
BAS FLA 2000). Analysis was performed using quantitative imaging software 
(AIDA 2.0, Raytek, Sheffield, UK). Transcript levels were expressed in arbitrary 
units (A.U.) relative to 18S RNA. 
 
2.2.1.1.4 Real time PCR  
2.2.1.1.4.1 cDNA synthesis 
 
 For reverse transcription (RT) PCR, 1 μg RNA was pre-treated with DNaseI 
(Invitrogen) and was then transcribed into cDNA using oligo-dT primers (or random 
hexamers if 18S was used as an internal control) and a Superscript III First Strand 
Synthesis kit (Invitrogen) according to the manufacturer instructions in a total 
volume of 20μl. 
 
2.2.1.1.4.2 Real time PCR analysis  
 
In the human study, GRα and 11β-HSD1 mRNA levels were quantified by Real 
Time PCR primer-probe sets using the ABI PRISM 7700/ 7900 Sequence Detection 
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System (PE Applied Biosystems, Cheshire, UK).  The primers and probes used are 
listed in Table 2.1. The PCR reaction contained 5μl of commercial Taqman mix, 4.5 
μl of Nuclease-free H2O and 0.5 μl of cDNA per sample. The PCR programme is 
described in Table 2.1. The relative amplification of each sample was measured. 
After each cycle, a probe signal indicates how much cDNA has been amplified for 
each individual sample. The program generates a threshold level (typically this is set 
within or slightly above this exponential phase), and a CT value was calculated as the 
number of cycles at which exponential amplification began. One primary assumption 
of the CT threshold is that amplification efficiency is identical in all samples. The 
more cycles the sample has to complete to reach that threshold the lower the initial 
expression. Data acquisition was  by Sequence Detector 2.03 software. Levels of 
GRα or 11βHSD1 mRNA are reported relative to human cyclophilin A mRNA 
(Hs99999904_m1,  Applied Biosystems, Cheshire, UK), the latter  previously 
optimized as an appropriate internal control for human fat (Wake et al., 2003), and 
are expressed in arbitrary units (A.U.). Each sample was run in duplicate, and the 
mean values of the duplicates were used to calculate transcript level. Values were 
calculated relative to the levels of the internal control. Negative controls, omitted RT 
or cDNA were used to identify genomic DNA contamination. A standard curve for 
each primer probe set was generated in triplicate by serial dilution of cDNA pooled 
from all subjects.  
For animal experiments, quantitative (real time) PCR was carried out using a 
LightCycler 480 (Roche). Primer-probe sets used to measure transcripts were as 
follows: β-actin (20x assay; Mm00607939_s1), 18S (20x assay; Hs99999901_s1), 
TATA binding protein (TBP; 20xassay; Mm00446973_m1), GR (20xassay;  
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Table 2.1 Primer-probe mixes used for human adipose transcript levels as  
previously described (Wake et al., 2003) 
GENE FORWARD PRIMER  
(5’ TO 3’) 
REVERSE PRIMER  
(5’ TO 3’) 
PROBE 

















incubation @ 50oC (2 min) 
Denaturation @ 95o C (10 min) 
40 cycles of PCR (95o C for 15 s, and 60o C for 1 min) 
 
 
Mm01260497_m1), 11β-HSD1 (20xassay; Mm00476182_m1) and angiotensinogen 
(20xassay; Mm00599662_m1). For all the amplification of transcripts a commercial 
20xassay (Applied Biosystems) and a commercial master mix was used (FAM-
hydrolysis probe, Roche). Each PCR reaction consisted of 0.5μl 20x assay, 5 μl 
master PCR mix, 2.5 μl nuclease-free water and 2μl cDNA. Each sample was 
assayed in triplicate. The Lightcycler 480 PCR programme was as follows: pre-
incubation at 95oC,5min, amplification 50x (95oC, 10sec; 60 oC, 30sec; 7 2oC, 1sec) 
and cooling, 40 oC, 30sec. Data were analyzed using the 2nd derivative maximum 
method. Briefly, in this method a fractional cycle (CP) is determined from the 
amplification curve’s second derivative max instead of the threshold crossing (figure 
2.1). The 2nd derivative max indicates the cycle at which exponential amplification 
can no longer be sustained and starts to decline towards linear growth.  In this 
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method, information from the curve shape promotes a better prediction of the starting 
concentration than the fluorescence level of the curve (in contrast to the threshold 
method). Moreover, since the CP value depends on the shape of the curve rather than 
on fluorescence level, this method rejects the assumptions of (a) identical 
amplification efficiency in all samples and (b) fluorescence-amplicon proportionality 
(Rasmussen et al., 2001; Luu-The et al., 2005).   The ratio of the gene of interest 
divided by the housekeeping gene concentrations was determined for each sample. 
The reasons for using two different real time PCR analysis methods and equipment 
were (a) the availability of the PCR equipment at the time and (b) for the human 
experiment to have consistency and comparable results with previous data published 
from this lab (eg Wake et al., 2003).  
 
2.2.1.1.4.3 Validation of internal controls  
The internal control used to correct for equal RNA concentrations between samples 
in the animal experiments (chapters 4 and 5) was β-actin. Overall, 3 internal controls, 
β-actin, TBP and 18S were tested. Figure 2.2 shows examples of the amplification 
plots for the 3 internal controls and also GR and 11β-HSD1 and figure 2.3 shows 
standard curves for actin, GR and 11β-HSD1. All the internal controls tested had 
similar CP values between genotypes (fig. 2.4A), but actin and TBP had a cycle-
amplification profile (mean CP~28 and 32, respectively) in the same range as 
11β−HSD1 and GR (CP~28), whereas mean CP for 18S was 15. Therefore actin was 
selected for internal control in all experiments. Negative samples (no RT, no cDNA) 
did not amplify (data not shown). Figure 2.4B confirms that concentration of actin is 




Figure 2.1 Schematic of a real-time PCR fluorescence amplification curve analyzed 
by two different analysis methods.  
The thick black line in each panel shows the same amplification data set with 
amplification cycle along the x axis and fluorescence on the y axis. Each analysis 
method identifies a fractional cycle (Cfrac) used to quantify sample copy number, as 
indicated by black arrows. (A) Threshold method. The arrow indicates Cfrac at the 
threshold crossing. (B) Second derivative maximum method with the amplification 
curve second derivative shown. The arrow indicates Cfrac at the second derivative 



















2nd derivative max 
A 
B 
Threshold Method  
2nd derivative max method  
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Figure 2.2 Amplification curves for internal controls and genes of interest. 
Representative amplification curves with x axis showing cycles of amplification and 
y-axis showing fluorescence level of (A) 18S, (B) TBP, (C) beta-actin (D) 11β-













Figure 2.3 Standard curves. 
Representative standard curves (SC) for actin, 11β-HSD1 and GR in mouse 
epididymal fat. SC constructed by serial dilutions (neat, 1:2, 1:4, 1:8, 1:16, 1:32, 
















Figure 2.4 Validation of Real time PCR internal controls. 
(A) Mean Crossing point (CP) values for internal controls. Actin and TBP appear to 
be better internal controls since they had a cycle-amplification profile in the same 
range as GR and 11βHSD1 (section 2.2.1.1.4.3), but the former was selected for all 
the experiments described in this Thesis.   (B) mean concentration of actin in every 
tissue measured is similar between genotypes and therefore appropriate internal to 













































2.2.1.1.5 In situ mRNA hybridization 
 
In situ GR mRNA hybridization was performed by E. Owen according to a standard 
protocol used in the lab (Seckl et al., 1990). Briefly, coronal brain sections (10μm) 
were fixed in 4% paraformaldehyde in 0.1M phosphate buffer and washed in 3x with 
2xSSC containing 0.02% diethylpyrocarbonate. Hybridization was carried out in 
buffer containing 50% deionized formamide, 600mM NaCl, 10mM Tris (pH 7.5), 
1mM EDTA, 0.02% Ficoll, 0.02% polyvinylpyrrodine, 0.1% bovine serum albumin, 
100µg/ml denatured sonicated salmon sperm DNA, 50µg/ml yeast tRNA, and 10% 
dextran sulphate. The GR probe was transcribed in vitro from a plasmid encoding a 
674bp Pst 1-Eco R1 fragment of rat GR cDNA (ligand binding domain) (Seckl et al., 
1990). For sense RNA, the plasmid was linearized with Ava I and cRNA was 
transcribed with T7 RNA polymerase, in a 10µl reaction containing 1µg linearized 
plasmid and 25µM [35S]-UTP. Probe (4x 106 cpm) was denatured (90oC), added to 
hybridisation buffer, cooled at 55 oC prior to adding 10mM dithiothreitol and 200µl 
of mix was added per slide. Hybridization was performed o/n at 55oC in sealed 
humidified boxes. The following day, slides were washed in 2x SSC, then treated 
with RNase A (20µg/ml) for 45min at 37 oC. Slides were then washed in 2x SSC to a 
final stringency of 0.1x SSC at 60 oC.  Radiolabelled sections were exposed to a film 
for ~2weeks. For densitometry, autoradiographs were viewed on a lightbox fitted and 
imaged using a coolsnap photometrics camera, then analysed using MCID software 
(Imaging Research Inc.). Control sense RNA was prepared from the same GR 
plasmid used for the antisense RNA (Seckl et al., 1990). The plasmid was linearized 
with EcoRI and cRNA was transcribed with SP2 RNA polymerase. 
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2.2.1.1.6 5’-Rapid amplification of cDNA ends (5’-RACE) 
 
5’-RACE was carried out essentially as previously described (Tate et al., 1998 and 
Sutherland et al., 2001). Table 2.2 details the sequences of primers used in 5’ RACE. 
Figure 2.5 illustrates the location of the primers used in the 5’-RACE protocol. 
Briefly, for reverse transcription, 10 ng P456 primer (specific for LacZ) was 
annealed to 5 μg total RNA, from ESKN92 cells, in a 12μl volume at 70°C . Reverse 
transcription was carried out in a final volume of 20μl by the addition of 10 mM 
DTT, 10 mM dNTPs and 200 U of Superscript II reverse transcriptase (Invitrogen) at 
37°C for 1 h 0.1 M NaOH was added to hydrolyse the RNA, and reactions incubated 
at 65°C for 20 min, before neutralising with 0.1 M HCl.  DNA was microdialysed for 
4 h on 0.025 μm nitrocellulose discs against TE to remove dNTPs and salt.  
Following dialysis the volume was adjusted to 20 μl with dH2O.  To add a poly A 
tail, first strand cDNA (20μl) was incubated with 2 mM dATP and 30 U of 
recombinant terminal deoxynucleotidyl transferase (TdT) (Invitrogen) at 37°C for 10 
min.  TdT catalyses the template-independent addition of dNTPs to the 3’ hydroxyl 
terminus of single stranded (ss) DNA. 10ng of primer 56 ( containing Ts at 3’ 
complementary to the added polyA) was added to 15μl tailed DNA  to synthesise the 
second strand cDNA. Two rounds of PCR reaction (summarized in Table 2.3) with 
nested LacZ primers (59, 80, and 79) followed by microdialysis steps on 0.1 μm 
nitrocellulose disks to size select larger PCR products, were used to amplify the 
specific 5’RACE product. These RACE products were directly sequenced (15μl 
RACE product & 4μl Big Dye) with a –40 LacZ sequencing primer (100ng) 
(ABISEQ, sequencing performed by MRC Human Genetic Unit sequencing service). 
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The sequence of the 5’-RACE product was compared with other sequences in 
Ensembl database using the BLAST algorithm. To assess the protein sequence for 
the GR-trapped gene, the SMART (Simple Modular Architecture Research Tool) 
was used.  
Table 2.2 Primers used in 5’RACE 












Figure 2.5 Primers used to identify the sequence of trapped genes by 5’RACE 
(adapted from Sutherland et al, 2001) 
 
 















Table 2.3 Nested PCR for 5’RACE 
PCR MIX PCR PROGRAMME 
1st round PCR:  
37μl cDNA, 5μl 10xbuffer, 4μl 25mM 
MgCl2, 1μl 10mM dNTPs, 100ng primer 
59, 100ng primer 80, 0.5μl ampliTaq.  
dH2O to final vol 50 μl 
94oC, 5min 
Cycles 30x ([94 oC, 90s], [60 oC, 90s], [72 oC, 
3min]) 
2nd round PCR: 
5 μl 1st PCR reaction, 5 μl 10xPCR buffer, 
4μl 25mM MgCl2, 1μl 10mM dNTPs, 
100ng primer 59, 100ng primer 79, 0.5μl. 
dH2O to final vol 50 μl 
94oC, 5min 




2.2.1.2 DNA methods 
2.2.1.2.1 Mouse genomic DNA extraction 
 
DNA was extracted using a commercial kit (DNeasy tissue extraction, Qiagen) 
according to the manufacturer’s instructions. Briefly, tissue samples (mouse ear 
biopsy) were incubated o/n at 55°C in lysis buffer with proteinase K (0.3mg/ml) 
(both provided in the kit). Genomic DNA was eluted in an appropriate volume of 
elution buffer provided (100μl per ear biopsy).  DNA was stored at -20 oC for further 
analysis. 
 
2.2.1.2.2 Genotyping of GR transgenic animals by PCR 
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PCR primers for LacZ genotyping were designed by Heidi Sutherland (MRC Human 
Genetics Unit, Edinburgh) and were 20 nucleotides in length with similar 
[G+C]:[A+T] ratios (H. Sutherland, personal communication). All genotyping PCR 
reactions were performed in 0.5 ml micro-centrifuge tubes in a volume of 25 μl. 
Reactions contained 1μl genomic DNA prepared from ear biopsy, 1U AmpliTaq® 
DNA polymerase (Applied Biosystems), 2.5μl 10x PCR buffer (supplied with the 
enzyme), 1.6μl of 2.5 mM MgCl2 (supplied with the enzyme), 2μl of 2.5mM dNTPs  
and 1μl of 25ng/μl each primer. The primer sequences and the respective 
amplification programme used in genotyping PCR is presented in Table 2.4. β-globin 
was used as an internal control (primers sequences in Table 2.4). For the genotyping 
of GR-/- mice, GR primers were designed (details in Table 2.4) that amplified a 
470bp product in wild type and heterozygous mice but not in the homozygous 
(discussed in section 4.2.2.1). 
 
2.2.1.2.3 Agarose gel electrophoresis 
  
2% (w/v) horizontal agarose gels in ½ xTBE (section 2.1.7) electrophoresis buffer 
were used to resolve cDNA PCR samples. Ethidium bromide (EtBr) was added to the 
molten agarose to a final concentration of 0.5 μg/ml to allow visualisation of the 
DNA under ultraviolet light (UV).  5μl loading buffer per sample (section 2.1.7) was 
added to each DNA sample before loading.  1kb of the DNA size markers (section 
2.1.7) were loaded into a well on each gel to enable the sizing and quantification of 
DNA fragments.  Stained DNA was visualized on a UV transilluminator at 260nm 
and imaged using UviPro 12.4 software. 
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Table 2.4 The primers and amplification programme for genotyping PCR 
 










GR primers for GR-/- genotyping  
GR F TGTTCCAACTGGTGAACTGACTG 
 
GR R TGTTACCAACTTCTAGCCACTGG 
β-globin primers  
Globin F CCAATCTGCTCACACAGGATAGAGAGGGCAGG 











2.2.1.2. Transfections  
All the plasmids used in the transfections assays (chapter 3) were generated by Val 
Lyons. Details of plasmids encoding the wild type GR and the GR-βgeo are provided 
in Appendix A with details of their construction. Transfections were performed as 
previously described (Bruley et al., 2006).  
 
2.2.1.3 Protein methods 
2.2.1.3.1 Total protein extracts from mammalian cells or tissues 
ESKN92 cells were grown in T25 flasks. Cells were washed once with PBS, lysed by 
the addition of 600 μl of cell lysis buffer and harvested by scraping from the surface 
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of the flasks. Total protein samples were filtered and stored at -20°C until required 
For epididymal fat tissue protein extraction, tissue samples were weighed and 50mg 
of tissue was homogenized in 600μl of protein extraction buffer. The homogenate 
was then centrifuged at 4krpm for 10 min at 4°C to remove any debris. The 
supernatant was then removed and 50μl aliquots frozen at -20°C for future use and 
protein quantification.  
 
Total protein concentration was measured by a Bio Rad protein assay. This is a 
colorimetric assay for protein determination. Sample concentrations were determined 
from a standard curve created from a series of Bovine serum albumin (BSA) 
dilutions, ranging from 0-1.2mg/ml. All samples were diluted according to the test 
assay and done in duplicated in 96 wells plates. 5μl of diluted samples and standards 
were added to each wells. 50μl of reagent A and 200μl of reagent B were added to 
each well. The plate was then incubated at room temperature for 15min before 
reading at a spectrometer at 750nm (Molecular device, OPTImax). The protein 
concentration was then determined off the standard cure. Typically, lysates contained 
1.5-3.0mg/ml protein. 
      
2.2.1.3.2 Resolution of proteins by SDS-PAGE and western blotting 
 
Proteins from ESKN92 (20-40μg total cell protein extracts) and 25μg of protein from 
epididymal fat tissue was adjusted to 6.5μl using ultra pure H2O and added to 6μl of 
a pre-prepared mix of 5μl NuPAGE® LDS sample buffer (Invitrogen) and 1μl of 
NuPAGE® Reducing agent (Invitrogen). Samples and 10μl of Plus2® pre-stained 
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protein standard (Invitrogen) were incubated at 70 ºC for 10 min to denature the 
protein. Samples were loaded onto a 4-12% (for ESKN92, 5-8% resolving and 4% 
stacking gels were used) Bris-Tris Novex® pre-cast Gel (Invitrogen) which locked to 
the buffer core in a vertical electrophoresis tank. The inner chamber filled with 
200ml of 1x Novex® MOPs running buffer (Invitrogen) and 500μl of NuPAGE® 
antioxidant (Invitrogen) and the outer chamber filled with 600ml of 1x Novex® 
MOPs running buffer. Samples were electrophoresed at 200V until the Bromophenol 
blue band had migrated to the bottom of the gel. Gel was then removed form plastic 
cassettes and proteins transferred from the gel to a nitrocellulose membrane using a 
wet transfer system. Transfer was effected at 30V for 90min. Following transfer, the 
membrane was rinsed in ultra pure H2O and left dry on Whatman No.3 filter paper. 
 
To reduce non-specific antibody binding, the membrane was rehydrated with 1xTBS 
for 5 min, then incubated with blocking solution (1xTBS, 5% Blocking grade blocker 
(Bio-rad), 0.1% Tween) for 1h at RT or overnight at 4°C with agitation. The 
blocking solution was then removed and the membrane was incubated with primary 
antibody diluted (Table 2.5) into blocking buffer for 2h at room temperature with 
agitation. Next, the membrane was rinsed in blocking solution three times, each for 
10 min then incubated with agitation for 2h at room temperature with secondary 
antibody (Table 2.5) diluted into blocker buffer. Finally, the membrane was rinsed in 
1x TBS for 15 min, followed by three washes in 1x TBS each for 5min. Protein 
bands were visualized by incubating the membrane in 1ml of ECL detection mix 
(reagent1:2 50:50; ECL kit- Amersham Biosciences UK) for 1 min before exposing 
against autoradiographic film for 5min and then developing. Autoradipgraphs were 
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scanned using scanner and quantitated using Aida software (Advance image data 
analyzer Version 3.44.035). In ESKN92, positive/negative control, depending on the 
antibody used (GR/βgal, respectively) rat liver protein extract was also examined. 
Table 2.5 Primary and secondary antibodies used in Western Blots 
ANTIBODY SPECIES DILUTION SOURCE 
   
Rabbit polyclonal 1:400 Santa Cruz Biotechnology, UK 
Primary: 
Anti-GR (M-20) 
Anti-βgalactosodase Rabbit polyclonal 1:2000 Europa Bioproducts 
Secondary: 







Amersham Biosciences, UK 
 
 
2.2.2 Embryonic Stem Cell Culture 
2.2.2.1 Maintenance of cell lines 
ESKN92 and E14 (parental WT) ES cells were frozen in 10% DMSO/90%FCS, and 
stored in cryotubes in liquid N2.  To retrieve cell lines from liquid N2, cells were 
rapidly thawed and centrifuged in culture medium to remove the DMSO. Then cells 
were  seeded into T25 cm2 culture flasks coated with 0.1% gelatin (Sigma, G-1890), 
prepared by firstly layering a solution of 0.1% gelatin in PBS over the bottom of the 
flask and aspirating off before adding cells and media. 
 
All cells were incubated at 37°C in 5% CO2 and tissue culture medium as described 
in Table 2.6.  ES cells were grown in Glasgow Modified Eagle Medium (GMEM, 
Invitrogen™) with supplements (Table 2.6) as described (Smith et al. in 1988). Cells 
were grown to near confluence before splitting into fresh tissue culture flasks coated 
in gelatin if required.  To split the cells, medium was poured off, flasks were rinsed 
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with PBS and monolayers were then covered with 1.5 ml of trypsin-EDTA and 
incubated at 37°C for 5 min.  Gentle agitation dislodged the cells, fresh medium was 
added, and the cells pelleted at 1000 g for 5 min before being replated or harvested 
for experiments. 
 
Cells were counted before seeded at the relevant density onto microscope slides for 
immunofluorescence (ES cells, 106 cells per slide). Slides were prepared by soaking 
in 100% ethanol before being left to dry in QuadriPerm slide chambers (2.1.5) inside 
a laminar flow cabinet. The slides were coated with gelatin for growth of ES cells. 
 
Table 2.6 Sources and maintainance of ES cells  
ES CELL 
LINES  







wt mouse ES cell, 
(129/Ola).   
 
 
Gene trap insertion 







GMEM, 10% FCS (v/v), 
100 U/ml LIF (prepared 
in house, MRC HGU, 
Edinburgh, pers. com.),  2 
mM glutamine, 50 μM β-
ME, 100 mM sodium 
pyruvate (Sigma), 1% 
NEAA (non-essential 












2.2.2.2 In vitro differentiation of ES cells (Strickland and Mahdavi, 1978)  
 
Cells were passaged as described (section 2.2.2.1), seeded (104 cells/cm2) onto 
gelatin-coated flasks and were grown overnight in normal media.  The next day, cells 
were rinsed with PBS and the media changed to LIF free medium supplemented with 
5x 10-6 M retinoic acid (all-trans-retinoic acid, stock solution 3.3x 10-3 M in DMSO, 
stored in the dark at -20°C).  The retinoic acid containing medium was renewed 
every 24h for a period of four to six days following induction. 
 
2.2.2.3 Fluorescence in situ hybridization (FISH) of ESKN92 cells 
2.2.2.3.1 Cell fixation in 3:1 methanol: acetic acid 
 
Cells for two-dimensional (2-D) fluorescence in situ hybridisation (FISH) were 
prepared as follows: cells were harvested and resuspended in 10ml hypotonic 
solution (0.033 M KCl, 0.017M tri-sodium citrate), which was added drop-wise with 
constant agitation (the concentration of cells should be <2x 107/ml).  The cells were 
left to swell for 10min at RT before centrifugation at 400g for 5min.  Cells were then 
fixed in fresh 3:1 methanol:glacial acetic acid (MAA), again added drop-wise with 
constant agitation before incubating on ice for 20min.  After centrifugation, the cells 
were resuspended in 8ml of MAA and the cells placed at 4°C o/n.  Cells were fixed 
twice more and stored indefinitely at -20°C.  
 
2.2.2.3.2 Preparation of FISH probes 
2.2.2.3.2.1 Nick translation 
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DNA was labelled using biotin-16-dUTP or digoxigenin-11-dUTP incorporation by 
nick translation.  1-1.5μg of DNA was added to 4μl 10x nick translation salts (0.5M 
Tris-HCl [pH7.5], 0.1M MgS04, 1mM DTT, 500μg/ml BSA), 4μl each of 2mM 
dATP, dGTP and dCTP, 2μl of 0.5mM dTTP and 4μl biotin-16-dUTP or 
digoxigenin-11-dUTP (Roche).  DNase I was added to a final concentration of 1U/ml 
along with 1μl of T4 DNA polymerase I (Invitrogen™, 10 U/μl).  The total volume 
was made up to 40μl with dH20 and mixed thoroughly before being incubated at 
16°C for 90min.  The reaction was terminated by placing at -20°C or immediately 
processed for the removal of unincorporated label. Quick Spin columns (Roche) 
containing G-50 Sephadex beads were used in accordance with the manufacturer’s 
instructions to remove any free biotin-16-dUTP, digoxigenin-11-dUTP or dNTPs 
remaining in the solution.  Cleaned probes were eluted in 40μl TE (pH 8). 
2.2.2.3.2.2 Quantification of label incorporation 
 
Gridded nitrocellulose membranes were prepared by brief soaking in dH20 followed 
by 20x SSC for 10min.  Labelled DNA probes were diluted to 1x10-3 and 1x10-4 in 
TE and 1 and 2μl of each were spotted onto the gridded membrane.  On the same 
membrane 20, 10, 2 and 1 pg of labelled lambda DNA standards (Roche) were also 
spotted.  DNA was cross-linked onto the membrane by exposure to 30mJ of UV 
irradiation. The membrane was immersed in buffer 1 (0.1M Tris-HCl [pH7.5], 
0.15M NaCl) for 5min at RT, then blocked in 5% Marvel (w/v) in buffer 1 at 37°C 
for 30min.  10μl streptavidin-alkaline phosphatase (Boehringer) and/or anti-
digoxigenin-alkaline phosphatase (Boehringer) were added to 10ml of buffer 1 and 
placed in a sealed polythene bag with the membrane for 30min at RT.  The 
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membrane was washed twice in buffer 1 then equilibrated for 5min in 0.1M Tris-HCl 
(pH 9.5).  The colour reaction was developed by incubation of the membrane in a 
sealed polythene bag, with 5ml of 0.1M Tris-HCl (pH 9.5) and two drops from 
bottles 1-3 from the alkaline phosphatase substrate kit IV (Vector).  The substrates in 
this colour reaction are 5-bromo-4-chloro-3-indolyl phosphate and nitroblue 
tetrazolium, which produce a blue reaction product.  A complete colour reaction was 
observed within a few hours of incubation at RT in the dark and an estimate of the 
concentration of DNA labelled probe was made by comparison with known lambda 
standards. 
 
2.2.2.3.2.3 The FISH protocol  
2.2.2.3.2.3.1 Slide preparation 
Glass slides were stored in a dilute solution of HCl in ethanol and were dried and 
polished with muslin before use.  MAA fixed cells (section 2.2.2.3.1) were removed 
from storage at -20°C and centrifuged at 400g for 5min.  Fresh MAA fix was added 
until the cell suspension reached a ‘milky’ appearance.  One drop of suspension from 
a fine tipped pastette was dropped onto a horizontal microscope slide from a 30cm 
height (the best chromosomal spreads were achieved when the air humidity was 
~50% and by breathing on the slides initially). Slides were stored for 2-6 days prior 
to hybridisation. 
 
2.2.2.3.2.3.2 Hybridisation and detection of FISH signal 
Slides were treated with 100μg/ml RNaseA in 2x SSC for 1h at 37°C, washed briefly 
in 2x SSC and dehydrated through an ethanol series (2min each in 70%, 90% and 
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100% ethanol).  Slides were dried under a vacuum for 10min before being heated in 
a 70°C oven for 5min and immediately denatured in 70% formamide (v/v) in 2x SSC 
(pH 7.8) at 70°C for 1-2min.  Slides were plunged in 70% ethanol at 4°C for 2min 
before dehydration through 90% and 100% ethanol. 
Labelled probes (section 2.2.2.3.2) were prepared by precipitation of ~75 ng probe 
with 5μg salmon sperm DNA and mouse Cot 1 DNA (Invitrogen™, 2.5-10μg 
depending on repeat content of probe).  After the addition of 2x vol of ethanol, 
probes were centrifuged under a vacuum before resuspension in 10μl hybridisation 
mix (50% deionised formamide [v/v], 10% dextran sulphate [v/v], 1% Tween 20 
[v/v], in 2x SSC) or 13μl of commercial mouse chromosome paints supplied in 
hybridisation buffer (Cambio).  All probes were denatured at 70°C for 5min and 
reannealed at 37°C for 15min before being spotted onto coverslips and picked up by 
the slides.  Slides were sealed with rubber solution (TipTop) before incubation o/n in 
a covered tray in a 37°C water bath. 
 
Rubber solution was removed from the slides and they were immersed in 2x SSC at 
45°C for 4 x 3min.  The coverslips fall off naturally.  Slides were washed a further 4 
x 3min in 0.1x SSC at 60°C before transfer to 0.1% Tween 20 [v/v] in 4x SSC.  
Detection was carried out in a moist chamber pre-heated to 37°C.  Biotin was 
detected with sequential layers of fluorochrome-conjugated avidin (FITC- or TxR- 
avidin), biotinylated anti-avidin, and a further layer of fluorochrome-conjugated 
avidin.  Digoxigenin was detected with sequential layers of Rhodamine (R)-
conjugated anti-digoxigenin and TxR-conjugated anti-sheep IgG.  Detection reagents 
 98
were diluted in SSCM (4x SSC, 5% Marvel milk powder [w/v]) to the appropriate 
concentration (Table 2.7).  After blocking with 40μl of SSCM for 5min at RT, 40μl 
of the appropriate detection layer was applied to each slide.  Slides were incubated in 
the same way at 37°C for 60min followed by 3 x 2min washes of 0.1% Tween 20 
[v/v] in 4x SSC at 37°C.  All slides were mounted in 0.5 μg/ml of DAPI in 
Vectashield.  Coverslips were sealed with rubber solution (PANG) and slides were 
stored in the dark at 4°C until imaged.  
 
The probe to detect pGT-3 DNA (the gene trap vector; Sutherland et al., 2001; 
details in Appendix, fig. A4) was labelled with digoxygenin-11-dUTP (DIG) and the 
probe to detect GR DNA (a 6 kb genomic clone located at the 5’ end of the gene, gift 
from H. Reichardt; details in Appendix, fig. A.5) was labelled with biotin-16-dUTP. 
A  mouse chromosome 18 paint, pre-labelled with biotin-16-dUTP was also used to 
distinguish chromosome 18 from the rest of the chromosomes. DIG was detected 
with Rhodamine-conjugated anti-digoxigenin primary antibody followed by Texas 
Red-conjugated anti-sheep IgG. Biotin was detected with fluorochrome-conjugated 
avidin (FITC), biotylated anti-avidin antibody followed by a further layer of 
fluorochrome-conjugated avidin. 
 
2.2.2.4 Immunofluorescence on fixed cells 
Mammalian cells were grown on slides as described (section 2.2.2.1). For the 
dexamethasone (DEX) experiments, ESKN92 or WT (ES14; parental ES cell line) 
cells were maintained in glucocorticoid-free (FCS treated with charcoal to remove 
GC) medium for 24h. The next day the cells were treated for 10min with 1μM DEX, 
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a synthetic glucocorticoid, and then immediately fixed and immunostained. All 
subsequent incubations were performed at RT.  Slides were rinsed in PBS containing 
1.5mM MgCl2 and 1mM CaCl2 and fixed for either 10 or 20min in 4% or 3% 
paraformaldehyde (pFa) (w/v) in PBS respectively.  All steps were performed with 
PBS containing Mg2+ and Ca2+.   




SPECIES SOURCE STOCK 
(MG/ML) 
DILUTION 
FITC-avidin Goat Vector 2.0 1:500 
TR-avidin Goat Vector 2.0 1:500 
Biotinylated anti-
avidin 
Goat Vector 0.5 1:100 
R-anti- digoxigenin Sheep Roche 0.2 1:20 
TR-anti-sheep (IgG, 
H&L) 
Rabbit Vector 0.5 1:100 
 
After a further 3 washes in PBS, the slides were quenched in 50mM NH4Cl in PBS 
for 10min and permeabilised for 12min in 0.1% Triton X-100 (v/v) in PBS.  Slides 
were washed a further 3 times in PBS before blocking in 5% donkey serum (v/v) in 
PBS for 20 min.  Slides were then incubated o/n in moistened chambers with primary 
antibody (diluted in 5% block) under a parafilm coverslip (Table 2.8).  After 
washing, slides were incubated in secondary antibody (Table 2.8) diluted in the same 
way but with incubation for 1h.  All secondary antibodies were species-specific 
fluorescein isothiocyanate (FITC) or Texas Red (TR) conjugates obtained from the 
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Jackson Laboratories or Vector Lab. Secondary antibody was washed as above and 
all slides were mounted with 0.5 μg/ml 4,6-diamidino-2-phenylindole (DAPI) in 
Vectashield (Vector). Coverslips were sealed with rubber solution (PANG) and 
slides were stored in the dark at 4°C until imaged (section 2.2.2.5). 
Table 2.8 Primary and secondary antibodies used in immunofluorescence  
















conjugate (IgG, heavy 










2.2.2.5 Fluorescence imaging of cells or nuclei  
 
2-D FISH slides or immunofluorescence experiments were examined using a Zeiss 
Axioplan fluorescence microscope (MRC HGU microscope facility, Edinburgh) both 
with 100 watt mercury bulb, and equipped with a triple band-pass filter (Chroma # 
83000).  Images were collected with a cooled CCD camera depending on the model 
of microscope (Pentamax with a Kodak KAF 1400 sensor or Micromax with Kodak 
KAF 1400e sensor respectively, Princeton Instruments) using IPLAB software v. 3.6 
(Scanlytics, USA).  
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2.2.3. Animals 
2.2.3.1 Pomc-null mice  
 
Pomc-null tissues were provided by Dr Tony Coll (University of Cambridge).  The 
animals were generated on a 129/SvEv background and maintained as described 
(Challis et al., 2004; Coll et al, 2005). Eight week-old male mice (n=5/group) were 
treated with corticosterone (25μg/ml) in their drinking water, a dose that  results in 
similar plasma glucocorticoid levels and hypothalamic CRH mRNA levels in Pomc-/- 
and wild type mice (Coll et al. 2005). All animal protocols used in these studies were 
approved under the auspices of the UK Home Office Animals (Scientific Procedures) 
Act, 1986. Animals were killed between 8:00 and 9:00am by cervical dislocation. 
Trunk blood samples were collected into EDTA coated tubes (Sarstedt, Germany), 
centrifuged (6000g x 10min) and plasma stored at -80 C until required for assay. 
 
2.2.3.2 B6N92 mouse line generation 
 
Blastocyst injection of embryonic stem cells (ESKN92) and generation of chimeric 
mice was carried by the transgenic service (BRR, Phase I, Edinburgh University). 
Genomic DNA form chimeric mice was tested for the presence of the pGT1-3 
transgene by PCR amplification using primers that amplify a 413 bp fragment within 
the LacZ gene (section 2.2.1.2.2).  Chimeras were mated to C57BL/6 female mice to 
achieve germ line transmission, and further backcrossed to C57BL/6 to generate an 
inbred colony. The conony was maintained as heterozygous (GR+/-) by backcrossing 
to C57BL/6.  To generate GR-/-, F3 or F7 GR+/-mice were intercrossed.   
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2.2.3.3 Housing and diets 
 
Animals were housed in standard cages with controlled lighting (12h light: 12h dark, 
lights on at 7am), and were fed standard chow from weaning. For unstressed plasma 
corticosterone, ACTH and glucose sampling experiments, animals were acclimated 
to single housing and tail nicks performed within 1min of disturbing the cage. For 
diet induced obesity (DIO) experiments mice were weaned on either high fat diet 
(58% kcal as fat, D12331; Research Diets, New Brunswick, NJ) or a low fat diet 
(11% kcal as fat, with corn startch, D12328; Research Diets). These diets are not 
isocaloric, the LF is 4.07kcal/g, the HF is 5.56kcal/g. Information on the exact 
composition of the diets can be found in http://www.researchdiets.com/. Mice 
remained on the diet for 22 weeks with ad libitum access to water and diet. Body 
weight was monitored weekly throughout the experiment and food intake was 
measured using singly housed mice for 3 weeks. Mice were culled by decapitation 
between 8-10 am.  Tissues were rapidly frozen in dry ice for RNA or protein analysis 
or in formalin for histology. 
 
2.2.3.4 Biochemistry 
2.2.3.4.1 Hormone Assays  
 
For morning corticosterone and ACTH measurements, animals were killed between 
0800 and 0900h by decapitation. Trunk blood samples were collected into EDTA 
coated tubes (Sarstedt, Germany), centrifuged (6000g x 10min) and plasma stored at 
-80oC until required for assay. Evening corticosterone was sampled between 19:00 
and 20:00 pm. 
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2.2.3.4.1.1 Corticosterone (B) Assay 
 
B levels were measured by an in-house radioimmunoassay, in which unlabelled 
sample B and [3H]-B compete for anti-B antibody. The concentration of B in each 
sample was determined from the standard curve. However, this method is not a 
quantitative method for determining free plasma B levels, since B is dissociated from 
CBG in the assay procedure. It therefore measures total B concentration. 
 
Plasma samples were diluted (1:10 for am cort and for the 120min after restraint time 
point, 1:20 for pm CORT and for the 20min after restraint stress time point) in borate 
buffer and heated at 65°C for 30min to denature CBG and allow dissociation of B. A 
series of B standards were prepared (0-320nM) to allow production of a standard 
curve. Samples and standards were incubated in duplicate in flexible 96-well plates 
with a mixture of [3H]-B (10,000cpm added per sample) and B antibody (1 in 10,000 
dilution of rabbit anti-rat B antiserum in borate buffer; kindly provided by Dr. Chris 
Kenyon) in borate buffer in a total volume of 70μl for 1h at 37°C. Anti-rabbit 
scintillation proximity assay beads were then added to each sample and the plates 
sealed and incubated overnight at 37°C. The beads bind to the primary antibody and, 
if the primary antibody is bound to [3H]-B, the radioactive signal is detected by the 
beads in close proximity and the resulting scintillation signal detected by β-
scintillation counter, and analysed using Multicalc software. The inter- and intra-
assay coefficients of variation were <10%, and the detection limit was 0.15μg/dl. 
 
2.2.3.4.1.2 ACTH Assay 
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 ACTH was measured with an enzyme-linked immunosorbent (ELISA) commercial 
assay (Biomerica, Newport Beach, CA), according to the manufacture’s instructions. 
Briefly, the assay measures the biologically active 39 amino acid chain of ACTH by 
a 2-site ELISA. The assay uses, a biotinylated goat polyclonal antibody to human 
ACTH (binds the C-terminal 34-39aa of ACTH) and a horseradish peroxidase- 
labelled mouse monoclonal antibody to human ACTH (binds the mid-region and N-
terminal 1-24aa of ACTH) the latter used for detection. 200μl of plasma samples, 
calibrators (0, 5, 18, 55, 165 and 500pg/ml) and controls (33 and 150pg/ml) were 
incubated (for 4.5h at RT on an orbital shaker) with the enzyme labelled antibody 
and a biotin coupled antibody in a streptavidin-coated microplate well. At the end of 
incubation, the microwell was washed to remove unbound components and the 
enzyme bound to the solid phase was incubated with the tetramethylbenzidine 
(TMB) substrate for 30min at RT, in an orbital shaker. An acidic (sulfuric acid) 
solution (provided in the kit) was then added to stop the reaction and converts the 
colour to yellow. The intensity of the colour is directly proportional to the 
concentration of the ACTH in the sample. The absorbance at 450nm was read within 
10min of adding the stop solution. A dose response curve of absorbance vs 
concentration was generated from the calibrators and the sample concentration was 
calculated by point-to-point interpolation. The sensitivity or minimum detection limit 
of this assay is 0.46pg/ml.    
 
2.2.3.4.1.3 Renin and angiotensinogen assays 
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Renin and angiotensinogen assays were developed in house (by Dr Chris Kenyon), 
and involve radioimmunoassay of angiotensin I generated from renin + 
angiotensinogen. Plasma renin activity, plasma renin concentration and 
angiotensinogen concentration were measured.   
 
For quantitative conversion of plasma angiotensinogen to angiotensin I, a small 
aliquot (1μl diluted plasma) of plasma is incubated with excess renin. Depending on 
the concentration of plasma angiotensinogen, which varies between mouse strains, 
plasma was diluted (1:5) with Tris buffer (section 2.1.7). The excess renin was either 
from mouse kidney or submaxillary glands and was prepared (by Dr Chris Kenyon) 
by homogenising tissues with 5vol of Tris and using the resultant supernatant after 
centrifugation (105,000g for 60min). The amount of renin added to the assay must be 
optimised. Addition of excess renin causes complete conversion of angiotensinogen 
to angiotensin I, even at 0˚C, whereas addition of too little renin causes the reaction 
to be incomplete. The optimised Ang I generating system for measuring 
angiotensinogen in these studies was 1μl dilute plasma + 9μl renin extract (a 100 fold 
dilution of cytosol from submaxillary glands). Plasma renin concentration measures 
the generation of angiotensin I when plasma is incubated with excess 
angiotensinogen. Plasma was diluted 5-fold with Tris buffer and incubated with 
plasma from a binephrectomised rat  (BNX) which contains no renin but high 
angiotensinogen levels (prepared by Dr Chris Kenyon). The optimised Ang I 
generating system for measuring plasma renin concentration in these studies  was 1μl 
dilute plasma + 9μl BNX. Plasma renin activity measures angiotensin I generated 
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from endogenous renin and endogenous angiotensinogen. The optimised angiotensin 
I generating system used in these studies was with 10μl undiluted plasma.  
Briefly the assay protocol was as follows: In 10μl Ang I generating system or 
standards (400pg/10μl, double dilutions with Tris), 10μl Ang I antibody in RIA cups 
(x4 tubes) was added at 0°C. The samples/standards were then centrifugated at 
2000rpm for 1min.  2 of 4 tubes were incubated at 0° and the other 2 tubes at 37 °C 
for 30min with shaking. Following, 150μl Tris (0°C) containing approx 4-5000cpm 
125I-Angiotensin I (section 2.1.3) was added and briefly agitated. All samples were 
incubated at 2°C for 18h. The next day, separation was carried by using 250μl of 
charcoal suspension (section 2.1.7), following samples were centrifugated at 3000 
rpm for 15min, the supernatant was aspirated and  the free charcoal pellet was 
counted. 
 
2.2.3.4.2 Glucose and insulin tolerance tests 
 
For glucose tolerance tests (GTT), animals were fasted for 6h and  2mg/g body 
weight D-glucose was injected (from a 25% D-glucose solution) intraperitoneally 
(ip). Blood sampling (a drop) was performed from a tail venesection at time 0 (prior 
to injection), 15, 30, 60 and 120min after injection. For insulin tolerance tests, fasted 
(6h) animals were injected ip with 1mU/g BW (females) or 1.5mU/g BW (males) 
human insulin (Humulin 100IU/ml, Lilly) and blood sampling was taken from a tail 
venesection at time 0, 15, 30 and 60min after injection. Plasma glucose was 
measured using a Glucose Monitoring System (One Touch Ultra, Lifescan, Johnson 
& Johnson) or a glucose assay in a 96 well plate as follows. Duplicates of 20μl of 
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plasma, or a series of dilutions from the stock glucose solution used to generate a 
glucose standard curve (0, 50, 100, 150, 200, 250, 300, 400 mg/dL, were incubated 
with 250μl of Thermo-infinity hexokinase reagent (Alpha Laboratories) for 5 min. 
The reagent causes the glucose present in the sample to be phosphorylated and 
NADH is generated, and consequently absorbance of the latter is measured at 340nm 
using a spectrophotometer. Sample concentrations (mg/dL) were extrapolated from 
the standard curve. 
 
2.2.3.4.3 Lipid Assays and Hepatic Tissue Morphology 
 
Hepatic triglycerides (TG) were extracted following homogenisation of 100mg of 
liver in isopropanol (10vol) and then incubation for 45min at 37oC. Following 
centrifugation (3000g x 10 min), 10μl supernatant was incubated at 37oC for 5min 
with 1ml Thermotrace triglyceride reagent (Alpha Laboratories, Hampshire, UK) and 
absorbance at 500nm was spectrophotometrically measured. A blank and a 
triglyceride calibrator or standard (2.5mmol/l) provided in the kit were also included 
in the assay. Sample triglycerides were calculated using the following formula: Liver 
TG=absorbance of the sample/absorbance of calibrator x2.5x10, where 2.5 is the 
concentration of calibrator and 10 the volume of isopropanol used. 
Levels of non-esterified fatty acid (NEFA) and triglyceride levels were determined 
by commercial kits (NEFA, Roche Diagnostics, West Suffolk, UK; triglyceride, 
Dade Behring, Marburg, Germany). 
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Neutral lipids, cholesterol and fatty acids were identified by light microscopy at  x 40 
magnification in cryostat liver sections (30μm) stained with Oil red O (Sigma) and 
counter-stained with haematoxylin. Briefly, frozen liver sections were rinsed in H2O, 
then 60% (v/v) isopropyl alcohol and stained for 10min with Oil Red O (section 
2.1.7). Following, sections were washed briefly in 60% isopropyl alcohol and then 
washed well in H2O. After washes, sections were stained with haematoxylin for 1min 
washed in 1%(v/v) ammonia for 30sec, briefly washed in H2O and mounted.   
 
2.2.3.5 Blood pressure measurements  
 
In the Pomc-null experiment (chapter 6) blood pressure was measured by Dr Tony 
Coll (Cambridge). Systolic blood pressure was measured photoelectrically in the tail 
of restrained conscious mice using an IITC model 179 analyser (Woodland Hills, 
California, USA). In the GR+/- experiment (chapter 5) blood pressure was measured 
by Dr Elaine Marshall (Endocrinology Unit, Edinburgh) using IITC Non Invasive 
Blood Pressure measuring system (Harvard Apparatus, Edenbridge, Kent, UK. Prior 
to recording measurements, all mice underwent 3 periods of training to acclimate 
them to the procedure.  
 
Non-invasive blood pressure (BP) measurements were determined by detection of 
return of tail pulsations (RTP) using tail cuff plethysmography, which can reliable 
detect systolic BP within <5mmHg in concordance with inter-arterial measuring 
systems.  The computerised RTP-computerised model was calibrated for sensitivity 
(maximum inflation, rate of deflation) and programmed to measure four single 
 109
inflation/ deflation cycles per experimental recording (giving eight measurements).  
The tail cuff plethysmographam has an integrated sensor-cuff occluder inflation and 
detects the return of tail pulsations passing through the occluder cuff on each 
deflation cycle.  This method has been validated by several methods, more recently 
by radiotelemetry (Pfeffer, 1971; Whitesall et al, 2004).  Variability in testing was 
minimized by: 1) a conditioning period of 3-5 days where mice restrained without, 
and then eventually with, BP being measured with tail cuff inflation to familiarise the 
mice to the procedure prior to commencing treatment and BP is recorded at the 
approximate normal level for a C57BL6 mouse (by use of 20-30 consecutive 
inflation and deflation cycles if tail cuff balloon and using the average) 2) other 
measures to reduce alarm reaction  of mice were the use of a quite room with 
dimmed lighting and measurements taken at the same time of each day, by the same 
person. Blood pressure was recorded as follows.  After 5-10 minutes in a heated 
chamber (30-35oC), mice were placed on the heated blood pressure platform and held 
in place with an opaque restraining chamber.  The mean arterial blood pressure (mm 
Hg) and pulse rate (beats per minute) was recorded for each mouse. Data 
measurements were averaged and presented as mean arterial pressure (MAP).   
 
2.2.3.6 Tissue morphology 
 
Tissues were fixed in formalin and processed for histopathology. The left adrenal 
was sectioned (4μm) and stained with haematoxylin and eosin (H&E) by the 
histology service (QMRI, University of Edinburgh) for histopathological 
examination.  
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2.2.3.7 Tissue fixation and X-gal Staining 
 
X-gal staining to detect β-galactosidase activity was carried out on frozen coronal 
brain sections and whole embryos. Embryos were washed twice at RT for 15 min in 
wash solution (0.05% BSA [w/v], 2mM MgCl2, 0.02% NP40 (v/v), 0.1% sodium 
desoxycholate [w/v] in 0.1M phosphate buffer) before staining. Brain sections were 
transferred directly from -80ºC into fixative (4% paraformaldehyde, 0.02% NP40, 
0.01% sodium deoxycholate, 5mM EGTA, 2mM MgCl2) for 15min at 4ºC, washed 
twice in PBS containing 2mM MgCl2, 0.02% NP40, 0.01% sodium deoxycholate and 
stained for 6h in PBS containing 2mM MgCl2, 0.02% NP40, 0.01% sodium 
deoxycholate, 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 1mg/ml 
X-gal, protected from light. Staining solution was removed and the samples stored in 
PBS until required.  Embryos or brain sections were visualised with a conventional 
light microscope. 
 
2.2.4 Human Study 
2.2.4.1 Subjects 
 
Informed, written consent was obtained from 21 women undergoing elective, 
laparascopic tubal ligation surgery; the study which was approved by the Mayo 
Clinic IRB. Tubal ligation surgery is done routinely in the follicular phase of the 
menstrual cycle to eliminate the risk of pregnancy. Prior to surgery, body 
composition was assessed by measuring weight, height, body fatness (% fat) using 
dual x-ray absorptiometry (DEXA; DPX-IQ; Lunar Radiation, Madison, WI) and 
abdomial fat distribution using a single sliced computerized tomography scan at the 
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L2-3 level as described (Jensen et al., 1995; Jensen et al., 1993). Visceral and 
subcutaneous adipose tissue areas were calculated as previously described (Jensen et 
al., 1993). All the data were kindly provided by Prof Michael Jensen (Mayo Clinic, 
Rochester, USA). Although 8 of 21 subjects were taking oral contraceptives (OC), 





Fasting plasma triglycerides, glucose and insulin levels were assayed as previously 
described (Jensen et al., 2003). HOMA-IR was calculated by the equation [fasting 
insulin (μU/ml) x fasting glucose (mmol/L)/22.5] (Matthews et al., 1985). All the 
data were kindly provided by Prof Michael Jensen (Mayo Clinic, Rochester, USA). 
 
2.2.4.3 Adipose tissue Biopsies 
 
Tissues were provided by Prof M. Jensen (Mayo Clinic). Subcutaneous fat from 
abdominal (n=13), thigh (n=16) and gluteal (n=18) regions were collected just prior 
to surgery and omental (n=21) adipose biopsies were obtained intra-operatively. Fat 
cell size (mean diameter of mature adipocytes in μm) was determined using the 
AdCount (Biomedical Imaging Resource, Mayo Clinic) approach as previously 
described (Tchoukalova et al., 2003) and data were provided by Prof Michael Jensen. 
For RNA, biopsies were washed to remove blood and then snap frozen in liquid 
nitrogen and stored at -80oC. Biopsies were homogenized in 1-2mls Trizol®, RNA 
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was extracted, quantified and integrity verified as described in section 2.2.1.1. Real 
time PCR was performed and analysed as described in section 2.2.1.1.4.  
 
2.2.5 Computational methods and Statistical analysis 
 
The Bioinformatics programmes and resources, with their website addresses, used in 
this thesis are listed below.  
Ensembl                                    http://www.ensembl.org/ 
NCBI (BLASTN/P, TBLASTN)            http://www.ncbi.nih.gov/BLAST/ 
NCBI (Entrez)    http://www.ncbi.nlm.nih.gov/Entrez/index.html 
SMART       http://smart.embl-heidelberg.de/ 
NURSA                                                                        http://www.nursa.org 
GraphPad                                           http://www.graphpad.com/quickcalcs/index.cfm  
                          
For the statistical analysis of the data obtained in this thesis, 2 main statistical 
software were used, Sigma Stat 3.1 and GraphPad Prism 4. Comparisons between 2 
groups (heterozygous vs control mice), was done by Students t-test. For the effect of 
genotype x treatment (either CORT or diet), 2-way ANOVA followed by post-hoc 
Tukeys’ tests for group differences. For GTT or ITT comparisons, the area under the 
curve (AUC) was calculated for every animal and then the means of groups 
compared with either Students t test (genotype comparisons) or 2-way ANOVA 
(genotype x diet). For the analysis of data obtained in the human study (chapter 7), 
repeated measures ANOVA followed by post hoc Tukey test were performed to 
determine differences in transcript levels in paired adipose compartments. Pearson 
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correlation was performed to examine the relationships between anthropometric and 
metabolic parameters with 11βHSD1 or GRα mRNA levels in different fat depots 
according to a priori hypotheses to minimize multiple interdependent. Multiple linear 
regression was performed to test if relationships between fat cell sizes or 
triglycerides with transcript levels are independent of obesity.  In the transfection 
experiments, analysis was performed as follows. After subtraction of background 
levels (determined from Gem negative controls), reporter activity (firefly luciferase) 
was divided by the internal standard (renilla luciferase) to control for variation in 
transfection efficiency and cell number in each sample. Data from separate 
experiments were combined by arbitrarily setting the empty vector value in absence 
of dexamethasone (DEX) equal to 1 for the PNMT data. MMTV data set the value of 
wild type GR in the absence of DEX equal to 1 (as empty vector data were not 
available). Values are means± SEM of 9 individual transfections (from 3 
experiments, each carried out in triplicate), and data analysed for statistical 
significance by one-way ANOVA.  All data presented in this Thesis was tested for 
normality and were normalized by log transformation where appropriate. 
Significance was set at p<0.05. Values are means ± SEM. For full details of 
statistical analysis please refer to figure legends in each chapter. The details of the 





Characterization of GR “Trapped” cells 
(ESKN92) 
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3.1 Introduction and Aims 
3.1.1. What is gene trapping:  advantages & limitations 
The International Gene Trap Consortium provides a thorough overview/tutorials 
regarding gene trap technology (http://www.genetrap.org/tutorials/overview.html).  
Briefly, gene trapping is a method of randomly generating embryonic stem cells with 
insertional mutations by inserting a gene trap vector construct into an intronic or 
coding region of genomic DNA (Skarnes et al., 1992). The gene trap vector 
constructs contain selectable reporter tags (ie lacZ) that provide the advantage of 
easily identifing cell lines where the vector has successfully interrupted a gene. 
Additionally, if the tag expression  mimics that of the endogenous gene, then 
monitoring the tag-fusion gene activity in cells, tissues or the whole organism (ie 
embryos) would enable easy visualization of the endogenous gene expression in an 
organ of interest in any developmental stage or during disease (Skarnes et al., 1992). 
Furthermore, gene traps seem to represent a more powrful insertional mutagenes 
(than other transgenes), since (a) the tag-endogenous gene fusion products may 
interfere with the normal coding capasity of the endogenous gene and generate a 
mutation (Skarnes et al., 1992) and (b) is less labor-intensive because cloning a 
portion of endogenous gene from the tag-fusion transcript limits the time-consuming 
process of searching for exons in flanking genomic DNA (Skarnes et al., 1992). 
Gene trap sequences are derived from cDNA or genomic DNA from the trapped 
locus using primer sequences from vector ends. These  sequences are used to identify 
and annotate the trapped gene (Skarnes et al., 1992 and http://www.genetrap.org). 
Gene trap cell lines are used to produce mutant mouse strains that are useful “tools” 
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for the functional characterization of genes. Although the insertion of the vector 
construct in region of a gene typically results in complete inactivation of the 
“trapped” gene (a null allele), this is not always the case (http://www.genetrap.org). 
For example, there is a possibility that the  vector insertion might lead to a 
hypomorphic gene function, or result in a dominant negative phenotype. Generally, if 
the  vector is  inserted close to the 5' end of a gene, but downstream of the 
untranslated region before the first exon, is more likely to create a null allele than 
insertion near the 3' end (http://www.genetrap.org).  
Limitations that should be considered when using a gene trap mutagenesis approach 
are as follows: (a) the genomic region surrounding the vector insertion in embryonic 
stem cell line should be carefully investigated to ensure that the gene of interest is 
fully and solely inactivated. Because a greater percentage of a gene's exons are 
prevented from being transcribed and translated, vector insertions near the 5' end of a 
gene are more likely to result in complete gene inactivation than insertion at the 3' 
end and (b) there is the possibility of inactivating multiple genes.  This can happen if 
the vector insertion is in a region where the coding regions of multiple genes overlap, 
or is upstream of an RNA gene such as a microRNA that would normally be 
transcribed along with the gene that has been identified as inactivated and (c) genes 
coding on the opposite strand can also be inactivated by vector insertion threfore 
ideally the strand orientation of the  gene of interest should be checked (extensive 
information on gene traps can be found in http://www.genetrap.org). 
3.1.2.  “Trapping” the glucocorticoid receptor in ES cells  
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To generate mice lacking one functional GR allele (GR+/- mice), an existing 
embryonic stem (ES) cell line (ESKN92) was used generously provided by Heidi 
Sutherland and Wendy Bickmore (MRC Human Genetics Unit, Edinburgh, UK).  
ESKN92 cells arose from a gene trap screen to identify chromosomal and nuclear 
proteins in mouse cells (Sutherland et al, 2001). A schematic representation of the 
gene trap screening strategy is shown in Figure 3.1. Briefly, a β-galactosidase-
neomycin phosphotransferase (βgeo or referred here as βgal) reporter cassette 
lacking a promoter and translation start, but with a splice acceptor site at the 5’ end 
of the cassette, was randomly integrated into the genome of mouse ES cells 
(129Ola). If the cassette integrated into an intron of an expressed endogenous gene, 
splicing (fusion of the endogenous and βgeo transcript) may occur from the splice 
donor site of the endogenous gene to the splice acceptor site of the cassette. The 
presence of a poly- adenylation (pA) site at the 3’ end of the cassette ensure that 
transcription terminated at the end of the cassette. If the resulting spliced transcript 
maintained the open reading frame (ie is in phase with the triplet codon message), 
then a chimaeric protein would be generated in which the N-terminal amino acids are 
derived from the endogeneous gene and the C-terminal amino acids derived from the 
β-geo cassette (Tate et al, 1998). This approach allowed the resulting fusion protein 
to be expressed from the endogenous gene promoter and additionally confers β-gal 
activity (for cell specific identification) and neomycin resistance (neoR; for 
subsequent selection of the gene-trap ES cell line). Thus, clones in which 




Figure 3.1 Gene-trapping strategy.  
The gene trap vectors (pGT1-3, Sutherland et al., 2001) contain a splice acceptor site 
(SA), a βgeo cassette and a poly-adenylation signal (pA).  The gene targeting vector 
integrated into an intron of the GR gene downstream of coding exons. This led to the 
splicing of the βgeo reporter in frame with the gene transcript. Translation results in a 
chimeric/fusion protein, comprising GR at the N terminus and βgeo at the C terminus, 
expressed from the endogenous GR promoter (modified from Sutherland et al, 
2001).Numbers 1, 2, 3 and 4 correspond to exons 1, 2, 3, 4 of the GR gene. 
Integration of the gene trap in the intro between exon 3-4 (DBD) results in the loss of 
exons 4-9 and therefore part of the DNA binding domain (exon 4) and the entire 
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fusion protein is determined by virtue of the β-gal activity using X-gal staining or 
immunofluorescence using a β-gal antibody. Frequently, the fusion of the 
endogenous gene with the β-geo reporter is mutagenic and alters or abolishes the 
normal function of the endogenous protein if domains critical for normal function are 
deleted by the fusion (Tate et al, 1998). In the ESKN92 cell line it was reported that 
the β-geo cassette had integrated into the GR gene (Sutherland et al, 2001), 
generating a fusion protein lacking part of the DNA binding domain (DBD) and the 
entire ligand binding domain (LBD). The fusion protein was predicted to be non-
functional and because it lacks both known nuclear localization signals (NLS) is 
predicted to be cytoplasmic (Picard and Yamamoto, 1987). However, the apparent 
diffuse nuclear localisation of the fusion protein (Sutherland et al, 2001) suggested 
that it might retain some residual DNA binding activity, or possibly a novel NLS, 
and may not be completely non-functional.  
 
The experiments described in this chapter (fig 3.2) were designed to characterise the 
ESKN92 cell line, prior to using the cells to generate a line of GR mutant mice. 
 
 Specifically I aimed to:  
• confirm a single gene trap integration in ESKN92 cells, and that the insertion 
was in the GR gene on chromosome 18. 
• determine the precise site of the splice junction (where βgeo fuses to the GR 
transcript), thereby identifying the intron into which the cassette had inserted.  
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• examine the cellular localization pattern of the fusion protein and whether it 
was affected by the presence of either ligand or the presence of endogenous 
GR (eg the wild type GR allele from the non-targetted chromosome). 
• determine the size of the expressed fusion protein 
• characterise the nature of the GR-βgeo allele (null, dominant negative or 
hypomorphic) by recreating the fusion protein and testing its ability to 


































Figure 3.2 Flow Chart of ESKN92 characterization experiments. 
(1) FISH was performed to confirm a single integration of the βgeo cassette and 
confirm localization to the GR locus on chromosome 18. (2). 5’RACE was performed 
to identify the integration site in the GR locus. (3). Immunofluorescence was used to 
examine the cellular localization of the fusion protein, using antibodies against GR 
and/or β-gal, and to determine whether this was influenced by cellular differentiation 
and glucocorticoid ligand (DEX).  Briefly, undifferentiated or differentiated ESKN92 
or a wild type parental cell line (ES14) were treated with 1μM DEX for 10 min to test 
if fusion protein responds to ligand by translocating to the nucleus and (4). Whole 



























+/- DEX (1μM) 












Total RNA  
 





5’ RACE products 
 






Hybridization with       
pGT3, GR & Chr18 
paint 











3.2.1 ESKN92 cells contain a single integration of the gene trap cassette 
in the GR locus, on chromosome 18  
 
The chromosomal location of the gene trap was determined by metaphase FISH 
analysis of DNA in ESKN92 cells, using probes specific for the gene trap vector 
(pGT-3), the GR and chromosome 18 (Table 3.1). To confirm that the gene trap 
insert was on chromosome 18, FISH was carried out using the pGT-3 probe together 
with a chromosome 18 ‘paint’. Both chromosomes 18 showed green diffuse staining 
along their length (fig. 3.3A). The gene trap (red signal) is present only in one copy 
of chromosome 18 (fig. 3.3A). No other red signals were seen confirming a single 
gene trap integration site on chromosome 18. To confirm that the insertion is at the 
GR locus, metaphase chromosomes were hybridized with both the pGT-3 probe and 
a GR specific probe. Both probes hybridize to the same site (merged the red and 
green signals to appear as a yellow signal) on both the two sister chromatids of 
chromosome 18 (fig. 3.3B), confirming integration into the glucocorticoid receptor 
locus. Finally, figure 3.3C shows a GR specific probe hybridized to both chromatids 
of chromosome 18, used as a positive control.  
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Table 3.1 Probes used to detect the insertion site of the pGT-3 (gene trap vector) into 
ESKN92 chromosomes by FISH.  
PROBE 1  PROBE 2 
pGT3-DIG-TxR Chromosome 18-BIOTIN-FITC 
pGT3-DIG-TxR Chromosome 18-BIOTIN-FITC 
GR-BIOTIN-FITC pGT3-DIG-TxR 
GR-BIOTIN-FITC pGT3-DIG-TxR 
GR-BIOTIN-FITC                      - 
DIG is digoxygenin-11-dUTP, TxR is Texas Red-conjugated anti-sheep IgG. FITC is 
fluorochrome-conjugated avidin. The GR probe used is a 6kb genomic fragment 























Figure 3.3 Maintenance and differentiation of mouse Embryonic Stem (ES) cells. 
Cells are cultured in the presence of Leukemia Inhibitory Factor (LIF) to maintain 
the undifferentiated state or in the absence of LIF and the presence of retinoic acid 
(RA) to differentiate them along a non-specific pathway. Cells are allowed to 
differentiate for 8 days and their differentiation state is microscopically examined. 
The majority of cells in the ESKN92 cell line grown in the presence of LIF, formed 
densely packed clusters. When cells were supplemented with 5x 10-6 M RA for 6-8 
days morphological changes were observed; densely packed cells became much less 
compact and moved apart from each other as reported previously (Strickland and 
Mahdavi, 1978).  Cell morphology also altered so that cells become larger, flatter 
and more irregularly shaped. 











Figure 3.4 Single integration of the gene trap into chromosome 18 at the GR locus in 
ESKN92 cells.  
Representative images of metaphase chromosomes hybridised with (A)  both the 
pGT-3 probe (labelled with DIG-TxR; red dot) and a “paint” for chromosome 18 
(biotin-FITC labelled; green diffuse stain); 2 copies of chromosome 18 are 
fluorescent along their entire length but only one contains the trap (white arrow), (B) 
both the pGT-3 probe ( labelled as above; red dot) and a GR probe (biotin-FITC 
labelled; green dot), indicating colocalization of the trap with the GR (yellow arrow) 
and (C) a GR specific probe (labelled as above) showed 2 copies, one in each 
chromatid (red arrow). Chromosomes are 4,6-diamidino-2-phenylindole (DAPI) 
stained. The images were acquired using filters appropriate for DAPI, FITC and 




3.2.2 Insertion of the gene trap into intron C of GR results in the 
removal of the second Zn finger of DBD and the entire LBD. 
 
5’-RACE was used to identify the insertion site of the βgeo cassette into the GR 
gene. cDNA was synthesized from ESKN92 cells using a βgal specific primer. A 
universal primer (section 2.2.1.1.6) was ligated to the 3’ end of the cDNA and a 
nested PCR carried out, again using a universal primer and an internal βgal primer. A 
single PCR product was obtained (not shown). This was sequenced using the nested 
βgal primer to identify the junction between the βgeo cassette and the GR mRNA. 
~400bp of the sequence is shown in figure 3.4A. The BLAST algorithm was used to 
compare with the Ensembl database. This verified that the gene trap was inserted in 
the GR gene in the ESKN92 cell line. Examination of the sequence revealed that the 
βgeo cassette was spliced onto the end of exon 3 of GR (fig. 3.4A). Therefore the 
cassette integrated into intron C, resulting in an mRNA encoding a fusion protein in 
which  the second zinc finger (ZF), encoded by exon 4,  of the DNA binding domain 
(DBD) and the entire ligand binding domain (LBD), encoded by exons 5-9,  of GR 
were replaced by βgeo (fig. 3.4B). Thus, the fusion protein lacks both known nuclear 
localization signals (NLS; Picard and Yamamoto, 1987). Translation is predicted to 
result in a GR-βgeo fusion protein (referred as GR-βgal throughout this Thesis) 








   
   
  RACE               1                   TCAGCAGCAGGATCAGAAGCCTGTTTTTAATGT     33 
                                           ||||||||||||||||||||||||||||||||| 
  mGR cDNA        1051 AATACAGCATCCCTTTCTCAGCAGCAGGATCAGAAGCCTGTTTTTAATGT   1100 
 
                      34 CATTCCNCCAATTCCTGTTGGTTCTGAAAACTGGAATAGGTGCCAAGGGT     83 
                         ||||||.||||||||||||||||||||||||||||||||||||||||||| 
                    1101 CATTCCACCAATTCCTGTTGGTTCTGAAAACTGGAATAGGTGCCAAGGGT   1150 
 
                      84 CTGGAGAGGACAACCTGACTTCCTTGGGGGCTATGAACTTCGCAGGCCGC    133 
                         |||||||||||||||||||||||||||||||||||||||||||||||||| 
                    1151 CTGGAGAGGACAACCTGACTTCCTTGGGGGCTATGAACTTCGCAGGCCGC   1200 
 
                     134 TCAGTGTTTTCTAATGGATATTCAAGCCCTGGAATGAGACCAGATGTGAG    183 
                         |||||||||||||||||||||||||||||||||||||||||||||||||| 
                    1201 TCAGTGTTTTCTAATGGATATTCAAGCCCTGGAATGAGACCAGATGTGAG   1250 
 
                     184 TTCTCCTCCGTCCAGCTCCTCCACAGCAACGGGACCNCCTCCCAAACTCT    233 
                         ||||||||||||||||||||||||||||||||||||.||||||||||||| 
                    1251 TTCTCCTCCGTCCAGCTCCTCCACAGCAACGGGACCACCTCCCAAACTCT   1300 
 
                     234 GCCTGGTGTGCTCCGATGAAGCTTCGGGATGCCATTATGGGGTGCTGANG    283 
                         |||||||||||||||||||||||||||.||||||||||||||||||||.| 
                    1301 GCCTGGTGTGCTCCGATGAAGCTTCGGTATGCCATTATGGGGTGCTGACG   1350 
 
                     284 TGTGGAAGCTGTAAAGTCTTCTTTAAAAGAGCAGTGGAAGGTC-------    326 
                         |||||||||||||||||||||||||||||||||||||||||.|        
                    1351 TGTGGAAGCTGTAAAGTCTTCTTTAAAAGAGCAGTGGAAGGACAGCACAA   1400 
  
                     327 --------------------------------------------------    326 
                                                                        
                    1401 TTACCTTTGTGCTGGAAGAAATGATTGCATCATTGATAAAATTCGAAGAA   1450 
 
                     327 --------CCAG-GTCCCGAAAACGAAAG-------AAG-----AAGAAC    355 
                                 |||| .|.|||..|.|||||.       |||     |.|||| 
                    1451 AAAACTGTCCAGCATGCCGCTATCGAAAATGTCTTCAAGCTGGAATGAAC   1500 
 
                     356 ---GCAGATCGCAGATCNNAGA----------------TCTG---GACTC    383 
                            |.||.|||.|.|.|..|||                ||.|   |.|.| 
                    1501 CTGGAAGCTCGAAAAACGAAGAAAAAAATTAAAGGAATTCAGCAAGCCAC   1550 
 
                     384 T--AGAGGTCCCNCTTNCC                                   400 
                         |  ||..|||.|.|....|                                
                    1551 TGCAGGAGTCTCACAAGACACTTCTGAAAACGCTAACAAAACAATAGTTC   1600 
 
Figure 3.5 5’RACE shows the βgeo cassette has replaced exons 4-9 of GR in the 
encoding mRNA. 
 
Figure 3.5 5’RACE shows the βgeo cassette has replaced exons 4-9 of GR in the 
encoding mRNA. 
(A) A schematic view of the functional domains of GR (upper), the GR cDNA, 
showing the regions encoded by individual exons (middle) and the predicted structure 
A  
GR cDNA 
GR-lacZ fusion transcript 





of the fusion protein. Green corresponds to the N-terminal domain (NTD; encoded by  
exon 2), red is the DNA binding domain (DBD; exons 3 and 4), grey is the ligand 
binding domain (LBD; exons 5 to 9) and blue is the lacZ with neo attached at the end 
of the fusion protein. Note that exon 1 is non-coding.) and (B) Alignment of mouse 
GR (black letters; starting from 1051bp) with the 5’RACE sequence product  (grey 
shaded portion; 1-400bp). Briefly, the alignment performed by firstly reverse 
complementing the RACE sequence (reading from the LacZ) using 
http://bioinformatics.org/sms/rev_comp.html, accessing the FASTA  mGR cDNA 
(accession number: X04435)  sequence. Then  pasted  both reverce complement of 
the RACE and the FASTA GR cDNA into the EBI alignment programme 
(http://www.ebi.ac.uk). Note that the first nucleotide of the RACE aligns with 
nucleotide 1068 of mGR and the red letters are exon 3 of GR. The alignment ends at 
GAAG of exon 3 (bold red letters). After the end of exon 3, the sequense corresponds 
to the splice site of the engrailed 2 gene of the gene trap vector. The dash (-) indicates 
that there is no corresponding nucleotide in a sequence. For complete information on 
























3.2.3 GR-βgal fusion protein is located both in the cytoplasm and 
the nucleus.  
3.2.3.1 Localization of wild type GR and GR-βgal fusion proteins in 
undifferentiated ESKN92 cells. 
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Previous data have shown diffuse nuclear localization of fusion protein (Sutherland 
et al, 2001) yet, as stated above, both the known GR NLSs (Picard and Yamamoto, 
1987) were not present. To examine localization, immunofluorescence was 
performed on undifferentiated ESKN92 using β-gal and GR specific antibodies. 
Contrary to expectations, in the absence of its ligand (dexamethasone), intact (wild 
type) GR was located in the nucleus in large, round spots (foci or clusters), 
distributed in a punctuate manner in both undifferentiated ESKN92 (fig. 3.6) and 
ES14 cells (wild type cell line; WT) (fig. 3.7). The GR antibody also showed some 
diffuse fluorescence in the cytoplasm of ESKN92 cells, probably detecting the fusion 
protein (not seen in the wild type cells; fig.3.7) with some strong fluorescence along 
lines at the periphery of the cytoplasmic membrane (possibly the cytoskeleton). In 
contrast, the fusion protein (detected using a βgal antibody), showed a diffuse 
localisation throughout the cytoplasm and the nucleus in undifferentiated ESKN92 
cells (fig. 3.8). As expected, no βgal immunofluorescence was apparent in WT cells 
(fig. 3.9) nor was there any specific fluorescence detected when the primary antibody 





Figure 3.6 GR immunostaining in undifferentiated ESKN92 cells detecting intact GR 
and GR-βgal fusion protein reveals discrete nuclear foci.  
Representative photographs of 3 independent ESKN92 cells (A, B and C, from top to 
bottom). The left column of each shows DAPI (labelling DNA), the middle column is 
FITC (attached to the secondary antibody, detecting GR) and the right column is the 
merged picture (DAPI is blue and FITC is green). White arrow (B, right image) 
indicates nuclear GR foci, and red and yellow arrows (B, left photo) shows a 
nucleolus (with the appearance of a hole in the DAPI staining) and heterochromatin 
respectively. Light blue arrow (C, right image) indicates the GR fluorescence along 
the cytoskeleton. The GR antibody detects both the intact and fusion protein in 
ESKN92 cells. Images captured from a conventional fluorescence microscope at 








Figure 3.7 Immunostaining of GR in undifferentiated WT ES cells reveals intact GR 
in discrete nuclear foci.   
Representative photographs of 3 independent WT cells (A, B and C, from top to 
bottom). The left column of each shows DAPI (labelling DNA), the middle column is 
FITC (attached to the secondary antibody, detecting GR) and the right column is the 
merged picture (DAPI is blue and FITC is green). The GR antibody detects the intact 
protein in WT cells. Images captured from a conventional fluorescence microscope 
at magnification x100.   






Figure 3.8 βgal immunostaining of undifferentiated ESKN92 cells reveals diffuse 
nuclear and cytoplasmic GR- βgal fusion protein localization.  
Representative photographs of 3 independent undifferentiated ESKN92 cells (A, B 
and C, from top to bottom). The left column of each shows DAPI (labelling DNA), 
the middle column is FITC (attached to the secondary antibody, detecting βgal) and 
the right column is the merged picture (DAPI is blue and FITC is green). The βgal 
antibody detects the fusion protein in ESKN92 cells. Images captured from a 









Figure 3.9 No βgal immunostaining is detected in undifferentiated WT cells (used as 
a negative control for the fusion protein).  
Representative photographs of 3 independent undifferentiated WT cells (A, B and C, 
from top to bottom). The left column of each shows DAPI (labelling DNA), the 
middle column is FITC (attached to the secondary antibody, detecting βgal) and the 
right column is the merged picture (DAPI is blue and FITC is green). Absent βgal 
immunoreactivity in WT cells. Images captured from a conventional fluorescence 








Figure 3.10 Omission of primary antibodies.  
Immunofluorescence performed on differentiated ESKN92 cells. Omitting the 
primary antibodies (GR or β-gal) and incubating only with secondary antibody (anti-
rabbit IgG). Channels have been split; on the left side is DAPI, middle is the FITC 










3.2.3.2 Fusion and intact GR protein localization in differentiated 
ESKN92 cells. 
 
To determine whether the unexpected nuclear immunofluorescence of endogenous 
GR is unique to undifferentiated ESKN92 cells, cells were differentiated and the 
localization pattern examined using GR and βgal specific antibodies. When cells 
were induced to differentiate, endogenous GR was evenly and diffusely distributed in 
the cytoplasm and the nucleus in both cell lines (fig. 3.11 and fig. 3.12). Cytoplasmic 
immunofluorescence seemed to be more prominent in the differentiated cells but this 
could be due to larger cytoplasmic volume in differentiated ES cells.  In contrast, the 
fusion protein, detected using a βgal antibody, showed a diffuse localisation 
throughout the cytoplasm and the nucleus in differentiated (fig. 3.13) ESKN92 cells.  






Figure 3.11 GR immunostaining in differentiated ESKN92 cells reveals diffuse 
nuclear and cytoplasmic intact GR and GR-βgal fusion protein distribution.  
Representative photographs of 3 independent ESKN92 cells (A, B and C, from top to 
bottom). The left column of each shows DAPI (labelling DNA), the middle column is 
FITC (attached to the secondary antibody, detecting GR) and the right column is the 
merged picture (DAPI is blue and FITC is green). White arrow (A, right image) 
indicates diffuse cytoplasmic staining, and yellow arrow (C, right image) shows 
diffuse nuclear staining. The GR antibody detects both the intact and fusion protein 
in ESKN92 cells. Images captured from a conventional fluorescence microscope at 
magnification x100.   








Figure 3.12 GR immunostaining in differentiated WT cells reveals diffuse nuclear 
and cytoplasmic intact GR protein distribution.  
Representative photographs of 3 independent WT cells (A, B and C, from top to 
bottom). The left column of each shows DAPI (labelling DNA), the middle column is 
FITC (attached to the secondary antibody, detecting GR) and the right column is the 
merged picture (DAPI is blue and FITC is green). White arrow (C, right image) 
indicates diffuse cytoplasmic staining, and yellow arrow (C, right image) shows 
diffuse nuclear staining. The GR antibody detects the intact GR protein in WT cells. 
Images captured from a conventional fluorescence microscope at magnification 











Figure 3.13 βgal immunostaining in differentiated ESKN92 cells reveals diffuse 
nuclear and cytoplasmic GR-βgal protein distribution. 
Representative photographs of 3 independent ESKN92 cells (A, B and C, from top to 
bottom). The left column of each shows DAPI (labelling DNA), the middle column is 
FITC (attached to the secondary antibody, detecting βgal) and the right column is the 
merged picture (DAPI is blue and FITC is green). White arrow (C, right image) 
indicates diffuse cytoplasmic staining, and yellow arrow (C, right image) shows 
diffuse nuclear staining. The βgal antibody detects the GR-βgal fusion protein in 
ESKN92 cells. Images captured from a conventional fluorescence microscope at 









Figure 3.14 GR-βgal fusion protein is not detected in differentiated WT cells 
(negative control for the GR- βgal fusion protein). 
Representative photographs WT cells (A and B; from top to bottom). The left 
column of each shows DAPI (labelling DNA), the middle column is FITC 
(attached to the secondary antibody, detecting βgal) and the right column is the 
merged picture (DAPI is blue and FITC is green). Images captured from a 
conventional fluorescence microscope at magnification x100.   




3.2.3.3 Fusion and intact GR protein localization in DEX-treated ESKN92 
  
The nuclear localization of GR in undifferentiated or differentiated ES cells was 
unexpected. To determine if this was due to the presence of residual glucocorticoid 
(GC) in the foetal calf serum of the culture medium, endogenous and fusion GR 
localisation was investigated in the absence of serum GC (removal by dextran-coated 
charcoal). In addition, DEX was used to induce nuclear localization of GR. Since the 
GR-βgal fusion protein lacked the entire LBD, it was predicted to be unresponsive to 
DEX. Removal of GC from serum had no effect on the localization of either intact or 
GR-βgal fusion protein in undifferentiated ESKN92 (fig. 3.15A, E) or WT ES cells 
(fig.3.15C)  No differences in immunofluorescence were observed with 1μM DEX-
treatment in either undifferentiated (fig. 3.15A-B) or differentiated (fig. 3.16A-B) 
ESKN92 cells. In contrast, DEX treatment of WT cells increased GR 
immunofluorescence in the nucleus and decreased GR immunofluorescence in the 
cytoplasm. This occurred in both undifferentiated (fig. 3.15C-D) and differentiated 
WT cells (fig. 3.16C-D). However, as noted above, GR immunostaining, whether in 
the nucleus or the cytoplasm was more diffuse in differentiated cells (fig. 3.16), with 
much smaller foci when compared to undifferentiated WT cells (fig. 3.15). There 
was no effect of DEX upon the pattern of βgal immunostaining in the nucleus of 
undifferentiated (fig. 3.15E-F) or differentiated ESKN92 cells (fig. 3.16E-F). As 
expected, no β-gal immunostaining was seen in WT cells under any conditions (fig. 
3.15G-H and fig. 3.16G-H).  
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Figure 3.15 DEX has no effect on the distribution of GR-βgal fusion protein in 
undifferentiated ESKN92 cells but WT cells respond to DEX with increased GR 
immunostaining in the nucleus.  
GR immunofluorescence in (A) ESKN92 cells before DEX and (B) 10 min after 
addition of 1μM DEX; (C) WT cells before DEX and (D) WT cells after DEX 
treatment. βgal immunofluorescence in (E) ESKN92 cells before DEX and (F) 10 min 
after DEX; (G) and (H) showing no βgal immunostaining in WT cells before or after 
DEX treatment (-ve control). One representative image per treatment, capturing the 
FITC channel (grey scale). Magnification x100. Note that the GR antibody detects 
both intact GR and  GR-βgal fusion protein in ESKN92 cells, but only intact GR in 
WT cells. Therefore by a subtraction process the fusion protein distribution can be 
deduced, and also determine whether the presence of the intact affects the distribution 














B A D C 
F G H E 




Figure 3.16 DEX has no effect on the translocation of intact or fusion GR protein in 
the nucleus of differentiated ESKN92 cells but   WT cells respond to DEX with 
increased GR immunostaining in the nucleus and subsequently decreased 
cytoplasmic GR signal.  
GR immunofluorescence in (A) ESKN92 cells before DEX and (B) 10 min after 
addition of 1μM DEX; (C) WT cells before DEX and (D) WT cells after DEX 
treatment. βgal immunofluorescence in (E) ESKN92 cells before DEX and (F) 10 min 
after DEX; (G) and (H) showing no βgal immunostaining in WT cells before or after 
DEX treatment (-ve control). One representative image per treatment, capturing the 
FITC channel (grey scale). Magnification x100. Note that the GR antibody detects 
both intact GR and GR-βgal fusion protein in ESKN92 cells, but only intact GR in 
WT cells. Therefore by a subtraction process the fusion protein distribution can be 
deduced, and also determine whether the presence of the intact affects the distribution 
of the fusion protein. 
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3.3 Immunoblotting demonstrates the presence of a 200kDa protein 
corresponding to the GR-β-gal fusion protein in ESKN92 cells. 
 
Western blot of whole protein ESKN92 cell extracts was performed in order to detect 
the intact GRa (~ 95 kDa) and also the GR-βgal fusion protein (predicted size ~200 
kDa). Because of the large predicted size of the chimeric protein, a 5% 
polyacrylamide gel was used to resolve proteins. Following transfer, the membrane 
was incubated with either GR antibody (epitope located at the N-terminus of GR) or 
an antibody against β-galactosidase. However, only the blot incubated with the GR 
antibody is presented because the β-galactosidase antibody bound to a variety of non-
specific proteins (data not shown). Immunoblotting with the GR antibody detected a 
protein of the predicted size (figure 3.17) in differentiated (-LIF) and  a weaker band 
in undifferentiated (+LIF) ESKN92 cells.   
 
3.2.5 The nature of the GR-βgal fusion allele 
3.2.5.1 Construction of plasmids expressing normal GR and the GR-
βgal fusion protein. 
 
Expression plasmids expressing intact GR and the GR-βgal fusion protein were 
constructed in the pcDNA 3.1(-) vector by Val Lyons, using DNA fragments derived 
from mouse GR expression plasmids, the 5’RACE PCR product from ESKN92 cells 
and the pGT-3 gene trap vector (see Appendix for details and fig. A1-3 for 







Figure 3.17 Western blotting with anti-GR antibody shows the presence of the 
predicted 200 kDa GR-βgal fusion protein in ESKN92 cells.  
Whole protein extracts (10μg) from duplicate samples of undifferentiated (U; +LIF) 
and differentiated (D; -LIF+Retinoic Acid) ESKN92 cells were resolved by 5% 
PAGE, transferred to membrane and incubated with anti-GR antibody. Rat liver 
protein extract was used as a positive and negative control for the intact GR and the 
GR-βgal fusion proteins, respectively. Molecular weights are indicated (determined 
by colour marker) at the left side of the picture. Black arrows indicate the intact GR 
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3.2.5.2 Transfection experiments show that GR-βgal is transcriptionally 
inactive. 
 
To address the nature of the GR-βgal allele, the ability of the fusion protein to 
activate transcription in transfected HEK293 cells, which lack functional GR, was 
tested. HEK293 cells were transiently co-transfected with either a PNMT (Adams et 
al., 2003; kindly provided by D. Pearce) or MMTV-LTR luciferase reporter 
(Lefebvre et al., 1991) and either of the following constructs (a) pcDNA3.1, the 
empty vector for wild type (WT) GR or GR-βgal  to test if there is any functional GR 
in the cells (b) WT-GR to confirm normal GR induction by DEX or  (c) GR- βgal 
mutant (lacks the ligand binding domain therefore should not be activated by DEX) 
to test the nature of mutant GR and (d) WT-GR co-transfected with GR-βgal to test if 
there is a dominant negative activity. All experiments were performed with or 
without 1μM DEX in charcoal stripped serum (fig. 3.19). Results using the PNMT-
luciferase reporter (fig. 3.20) show a small induction of GR promoter activity with 
the vector alone suggesting that there is a low level of functional GR in the HEK293 
cells. This was not apparent in the ransfection experiments with the MMTV-
luciferase reporter (fig. 3.21). The GR-βgal fusion protein had no effect on promoter 
activity in the absence of DEX, indicating that it was not constitutively active(fig. 
3.20 and fig.3. 21). As expected, DEX treatment had no effect on GR-βgal activity.  
Importantly, addition of GR-βgal fusion protein had no effect upon the DEX 
induction via WT-GR of either MMTV-LTR (fig. 3.21) or PNMT (fig. 3.20), 
indicating that it had no dominant negative activity. Overall, these results show that 






Figure 3.19 Schematic overview of HEK293 transfection experiments to evaluate the 
nature of GR-βgal allele in vitro.  
Human embryonic kidney (HEK293) cells were maintained with charcoal stripped 
serum. Following 24h in culture, cells were transfected with reporter (MMTV-LTR-
luciferase or PNMT-luciferase) and either the vector pcDNA3.1(-) alone (used for 
subcloning the wild type GR and GR-βgal mutant) or wild type (WT) GR or GR-βgal 
mutant or both the wild type GR and GR-βgal mutant together using lipofectamine 
2000. 48h later, 1μM dexamethasone (DEX) was added and cells were lysed and 
firefly (reporter) and renilla (internal control) luciferase activity assayed. PNMT; 
phenylethanolamine N-methyltransferase promoter (Adams et al, 2003), MMTV; 
mouse mammary tumour virus promoter. The PNMT construct was kindly provided 
by David Pearce. For details on constructs used please refer to appendix A. 
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Figure 3.20 WT-GR activates the PNMT promoter in the presence of DEX, but the 
GR-βgal fusion protein had no effect on PNMT promoter activity.   
In the absence of DEX, WT-GR or GR-βgal had no significant effect on promoter 
activity. DEX treatment increased wild type GR promoter activity but had no effect 
on the GR-βgal activity. Co-transfection of WT-GR with the mutant GR results in 
similar to WT-GR promoter activity after DEX treatment, ruling out a dominant 
negative activity of the GR-βgal fusion protein. Data are mean±SEM of 3 
independent experiments, each  performed in triplicates. 2-way ANOVA was used to 
test the construct x DEX interaction, following by post hoc tests. *p<0.05, 
***p<0.001 indicating significant difference between DEX treated and untreated. 
PNMT; phenylethanolamine N-methyltransferase promoter (PNMT-998/-466-Luc), 
that does not require GR dimerisation to be activated (Adams et al, 2003). Note that 
co-transfections used equal amounts of WT-GR and GR-βgal and expression of the 
latter was verified by βgal activity measurement in transfected cell lysates (data not 














Figure 3.21 WT-GR activates the MMTV-LTR promoter in the presence of DEX, but 
the GR-βgal fusion protein had no effect on MMTV-LTR promoter activity.   
In the absence of DEX, WT-GR or GR-βgal had no significant effect on promoter 
activity. DEX treatment increased WT-GR promoter activity but had no effect on the 
GR-βgal activity. Co-transfection of WT-GR with the mutant GR results in similar to 
WT-GR promoter activity after DEX treatment, ruling out a dominant negative 
activity of the GR-βgal fusion protein. Data are mean±SEM of 3 independent 
experiments, each  performed in triplicates. 2-way ANOVA was used to test the 
construct x DEX interaction, following by post hoc tests. *p<0.05, ***p<0.001 
indicating significant difference between DEX treated and untreated. MMTV; mouse 
mammary tumour virus promoter that requires dimerisation and DNA binding of GR 
to be activated. Note that co-transfections used equal amounts of WT-GR and GR-
βgal and expression of the latter was verified by βgal activity measurement in 
transfected cell lysates (data not shown). These data were generated by Kathryn 













 3.3 Discussion  
 
The ESKN92 cell line identified during a large scale gene trap screen (Sutherland et 
al, 2001), and had not been extensively characterised. Furthermore, there was some 
uncertainty regarding the nature of the fusion product, as the preliminary 5’RACE 
data suggested the absence of all NLS yet it was clearly localized in the nucleus 
(Sutherland et al., 2001). Therefore, prior to generating the GR mutant mice, it was 
essential to confirm the insertion site within the GR gene.  
 
FISH performed on ESKN92 metaphase chromosomes confirmed the location of the 
gene trap cassette at the GR locus on chromosome 18. In addition, FISH revealed 
that the gene trap is located on both chromatids of only one copy of mouse 
chromosome 18. This showed that the cassette had integrated at a single genomic 
location.   
 
5’ RACE confirmed that the cassette had inserted into the GR gene and showed that 
it was located in intron C. This is predicted to generate a “null” allele lacking the 
second ZF of the DBD and the entire LBD. Both are essential for DNA binding 
(Picard and Yamamoto, 1987) therefore in theory the mutant GR protein will not be 
able to bind its target genes. The gene trap also removes the LBD, and therefore the 
mutant GR-βgal protein presumably will not bind glucocorticoid.  
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Western blot analysis of ESKN92 cells using a GR antibody directed against the 
amino-terminus of GR, detected both the intact /wild type GR (95kDa) and an 
additional protein of 200kDa, the predicted size of the fusion protein, in both 
differentiated and undifferentiated ESKN92 cells. The intensity of the fusion protein 
band was weaker in undifferentiated compared to differentiated cells. Because 
transfer of large proteins maybe inefficient, any differences in GR expression 
between differentiated and undifferentiated ES cells must be regarded with caution. 
To confirm whether GR protein levels (intact and fusion) change with differentiation 
of ES cells and to control for equal protein transfer, future immunoblotting 
experiments using different GR antibodies and wild type ES cells (for the intact GR) 
could be informative, but were beyond the scope of this work. As the expressed 
fusion protein could potentially have residual function or even act as a dominant 
negative it was essential to characterize the activity of the encoded protein.  
 
Although ESKN92 cells were selected on the basis of the nuclear localization of the 
βgal fusion protein (Sutherland et al., 2001), the 5’ RACE showed that the fusion 
protein was missing both NLS of GR.  The nuclear localization of the GR-βgal 
fusion protein is therefore perplexing. Immunofluorescence, using a β-gal antibody 
to detect the fusion protein, showed that in both undifferentiated and differentiated 
ESKN92 cells the fusion protein was diffusely located in both the cytoplasm and 
nucleus. These observations could reflect a unique property of the undifferentiated 
ES cells or could be due to other NLS not previously described. To test the former 
possibility, the cells were differentiated. However, the localisation pattern of the 
 150
fusion protein was not affected by differentiation. The fusion protein is too big to 
passively diffuse into the nucleus, therefore this may reflect the presence of the 
fusion protein in the nucleus, as originally reported (Sutherland et al, 2001) or may 
be due to fusion protein immunostaining in the cytoplasm overlying the nucleus. 
Future examination by confocal microscopy should provide more accurate 
information regarding the localization of fusion protein. In any case, ESKN92 
immunofluorescence experiments suggest that the GR-βgal fusion protein is mis-
localised and transfection experiments indicate that it is probably non-functional. To 
shed further light on the localization of GR in ES cells, expression of intact GR was 
examined in a parental (WT) ES cell line.  Similar to ESKN92, GR immunostaining 
in WT cells appeared to be also in the nucleus. It still remains puzzling how (a) intact 
GR in the WT ES cells can be detected in the nucleus in the absence of ligand and 
(b) a proportion of the fusion protein inserts into the nucleus when both NLSs are 
missing, since it is widely accepted that GR has two NLSs, one located to the second 
ZF (NL1) and the other to the LBD (NL2) (Picard and Yamamoto, 1987). One 
hypothesis could be that a third NLS exists in GR that has not been described 
previously. Alternatively, GR maybe trans-locates into the nucleus complexed to 
other NLS-containing proteins, but this will need further investigation. Previous 
experiments have only examined nuclear translocation of transfected (over-
expressed) GR and not expressed at physiological levels. Finally, translocation of GR 
into the nucleus might happen via an ES cell-specific mechanism.  
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The intact (WT) GR was located in large punctuate foci in the nucleus in 
undifferentiated ESKN92 cells, and also diffusely in the cytoplasm, with a few 
smaller focal patterns and along the cytoskeleton periphery. The same distribution 
was observed in the parent WT ES cell line. Similar results were obtained using 
medium containing charcoal-stripped serum, therefore it is unlikely that the nuclear 
localization was due to residual GC in the serum. These results are surprising, since 
it is accepted that the unliganded GR is located in the cytoplasm and that receptor 
translocation into the nucleus occurs after hormone binding (Picard and Yamamoto, 
1987; Beato, 1989; Jewell et al, 1995). It has been previously reported that GR 
accumulates in clusters in the nucleus only after agonist treatment using 
immunofluorescence on fixed cells representing a number of human and rat cell lines 
(Van Steensel et al, 1995). This pattern was also observed, using confocal laser 
scanning microscopy, for a green fluorescent protein (GFP)-tagged GR in living cells 
after DEX treatment (Htun et al, 1996). However, one study in A549 human alveolar 
cells reported that GR was located both in the cytoplasm and nucleus, with a stronger 
signal in the nucleus (Jaffuel et al, 1999). The discrepancies in the above studies 
could be due to differences in methodology, cell types, transfected vs non-transfected 
and antibodies used.  
 
The experiment designed to investigate the response of GR-βgal fusion and 
intact/WT GR proteins to DEX showed that the fusion protein (detected with βgal) 
does not respond to DEX, as predicted. In contrast, there was an increase in the GR 
signal in the nucleus of undifferentiated and differentiated WT and ESKN92 cells 
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following DEX.  WT cells responded more robustly to DEX by displaying a stronger 
nuclear signal and a weaker (almost undetectable) cytoplasmic signal compared with 
untreated cells. ESKN92 cells also seemed to respond to DEX by increasing the 
intensity of nuclear signal (to a lesser extent than WT cells) but still there was a 
detectable cytoplasmic signal. This is likely due to the fact that the GR antibody used 
can detect both the WT GR and GR-βgal fusion protein in ESKN92 cells. However, 
to confirm the difference between treated and untreated cells it would be better to 
treat the cells with dexamethasone for longer (30 minutes to an hour) since complete 
translocation of GR has been observed at 30 minutes (Htun et al, 1996). Also, future 
immunofluorescence experiments should include a cell line (i.e. A549) as a control 
to exclude the possibility that the WT GR distribution observed in this study is due to 
the GR antibody used. 
 
What could be the determinants of the large focal domains (punctate pattern) to 
which GR localize in the ESKN92 and WT ES cells? From separate examination of 
the DAPI and FITC channels it is obvious that the GR clusters can not be associated 
with heterochromatin (round white full spots in DAPI) or nucleoli (seen as holes in 
DAPI). Splicing speckles, RNA polymerase II (poly II) and coilin are unlikely to 
form these clusters with GR (Sutherland, personal communication).  Splicing 
speckles usually do not tend to form round clusters, poly II forms smaller foci than 
the ones observed here and coilin forms only 2-3 focal domains per cell (Sutherland, 
personal communication). Moreover, van Steensel et al showed that GR clusters (or 
foci) do not colocalize with newly synthesized pre-mRNA, poly II or splicing factor 
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SC35 proposing that the observed GR clusters are not involved in transcription 
activation (Van Steensel et al, 1995). An attractive hypothesis proposes that GR foci 
may represent receptor storage sites (Van Steensel et al, 1995). A similar hypothesis 
has also been proposed for splicing speckles based on the observation  that 
accumulation of splicing factors into large foci occurs after transcription inhibition 
and not when transcription is active (Jimenez-Garcia and Spector, 1993; Wanskink et 
al 1993; Sutherland et al, 2001).  
 
In the present study, a possible candidate that might co-localize with GR containing 
foci could be the promyelocytic leukemia (PML) nuclear bodies, which usually 
appear round but finer bright spots in nucleus (illustrated in  fig. 3.22). The average 
mammalian cell contains 10-30 PML nuclear bodies per nucleus which have been 
associated with transcription, DNA repair, viral defence, stress, cell cycle regulation, 
proteolysis and apoptosis (Maul et al, 2000; Borden, 2002; Ching et al., 2005). For 
the above reasons, future experiments will test this hypothesis by 
immunofluorescence using dual labeling (an antibody against PML bodies together 
with the GR antibody).  
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Figure 3.22 PML nuclear bodies in a cell nucleus (taken from 
http://npd.hgu.mrc.ac.uk/compartments.html).  
 
It is intriguing that the large foci containing GR are not detected following 
differentiation of ESKN92 or WT cells. The GR signal in differentiated WT cells 
was detected both in the cytoplasm and nucleus in a diffuse pattern with a stronger 
signal still observed in the latter. These results are in accordance with the literature 
(van Steensel et al, 1995; Jaffuel et al, 1999). It can be speculated that differentiated 
cells are more transcriptionally active, with GR appearing in small diffuse foci, 
whereas in undifferentiated cells the large GR clusters may represent storage sites. 
Although it was beyond the scope of this thesis, in the future it will be very 
interesting to explore the mechanisms behind these pronounced differences. 
 
Finally, the question regarding the nature (null, hypomorphic or dominant negative) 
of the GR-βgal allele was addressed by recreating it and testing its ability to activate 
glucocorticoid-responsive reporters (PMNT and MMTV) in transiently transfected 
HEK293 cells. The GR-βgal fusion protein appears to be transcriptionally inactive.  
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The possibility of it acting as a dominant negative allele was ruled out since the 
mutant GR failed to interfere with the WT-GR when co-transfected, and the response 
of promoter activity to DEX was similar to that of WT-GR alone.   Overall, the 
results suggest that the GR-βgal is a null allele.  Therefore, ESKN92 cells were 
considered suitable to generate GR mutant mice. The β-gal cassette will also provide 
a valuable reporter of GR promoter activity in vitro which could be explored further 
in the future. 
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Chapter 4 
B6N92 mouse line generation 
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4.1 Introduction and Aims 
 
Although lines of mice with reduced or eliminated GR have been generated 
(described in section 1.6.2), the effect of homozygous or heterozygous disruption of 
the GR gene upon adiposity and body composition in mice has not previously been 
described. The disruption of the GR gene with the β-geo cassette in ESKN92 cells 
provides a way to study the effects of altered GR gene dosage on body composition 
and fat distribution. An additional advantage of the use of ESKN92 cells to generate 
GR+/βgeo mice (referred to as GR+/- throughout this Thesis)  is that expression of the 
GR-βgeo (or βgal) fusion protein is under the control of the endogenous GR 
promoter and therefore acts as a “reporter” of promoter activity, allowing ready 
detection of expressing cells/tissues. In chapter 3, I showed that the resulting fusion 
protein lacks part of the DNA binding domain and the entire ligand binding domain 
and is transcriptionally inactive. In this chapter, the generation and breeding strategy 
of two mouse lines – on either C57BL/6J or 129Ola genetic backgrounds - from 
ESKN92 cells (described in chapter 3) is presented. The reason for choosing 2 
different genetic backgrounds was because on C57BL/6 mice are prone to develop 
diet-induced obesity (DIO) whereas on 129Ola are resistant to DIO 
(http://jaxmice.jax.org/). Unfortunately the generation of GR+/- on 129 Ola 
background was not successful, thus the mice were bred only onto C57BL/6 
background. The MGI nomenclature of the GR-trapped mouse line generated here is 
Nr3c1Gt(ESKN92)mrchgu indicating the gene trap (Gt) allele of the GR gene, in mutant ES 
cell line ESKN92, made by the MRC Human Genetic Unit, Edinburgh 
(http://www.informatics.jax.org/mgihome/nomen/gene.shtml#iim). However,  for 
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simplicity reasons here is refered as B6N92 line. Finally, here I validate and quantify 
the actual GR expression levels in this model.  
4.2 Results 
4.2.1 Generation and breeding of B6N92 and 129N92 transgenic lines 
4.2.1.1 Generation of chimeric mice 
 
GR+/- mutant mice were generated from ESKN92 cells (Sutherland et al, 2001) by 
blastocyst injection (animal facility staff).  C57BL/6J blastocyst recipients at 2.5 d 
post coitum (dpc) were injected with early passage (passage 4) ESKN92 cells. Five 
chimeras (identified by a mottled coat colour), four male and one female,  designated 
chimera 1, 2, 3, 4 and 5 respectively, were obtained (Table 4.1).   Each chimera was 
mated with a C57BL/6J mouse. Chimera 3 (male) gave 6 cinchilla offspring 
(indicating they were derived from the ES cells and not the C57BL/6J host 
blastocyst), 5 of which produced a PCR product with lacZ primers (figure 4.1 and 
data not shown), and therefore carried the β-geo cassette.  Chimera 1 (male) 
produced 1 chincilla pup which did not carry the β-geo transgene (data not shown). 
Chimeras 2, 4 and 5 did not produce any offspring when crossed to C57BL/6 
(summarised in Table 4.1).  
To establish the line on a 129Ola background (the same as the ESKN92 cells; 
129N92), chimeras 1 and 3 (which had already produced offspring with C57BL/6J 
females) were mated with 129Ola females. Chimera 1 mated with 129Ola produced 
44 offspring but none carried the transgene (Table 4.1). Chimera 3 did not produce 
any offspring (summarised in Table 4.1). Therefore the breeding on 129Ola was 
stopped. 
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 +VE (+/-) 
 1* ♂ 1 0 
2 ♂ 0 - 
 3† ♂ 6 5 








 1* ♂ 44 0 129N92 




* and † indicate that is the same chimera 1 and 3 respectively; NONE indicates that 
there are no offspring born. 
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4.2.1.2 Genotyping of transgenic mice for LacZ transgene expression 
 
GR heterozygous mice (GR+/-) carrying both a wild type allele (LacZ negative) and 
the GR-βgeo allele (LacZ positive) were identified by PCR with primers which 
amplified a 413 bp fragment of the LacZ transgene.  The primers and amplification 
programme used are described in section 2.2.1.2.2 (Table 2.4).  The LacZ genotyping 
PCR protocol is used throughout this thesis and has previously been used in the 
Bickmore laboratory, MRC Human Genetics Unit, Edinburgh (Heidi Sutherland, 
personal communication, details in section 2.2.1.2.2).  Heterozygous mice (GR+/-) 
were distinguished from wild type mice (GR+/+) by visualisation of the 413 bp band 
after resolution of PCR products on a 2% agarose gel. A βglobin internal control 
confirmed the integrity of DNA in all samples. Figure 4.1 shows a typical genotyping 
PCR of offspring from a heterozygous x wild type cross.   
 
4.2.1.3 Establishment and propagation of B6N92 transgenic mouse line  
 
Offspring of chimeric mice were subsequently backcrossed onto the C57BL/6 
genetic background to produce a congenic line (>10 backcrosses, designated 
B6N92).  The genotypes of litters were assayed by LacZ PCR (section 4.2.1.2) and 




Figure 4.1 Representative gel showing PCR genotyping of GR+/- mice 
Heterozygous mice (het) carrying a wt allele (LacZ negative) and the ESKN92 GR-
βgeo allele (LacZ positive) were identified by PCR using primers which amplify a 
413 bp fragment of the LacZ transgene. A 506 bp PCR product from the β-globin 
gene serves as a positive control for the presence of DNA and successful PCR. L 
indicates 1kb DNA ladder, 1-9 are DNA from offspring (from het x wt cross), 10 is a 
+ve LacZ DNA control and 11 is a –ve LacZ control. Both controls were gifts from 
Heidi Sutherland. Offspring 2, 7 and 8 all carry the GR-βgeo allele (LacZ positive). 
L   1  2   3   4   5   6  7  8  9 10 11
  β-globin (506 bp)
LacZ (413 bp) 
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   +/+ +/-   
N1 75% 7±1 6 8 14 57% 
N2 87.5% 7±1 33 21 54 39% 
N3 93.7% 8±1 37 42 79 53% 
N4 96.9% 6±1 9 10 19 53% 
N5 98.5% 6±1 136 115 251 46% 
N6 99.3% 5±1 6 10 16 62% 
F7 99.7% 6±1 18 16 34 47% 
N8 99.9% 6±1 10 8 18 44% 
TOTAL  6±1 255 220 475 46.3% 
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shows that the ratio wt:heterozygotes approximate to the predicted Mendelian ratio 
(slightly fewer than 50% heterozygotes; 46.3%). The slight under-representation of 
heterozygotes from the B6N92 line might suggest that the survival of heterozygotes 
is compromised.  However, genotyping by PCR carries a risk of false negative 
results, which must be considered when analysing the percentages of heterozygous 
offspring. The backcrosses were continued and currently the line reached N9 (9 
generations of backcross with C57BL/6J meaning this genotype contributed 99.997% 
of the genome). 
 
4.2.2 Production of homozygous mutant mice 
 
Whilst B6N92 mice are not fully congenic with C57BL/6 before F10, due to time 
constrains mice from intermediate generations phenotypically characterized. To 
determine whether the GR-βgeo allele is a “null” allele and therefore predicted to be 
lethal at birth (Cole et al., 1995) GR+/- mice (F3 or F7) were intercrossed. 146 
progeny were generated from these crosses and their genotypes analysed by LacZ 
PCR to identify mice that carry the transgene (Table 4.5). The results for the B6N92 
line are consistent with lethality of homozygousity for the GR-βgeo allele , predicted 
to give a ratio of 2:1 for LacZ positive:negative offspring (compared to 3:1 predicted 
if homozygotes survived). 
 
Of 146 progeny survived to adulthood from 32 litters (~ 4-5 progeny/litter), 60% 
carried the LacZ transgene and 40% did not (LacZ negative) and were therefore wt 
(Table 4.5).  In addition, ~7% (10 out of 156 born in total) of which were found dead 
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at approximately 3 weeks (mean 27.5±1.5 days) after birth.    However, it is possible 
that some heterozygote embryos fail to survive. Thus, C57BL/6 heterozygous mice 
can breed, but perhaps there are also problems with the heterozygotes during 
embryonic development. 
 
4.2.2.1 Genotyping of homozygous GR-/- mice by PCR 
 
 The site of the gene trap cassette within the itron between exons 3 & 4 was 
determined. To locate the site and thus identify GR-/- mice, a series of primers was 
designed to PCR the engrailed gene (en2; primer details in Appendix C) and GR 
intronic sequences (fig. 4.2).  All attempts were unsuccessful (data not shown). It is 
possible that the splice acceptor (SA) region of β-geo has been disrupted in some 
way during integration. This problem was also encountered in other transgenic lines 
generated by gene trap approach (Heidi Sutherland, personal communication). 
Accordingly, an alternate strategy was adopted. Because the cassette is >4kb, 
integration would disrupt a PCR reaction where the primers spanned the integration. 
A series of primers (fig. 4.2A, arrows and fig. 4.2B predicted genotype results) were 
designed to PCR “walk” across the intron between exons 3 & 4.  The primer 
sequences and PCR amplification programme are described in detail in section 
2.2.1.2.2 (Table 2.4) and Appendix C.  Previous reports predict that the allele would 
not be embryonic lethal (Cole et al., 1995). Accordingly, to ensure representation of 
homozygotes, genomic DNA from E18.5 embryos was subject to PCR. All primer 
pairs except one gave the predicted product from all the DNA samples. For the “red” 
primer pair (fig.4.2), a 470bp product was produced from 6 of the DNA samples but 
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not from the other 3 (fig. 4.3). All except samples 2&3&8 yielded a 413bp LacZ 
product (summarized in Table 4.4) indicating they are GR-/-. The embryos were also 
stained with X-gal (fig. 4.4). Embryos 1 & 6, which tested negative for the LacZ 
transgene, did not stain with X-gal confirming the GR+/+ genotype. Although non-
quantitative, embryos 2 & 3 & 8, which were genotyped as GR-/-, showed the 
strongest stain with X-gal (Table 4.4, fig. 4.4) consistent with expression of the GR-
βgeo transgene in these embryos.  A total of 60 embryos were genotyped (Table 4.5). 
The results showed fewer than expected GR+/- (36.7% instead of 50%), close to the 
expected number of GR-/- (26.6%), but a higher percentage for GR+/+ (36.7% instead 
of 25%).    To confirm the homozygous and heterozygous mice as identified by PCR, 
the generation of a Southern blot assay will be informative. A greater number of 
adult progeny will need to be assessed in this line to conclude the phenotype of 
homozygous lethality. 
 
4.3 Adult GR+/- mice show reduced GR expression  
 
All the GR expression analysis data presented here were performed on F5 adult GR+/- 
mice and littermate controls (GR+/+). GR mRNA levels were measured in a variety of 










B) Predicted results from LacZ and GR PCR assays 
  GENOTYPES 
PCR primers +/+ +/- -/- 
lacZ (413bp) - √ √ 
GR (470bp)  √ √ - 
Figure 4.2 A schematic view of the GR PCR primers designed for the identification 
of GR-/- mice and predicted results.  
(A) 5 sets of GR primers (arrows with same colour represent a set of primers) were 
designed to amplify sequences within intron C, where 5’RACE results (section 3.2.2, 
fig. 3.4) showed that the gene trap was integrated. The numbers refer to sizes of 
exon3 (167bp), intron C (4.1kb), en2 intron (1.5kb) and gene trap cassette (~4kb) and 
exon4 (117bp) (B) summary of the predicted results to identify wild type (+/+), 
heterozygous (+/-) and homozygous (+/-) mice. Heterozygotes carry both the wt 
allele (470 bp band; purple set of primers) and the gene-trap allele (LacZ; 413 bp 
band).  Homozygotes carry the gene-trap allele only (two copies of LacZ,) and 
therefore only the 413 bp band and not the wt allele would be seen on a gel. Wild 


















































Figure 4.3 PCR of E18.5 DNA from heterozygous intercross using primers from        
intron C. 
A PCR with 5 sets of GR primers (1-5)(amplifying various intronic C sequences; see 
figure 4.2) was performed using DNA from 9 E18.5 embryos to identify the site of 
integration and thus the appropriate set of primers to be used for the GR-/- 
genotyping. PCR products were resolved on a  2% agarose gel. In each case, lanes 1-
9 contain DNA from embryos, lane 10 is a negative control (no DNA). GR primers 
amplifying a 470bp region from intron C were used for the GR-/- genotyping. 
Embryos 2, 3 and 8 lack the 470 bp band identifying them as homozygous. For 
details on the primers used refer to Appendix C (Table C.1). 
1  2  3  4  5  6  7  8  9  10   1  2  3   4   5   6   7   8  9  10   
1  2   3  4  5  6   7  8   9  10   1  2  3  4   5   6  7  8 
  9   10     1      2     3       4    5      6     7      8     9      10  
GR1 (620bp) GR2 (820bp) 
GR3 (770bp) GR4 (600bp) 























Figure 4.4 X-gal staining of whole E18.5 embryos.  
E18.5 embryos from a heterozygous intercross (F7) were harvested, washed briefly 
in PBS, fixed in LacZ fixative for 3 hours at 40C. They were then washed twice with 
LacZ wash for 15 minutes, stained overnight in LacZ staining buffer at 370C and 
then transferred into PBS. Note intense blue stain in the GR-/- (KO), less stain in 










Table 4.4 Combined results from LacZ and GR PCR reactions to identify genotypes, 
and X-gal staining   of E18.5 embryos from a heterozygous intercross.  
 
 
Embryos 2, 3 and 8 are homozygous (-/-), carrying only the LacZ transgene (note 
absence of GR470bp band) and stain strongly with X-gal (+++++). Embryos 4, 5, 7 
and 9 are heterozygous (+/-), carrying both the LacZ and GR bands and show less  
X-gal staining (+ to +++). Embryos 1 and 6 are wild type (+/+), carry only the GR 
band (note absence of LacZ band) and do not stain with X-gal. √ indicates the 
presence of band (either LacZ or GR or both), - absence of band and + X-gal staining 
with increasing numbers of + indicating increasing intensity of staining.The LacZ 
(413bp) and GR (470bp) primers could not be combined in the same PCR due to 
very similar PCR product sizes (data not shown).  Therefore two sets of PCRs were 



















1 - √ √ √ √ √ - +/+ 
2 √ √ √ √ √ - +++++ -/- 
3 √ √ √ √ √ - +++++ -/- 
4 √ √ √ √ √ √ +++ +/- 
5 √ √ √ √ √ √ + +/- 
6 - √ √ √ √ √ - +/+ 
7 √ √ √ √ √ √ + +/- 
8 √ √ √ √ √ - +++++ -/- 
9 √ √ √ √ √ √ + +/- 
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The expected Mendelian ratio from a heterozygous intercross is 1:2:1 
(wt:het:homo).In the adult F3 offspring, the ratio is 60:85:1. If the data are analysed, 
excluding the one homozygous mouse, the ratio wt:het should be 48:97, however, 
here it is 60:85 (for a total of 145 mice). A Chi-square analysis with Yates correction 
gave a value of 3.9, p<0.05. This suggests that the heterozygous mice are under-
representative in the adult population. If all the pre- and post-natal mice are added 
up, the ratio is 82(wt):107(het):17(homo). If the homozygous mice are excluded from 
the analysis, for a total of 189 mice, the expected Mendelian ratio should be 
63(wt):126(het). A Chi square analysis gave a value of 8.15, p<0.05 suggesting again 










                                                    GENOTYPES 
Stage Generation +/+ +/- -/- Total % wt:het:ko 
Adult F3 60 85 1 146 ~60% hets 
E11.5 F7 3 2 1 6 
E14.5 F7 4 2 1 7 
E15.5 F7 2 2 3 7 

















4.3.1 Reduced GR mRNA levels in GR+/- peripheral tissues by real time 
PCR 
 
To estimate the reduction of GR mRNA levels in GR+/- mice in various peripheral 
‘metabolic’ tissues (adipose, muscle, adrenal, liver), RNA was extracted, reverse 
transcribed and analysed by real time PCR using a commercial GR primer-probe 
specific for exons 5-6 (missing from the mRNA encoding GR-βgeo, details in 
section 2.2.1.1.4.2.). β-actin (for validation see section 2.2.1.1.4.3) was used as an 
internal standard to correct for RNA concentration. Negative controls omitting 
reverse transcriptase (Superscript III) or RNA were included in every assay. Table 
4.6 shows that loss of one functional GR allele in the GR+/- mice resulted in  45-50% 
lower levels of GR mRNA in all fat depots examined (epidididymal, inguinal, 
mesenteric), ~60% lower in muscle (soleus and extensor-longus digitalis; EDL), 30% 
lower in the liver and 65%  lower in the adrenal gland. 
 
4.3.2. In situ hybridization showed reduced GR mRNA levels in GR+/- 
brain. 
 
GR mRNA was localised to all subfields of the hippocampus (CA1, CA2, CA3) and 
the dentate gyrus (DG), the paraventricular nucleus (PVN) of the hypothalamus and 
the pituitary gland, in both wild type and heterozygous mice (fig.4.5). Consistent 
with previous data in brain (Herman et al. 1989), expression of GR mRNA was  
highest in CA2 and DG, with lower levels in CA1, 3 in both genotypes. 
Nevertheless, GR+/- mice showed a ~50-60% reduction in GR mRNA levels in all 
fields of the hippocampus (fig. 4.5A-C, Table 4.6), 60% in the pituitary (fig. 4.5D,  
Table 4.6) and 50% in the PVN (fig. 4.6B, E, F, Table 4.6). 
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Table 4.6 GR+/- mice have decreased GR mRNA levels in the brain and peripheral 
tissues. 
 




BRAIN                                GR mRNA LEVELS (AU)  
0.4±0.05 0.2±0.03 50% 0.002 
0.5±0.06 0.2±0.05 60% 0.003 
0.14±0.01 0.06±0.02 57% 0.002 
Hippocampus: CA1 
                        CA2 
                        CA3 
                         DG 0.4±0.03 0.2±0.03 50% 0.002 
PVN  0.4±0.1 0.2±0.05 50% 0.05 
Pituitary  0.5±0.07 0.2±0.04 60% 0.002 
PERIPHERY                    GR mRNA LEVELS (AU)  
Adrenal 1.7±0.3 0.6±0.08 65% 0.002 
Liver 1.0±0.05 0.7±0.06 30% 0.002 
Epididymal fat 1.3±0.09 0.7±0.05 46% 0.0002 
Inguinal fat 1.1±0.06 0.6±0.1 45% 0.006 
Mesenteric fat 0.6±0.07 0.3±0.08 50% 0.05 
EDL muscle 1.4±0.1 0.6±0.1 57% 0.004 






4.3.2.1 X-gal staining of adult brains mirrors GR mRNA expression 
levels. 
 
GR+/- brain sections were stained with X-gal in order to investigate the GR-βgeo (will 
be referred as βgal) distribution pattern throughout the brain. The results showed that 
GR-βgal is present throughout the brain, with strongest staining in the cortex, 
hippocampus (CA1/2/3, DG) and PVN (fig. 4.6A,C). No staining at all was seen in 
GR+/+ brains (fig. 4.6D) The staining pattern (fig.4.6A) mirrors the distribution of 
GR mRNA expression seen in GR+/+ mice (fig. 4.6B). 
 
4.3.3 GR protein levels in GR+/- mice by western blot analysis 
 
GR protein levels in epididymal fat of GR+/- mice were analysed by western blot. The 
epitope of the M20 antibody (GR specific; Table 2.5) is located in the N terminus of 
GR and thus is present in the endogenous and fusion proteins. Figure 4.7 shows 
reduced levels of the 95kDa functional GR protein in epididymal fat of GR+/- 
compared to GR+/+ littermates. Furthermore, the 191kDa GR-βgal fusion protein was 
evident in the samples from GR+/- mice (fig. 4.7).  
 
4.4 Unaltered 11β-HSD1 mRNA expression levels in GR+/- mice 
 To investigate if altered GR density and subsequently compensatory increased 
corticosterone secretion (described in chapter 5) modulates expression of 11β-HSD1 
(the enzyme that converts inactive to active GCs; details in chapetr 1; fig. 1.3), real 
time PCR was used to measure mRNA levels of the enzyme in the liver and 
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epididymal adipose tissue of adult GR+/- mice. A commercially available 11β-HSD1 
set primer-probe was used (section 2.2.1.1.4.2) and three house keeping genes (β-
actin, TATA binding protein; TBP and 18S ribosomal RNA; 18S) were used to 
correct for variations in RNA concentration between samples. The results showed 
that hepatic (fig. 4.8A) and epididymal fat (fig. 4.8B) 11β-HSD1 mRNA levels are 




Figure 4.5 GR+/- mice have reduced GR mRNA expression in brain (hippocampus 
& pituitary).  
A&B, Representative photomicrographs of in situ GR mRNA hybridization 
illustrating higher expression in wild type (A) than in heterozygous mice (B) in the 
CA1, CA2 and CA3 subfields of the hippocampus and in the DG. Semiquantitative 
analysis by optical densitometry measurements in the hippocampus (C) and pituitary 
(D). Two-way analysis of variance revealed a significant effect of genotype and 
hippocampal subfield and a significant genotype x hippocampal subfield interaction. 
Post-hoc paired comparisons were performed for differences between subfields. 
(CA1<CA2, p=0.032; CA1>CA3, p=0.032; CA1=DG, p=0.277; CA2*CA3, 
p<0.001). n=6/group.** p<0.01. Hippocampal subfields were defined in accordance 
with the stereotaxic atlas of Paxinos and Watson. Comparison of GR levels in the 
pituitary by Student’s t test. Note that the pituitary has been moved during dissection 
and placed on the top of the cortex. Data presented here were produced by E. Owen, 
a MSc project student under my supervision.  
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Figure4.6 The pattern of GR-βgal protein distribution mirrors the endogenous GR 
expression in the brain.  
A) Representative brain sections from GR+/- mice stained with X-gal 
B).Representative autorad  images showing in situ hybridization (ISH) of GR+/+ brain 
sections (cortex, hippocampus, PVN), (C)-(D) Images showing X-gal staining in 
hippocampal subfields of GR+/- (C) but not GR+/+ (D) mice, E) ISH showing GR 
expression in the PVN of GR+/- brain and  F)  Quantification of GR mRNA levels in 
the PVN of GR+/+ (white bar)   and GR+/- (black bar)   mice showing 50% reduction 
in the latter. CA1/2/3; hippocampal subfields, DG; dentate gyrus and PVN; 
paraventricular nucleus. n=6/group, * p<0.05. Data presented here were produced by 
E. Owen, a MSc project student under my supervision.  
X-gal (GR+/-) GR in situ (GR+/+) 
/
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Figure 4.7 GR wild type and fusion protein levels in epididymal adipose tissue. 
Representative image of western blot in which wild type (wt) GR and GR-βgal were 
detected in protein extracts from epididymal fat of adult male GR+/+ and GR+/- mice 
were analysed by western blot (n=6/group). Fusion protein (191 kDa) was apparent 
only in the GR+/- mice (upper blot). Results showed decreased wt GR protein (95 
kDa) levels in GR+/- compared to GR+/+ mice. Rat liver protein was included in the 
analysis as a positive control for the wt GR protein. A tubulin specific antibody and 
ponceau red were used to check for control for protein loading.  
liver
GR-βgal 191 kDa 
+/+ +/++/- +/++/- +/-
GR 95 kDa 


































Figure 4. 8 Hepatic and adipose 11β-HSD1 mRNA levels are unaltered in GR+/-mice. 
11β-HSD1 mRNA levels were measured by real-time PCR using β-actin as an 
internal control in (A) liver and (B) epididymal fat. Note that in (B) irrespective of 
the internal control used (18S; ribosomal RNA, TBP; TATA binding protein and β-
actin) the results are similar. Student’s t test was performed for the comparison of 
















   


























   















The approach taken here to generate GR+/- mice has the advantage that the GR-βgal 
fusion protein is under the control of the endogenous GR promoter and therefore is 
expressed at physiological levels in the cell. Furthermore, the presence of the β-gal 
cassette greatly facilitates genotyping of heterozygous mice and provides a dynamic 
reporter of gene activity, another advantage over existing GR-deficient mice. 
 
The B6N92 line was backcrossed onto the C57BL/6 genetic background for > 9 
generations and it is therefore now ‘congenic’ by current standards (Banbury 
Conference on Genetic Background in Mice report 1996), though some 129 
sequences may remain, especially around the transgene/GR locus if subject to 
linkage disequilibrium.   
 
The generation of mice homozygous for the GR-βgal allele provided a way to study 
the potential lethality of the allele. With one exception, all homozygous mice died at 
birth, consistent with previous models (summarised in Table 1.1). Briefly, 10-20% 
GRhypo/hypo (hypomorphic allele) mice survived to adulthood (Cole et al., 1995) while 
GRnull/null mice were all died shortly after birth (Finotto et al., 1999). Although, 
possibility still remains that the GR-βgal might be a hypomorphic allele, it is 
certainly less “leaky” (incomplete penetrance) compared to GRhypo/hypo since only one 
homozygote mice survived to adulthood and consistent with lack of transactivation 
capacity as shown in chapter 3 (section 3.2.5.2).  Because a southern blot was not 
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performed in the model presented here, it still remains a possibility of a genotyping 
error. In the future, genotyping of offspring from intercrosses of GR+/- mice will be 
necessary to rule out the possibility of a hypomorphic allele.  Interestingly, the fewer 
number of heterozygotes (46% instead of the expected 50%) from the B6N92 
transgenic line could suggest that the survival of heterozygotes may be compromised 
in this line. Indeed,  analysis performed using a Chi-squared test (Table 4.5) 
suggested that the both homozygous and heterozygous mice are under-representative, 
with some lost in utero and others post-natally. 
 
Heterozygous mice have only a single intact GR allele and, as predicted, functional 
levels of mRNA encoding GR were decreased (30-60%) in every tissue analysed in 
the heterozygous mice. It is interesting that the tissue with the highest down-
regulation of GR mRNA expression (65%) was the adrenal gland. Adrenal 
morphology is completely disorganized in GRhypo/hypo mice (Cole et al., 1995) and is 
also disrupted in GR+/- mice (chapter 5). Greater than 50% decrease, cannot be 
simply explained by autoregulation (as in tissues with <50%). It may reflect an 
altered adrenal morphology with different populations of cells differentially 
represented (eg higher expressing subset of cells may be under-represented in GR+/- 
mice). Moreover, the reduction in mRNA expression translated to reduced wild type 
GR protein consistent with previously reported GR+/- mice (Ridder et al, 2005) and 
the presence of the GR-βgal fusion protein in the GR+/- mice.  Indeed, in brain, X-gal 
staining faithfully reflected the expected expression pattern of GR. Preliminary data 
have confirmed expression in both embryonic and adult tissues and highlighted 
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possible novel sites of expression in the former (unpublished observations). 
However, detailed analysis is beyond the scope of this Thesis.   
 
The major determinants of tissue GC action, apart from  GR density, are the 
intracellular levels of ligand, the latter determined both by activity of the HPA axis 
and cellular activity of 11β-HSD enzymes that interconvert active 11-hydroxy 
(corticosterone, cortisol) and inactive 11-keto (11-dehydrocorticosterone, cortisone) 
GCs. Here, I showed that 11β-HSD1 mRNA levels in 2 key metabolic tissues (liver 
and epididymal fat; neither of which express 11β-HSD2) are unaltered in this model 
of reduced GR density. This suggests that a reduction in the GR per se does not 
appear to regulate the levels of 11β-HSD1 at least in these tissues.  
 
The following chapter describes the use of this model to investigate the effects of 
reduced GR density in the regulation of HPA axis, body fat distribution and 
metabolic parameters.  
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Chapter 5   
 
GR+/- mice phenotyping:  












5.1 Introduction and aims 
 
In humans, polymorphisms in the GR gene have been linked to altered GC sensitivity 
and metabolic abnormalities (Rosmond et al., 2000a, 2000b, 2001). GC 
hypersensitivity has been associated with visceral obesity, insulin resistance, 
hypertension and increased cardiovascular disease risk (Buemann et al. 1997; 
Rosmond et al., 2000b; Ukkola et al., 2001; Dodson et al., 2001; van Rossum et al. 
2003 and extensive description in section 1.6.2). However, individuals with 
substantially reduced GR density are very rare (details in section 1.6.2). The 
incidence is too low and the underlying variance in humans too great to permit 
effective study of the effects of GR mutations on body composition.   
 
Given the important associations between GR polymorphisms, fat distribution and 
hypertension it is perhaps surprising that the effects of globally reduced (transgenic, 
gene targeted) GR density on body fat distribution (rather than merely whole body 
fat content) and blood pressure have not previously been described (discussed in 
section 1.6.2). GC excess (pharmacological) can induce dose-dependent increases in 
blood pressure and endogenous overproduction of GCs leads to hypertension both in 
humans and animals (Saruta et al., 1986; Grunfeld, 1990; Sholter and Armstrong, 
2000). On the other hand, adrenal insufficiency or GR blockade lowers blood 
pressure (Gardiner and Bennett, 1983; Udelsman et al., 1986). 
 
Several mouse lines with altered GR expression or function have been generated, and 
the effects on behaviour and HPA axis regulation have been extensively studied 
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(reviewed in Gass et al, 2001; Muller et al, 2002; Howell and Muglia 2006, Neigh 
and Nemeroff, 2006).  As described in chapter 1 (section 1.6.1) there is limited 
exploration on the down-stream effects of altered GR density in peripheral and more 
metabolically relevant tissues. 
 
 In this chapter, the effects of “globally” reduced GR density (GR+/- mice) upon HPA 
axis function, fat distribution and glucose homeostasis under basal (chow fed) 
conditions and following a high fat (HF) feeding (that models a high calorie/obesity 
situation) are described. Furthermore, I tested if reduced GR density affects blood 
pressure regulation. All the experiments described here were performed on F5 GR+/- 
and GR+/+ littermates. Basal characterization was carried out in both male and female 
chow-fed mice while the HF experiment was performed on male mice. Figure 5.1 















Figure 5.1 Experimental design. 
Basal phenotyping was carried out in F5 chow-fed male and female mice. The  HPA 
axis function was studied under basal conditions and acute stress (10 min restraint in 
a falcon tube) conditions. Briefly, mice were acclimated to single housing and tail 
nicks performed within 1 minute of disturbing the cage to ensure unstressed plasma 
corticosterone plasma levels. For corticosterone levels, sampling was performed in 
the nadir (7am) and peak phase (7pm). For restraint stress, tail tip blood sampling was 
performed at 20 and 120min after restraint. ACTH secretion was evaluated only in the 
nadir phase from trunk blood collected by decapitation.  Body weight was monitored 
weekly. Food intake was monitored for 3 weeks when the mice were single caged for 
individual experiments. At the end of the experiment, mice were culled and tissues 
were dissected and weighed. To evaluate glucose homeostasis, male and female mice 
were subjected to   glucose tolerance (GTT) and insulin tolerance tests (ITT). 
Animals were fasted for 6h. For GTT, 2mg/g body weight (BW) of 25% glucose was 
intraperitoneally (i.p) injected and tail tip blood sampling was performed at time 0 
(prior to injection), 15, 30, 60 and 120min after injection. For ITT, 1mU/g BW 
(females) or 1.5mU/g BW (males) insulin was i.p. injected and blood sampling was 
performed at time 0, 15, 30 and 60min after injection and plasma glucose was 
measured. For the diet-induced obesity (DIO) experiment, male mice weaned on high 
fat (HF) or low fat (LF) control diets and remained for 22 weeks with ad libitum 
access to water and diet. All measurements performed as in basal phenotyping. 
Systolic blood pressure was measured in conscious warmed mice by tail cuff 
plethysmography using a tail cuff designed for mice (described in section 2.2.3.5).  
 
F4 
+/+ x +/- 
F5 
+/+ and +/- 
Basal characterization: 
wean on chow diet 
HF experiment (6months on diet): 
wean on HF (58% kcal as fat) or LF (11% fat) 
♀ ♂ ♂ 
Am & pm plasma CORT (4months of age)  
Am plasma ACTH (♀&♂ @ 5months) 
10min restraint Stress (♂ & ♀ 4 months) 
BW (from weak 5 to 24 of age) 
FI (monitored for 3weeks; w22-w24) 
GTT (♀5months; ♂4 months) 
ITT (♀6months; ♂5 months & repeat 1yr old)  
Tissue weights (culls:♀&♂ @ 5months)
Am (7months of age) & pm plasma CORT (6 
months) 
Am plasma ACTH (7months of age) 
BW (from weaning to week 22 of age)  
GTT (5months of age) 
BP (8 months of age) 
Hepatic triglycerides 
Tissue weights (culls: 7months of age) 
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5.3. Results  
5.3.1. Experiments performed under basal (chow fed) conditions. 
5.3.1.1. GR+/- mice show HPA axis hyperactivity and have bigger 
adrenals.  
 
Nadir (morning) and peak (evening) plasma corticosterone levels as well as morning 
plasma ACTH levels were measured in order to assess HPA axis function in chow 
fed adult male and female GR+/- mice. Morning corticosterone levels did not 
significantly differ between genotypes in either gender (although there was perhaps a 
trend for higher corticosterone in both male (fig. 5.2A) and female (fig. 5.2C) GR+/- 
mice. However, evening circulating corticosterone levels were significantly elevated 
in GR+/- male (fig. 5.2B) and female (fig. 5.2D) mice (male GR+/+ vs GR+/-; 177±28 
vs 277±17 nM, p<0.01; female, 401±35 vs 735±56nM, p<0.001). Morning plasma 
ACTH levels were similar in both genotypes in both males (fig. 5.3C) and females 
(fig. 5.3D). ACTH levels were variable between mice, possibly due to its pulsatile 
secretion pattern (Lappaluoto et al., 1975; Lopez et al., 1988; Carnes et al., 1989; 
Goodman et al., 1994 and reviewed in Gudmundsson and Carnes, 1997) and to the 
fact that blood sampling was performed over a somewhat broad time window (8-
10am). All ACTH values measured are presented in figure 5.3A-B. This clearly 
shows that there are two statistical outliers from the group mean. However, even 
when the analysis is performed excluding these outliers, the results show that there 
are no differences between genotypes in either male (fig.5.3C) or female (fig.5.3D) 
mice, and they are included here to highlight the inherent variability in this 




Figure 5.2 GR+/- mice have elavated peak plasma corticosterone levels 
(A) Morning (nadir) plasma corticosterone (Cort) levels in male GR+/+ and GR+/- 
mice (n=11/group), (B) Evening (peak) Cort in male GR+/+ and GR+/- mice 
(n=11/group), (C) Morning plasma Cort levels in female GR+/+ and GR+/- mice 
(n=9/group) and (D) Evening Cort in female GR+/+ and GR+/- mice (n=9/group). 
Student t test was performed to identify differences between genotypes. ** p<0.01 







































































Figure 5.3 GR+/- mice have similar plasma ACTH levels to their GR+/+ littermates.  
Morning plasma ACTH levels in GR+/+ and GR+/- male (A and C) and female (B and 
D) mice. Student t test was performed to identify differences between genotypes 
(n=6/group). Panels A and B show all the ACTH levels per animal. Panels C and D 
show the mean±SEM per group. Note that values that “looklike” outliers in panels A 
and B have been excluded from the analysis after identified as outliers according to 
the ESD (extreme studentized deviate). Note that in (A) and (B) the red dotted line 
indicates the sensitivity lower limit of detection in this assay (0.4pg/ml). Because 
some values were below this sensitivity limit I set them to 0.4 pg/ml to allow 











































































Female morning ACTH 
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Figure 5.4 Male GR+/- mice have elevated corticosterone response after acute 
stress. Both male and female GR+/- mice have bigger adrenals. 
Plasma corticosterone levels after 10min restrain stress in (A) male (n=9/group) and 
(B) female (n=7-8/group). Mice were put in a restrain tube (in the morning) for 
10min and tail tip blood collected 20 and 120min after restrain.  Left adrenal weights 
corrected for body weight in GR+/+ and GR+/- (C) male and (D) female mice. 
(n=6/group). The reason for male adrenals appear to be smaller than female adrenals 
is because the former were weighted after their transfer from formalin to 70% 
ethanol whereas the latter weighted prior to transfer. Student t test was performed to 
identify differences between genotypes. For restrain stress, repeated measures 2-way 
ANOVA (factor A being genotype and factor B time) was used to test for differences 
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Male GR+/- mice showed a higher corticosterone secretion after 10min restraint and a 
delay in the return to basal levels after 120min compared to GR+/+ littermates (fig. 
5.4A). In contrast, female GR+/- mice had a similar plasma corticosterone response to 
restraint stress to GR+/+ mice (fig. 5.4B).   Moreover, GR+/- male (fig. 5.4C) and 
female (fig. 5.4D) mice had  bigger left adrenal glands.  
5.3.1.2. Similar body weight and food intake in GR+/- and GR+/+ mice. 
 
There were no differences in body weight in males (fig. 5.5A) or females (fig. 5.6A) 
between genotypes. Both GR+/- and GR+/+ male (fig. 5.5B-C) and female (fig. 5.6B-
C) mice showed similar food intake patterns.  
5.3.1.3. Similar body composition in GR+/- and GR+/+ mice. 
To assess whether GR+/- mice have altered body fat distribution or lean mass, fat 
depots (epididymal, inguinal, mesenteric and brown adipose tissue) and muscle 
(extensor digitorum longus; EDL and soleus) were weighed. Fat distribution and lean 
mass were similar in GR+/+ and GR+/- male or female mice (Table 5.1). Furthermore, 
there were no differences in tissue weight apart from the adrenal gland as described 
above (Table 5.1). 
5.3.1.4. Unaltered glucose homeostasis in GR+/- mice. 
To investigate the effect of reduced GR density on glucose homeostasis, both glucose 
and insulin tolerance tests were performed. Analysis of the area under the curve 
(AUC) showed no differences in GTT responses (fig. 5.7A-B) between genotypes. 
Both male (fig. 5.6C) and female (fig. 5.6D) GR+/- mice showed similar ITT 
responses to GR+/+ littermates. 
 
 191
Table 5.1 Tissue weights in GR+/- male and female mice. 
 MALES FEMALES 
Tissue 
weights (mg) 
GR+/+ GR+/- p GR+/+ GR+/- p 
Liver (g) 1.5±0.03 1.4±0.09 NS nd nd  
Epididymal 
fat 
445±49 378±78 NS 219±20 219±18 NS 
Inguinal fat 297±18 292±42 NS 269±16 250±12 NS 
Mesenteric fat 309±31 270±51 NS 182±9 173±12 NS 
BAT 94±11 102±10 NS 72±5 82±4 NS 
EDL muscle 
(right) 
     56±2
  
145±99 NS 170±17 161±9 NS 
Soleus muscle 
(right) 
16±0.7  15±1.5 NS 58±3 71±7 NS 
Pancreas 184±7 196±9 NS nd nd  
Spleen 81±12    92±5  NS nd nd  
Thymus 59±12  47±5 NS nd nd  
Adrenal (left) 1.1±0.05 1.9±0.15 0.0013 4.8±0.3 6.0±0.3 0.015 
 
Student t test was performed to test if there are differences in tissue weights between 
genotypes (n=6/group). Significance was set at p<0.05. NS and nd indicate non 
significant difference between genotypes and not done respectively. EDL; extensor 






Figure 5.5 Male GR+/- mice have similar body weight and food intake to GR+/+ mice. 
Panels show A) body weights (BW), n=22/group, B) Weekly food intake. Mice were 
individually caged for 3 weeks for food intake monitoring and C) food intake 
corrected for body weight in GR+/+ and GR+/- mice. n=10/group. Weeks in the x axis 
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Figure 5.6 Female GR+/- mice have similar body weight and food intake to GR+/+ 
mice. 
Panels show A) body weights (BW), n=14/group, B) Weekly food intake. Mice 
individually caged for 3 weeks for food intake monitoring and C) food intake 
corrected for body weight in GR+/+ and GR+/- mice (n=10/group). Weeks in the x axis 
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Figure 5.7 Unaltered glucose homeostasis in GR+/- male and female mice. 
Glucose tolerance test (GTT) in (A) male and (B) female GR+/+ and GR+/- mice. 
Insulin tolerance test (ITT) in (C) male and (D) female GR+/+ and GR+/- mice  For 
GTT and ITT, mice were fasted for 6h. Blood was collected before and after 
intraperitoneal injection of glucose (2mg/g body weight) or insulin (male; 1.5mU/g 
BW, female; 1mU/ g BW) at the indicated times. The area under the curve (AUC) 
per animal was estimated and the mean±SEM AUC per genotype was compared by 
Student t test (n=6/group). In panels A,B,D, glucose was measured by glucose assay 
(details in section 2.2.3.4.2). In panel C, glucose measured by a glucose meter 
(details in section 2.2.3.4.2). GTT: male; GR+/+ vs GR+/-; 25040±1358 AUC vs 
24010±1741 AUC, p=0.65, female; 21970±1165 AUC vs 22500±611 AUC, p=0.7. 
ITT: male; GR+/+ vs GR+/-; 243±25AUC vs 279±17 AUC, p=0.27, female; 
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5.3.2. DIO experiment. Interaction effects of reduced GR and high fat 
feeding.  
 
To assess if responses to HPA axis regulation, fat distribution, glucose and lipid 
homeostasis and blood pressure are differentially affected in the GR+/- mice after a 
high fat challenge (consider as a chronic stressor), male mice were weaned on either 
high fat (HF) diet (58% kcal as fat) or a control low fat (LF) diet (11% kcal as fat). 
For the diet-induced obesity (DIO) experiment, mice were kept on the diet for 6 
months with ad libitum access to water and diet. The experimental design (with the 
timings of the measurements) is presented in figure 5.1.  
 
5.3.2.1. GR+/- mice have altered HPA axis activity and hypertrophic 
adrenals. 
 
Nadir (morning) and peak (evening) corticosterone as well as nadir ACTH hormone 
levels were measured in order to assess HPA axis function in LF and HF fed GR+/- 
mice. There was a significant increase in both circulating nadir (GR+/+ vs GR+/-; 22±2 
vs 68±8 nM, p<0.001) (fig. 5.8A) and peak corticosterone levels (GR+/+ vs GR+/-; 
77±13 vs 179±26 nM, p<0.001) in GR+/- mice (fig. 5.8B). HF diet induced a 3-fold 
(p<0.01) increase in morning corticosterone only in the GR+/+ mice (fig. 5.8A). 
Although plasma corticosterone levels were unaffected by HF in GR+/-, the peak 
circulating corticosterone was still higher (GR+/+ vs GR+/-; 100±15 vs 174±25 nM, 
p<0.01) compared to GR+/+ mice (fig. 5.8B). There were no significant differences in 
morning circulating ACTH levels between GR+/+ and GR+/- mice (fig. 5.8C). 
However, HF diet increased ACTH levels in both genotypes, 80-fold in GR+/+ 
(p<0.01) and 13 fold (p<0.05) in GR+/- mice (fig. 5.8C). Moreover, whereas  
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Figure 5.8 GR+/- mice show a hyperactive HPA axis when fed low and high fat diets. 
A) Morning plasma corticosterone (Cort) levels in control LF fed GR+/+ and GR+/- 
mice and in HF fed GR+/+ and GR+/- mice, B) Evening Cort in control LF fed GR+/+ 
and GR+/- mice and in HF fed GR+/+ and GR+/- mice, C) Morning plasma ACTH 
levels in control LF fed GR+/+ and GR+/- mice and in HF fed GR+/+ and GR+/- mice 
and D) Left adrenal weights in control LF fed GR+/+ and GR+/- mice and in HF fed 
GR+/+ and GR+/- mice. The effects of genotype and diet interactions were assessed by 
2-way ANOVA followed by post-hoc Tukeys’ tests for group differences n=8-
9/group. * or † p<0.05, ** or ‡ p<0.01 and *** or ††† p<0.001. ‡ indicates statistical 
significant difference between +/+ and +/- HF-fed mice. 





















































































HF diet caused adrenal hypertrophy (38% increase in adrenal weight; p<0.05) in 
GR+/+ mice, such an effect was not seen in GR+/- mice (fig. 5.8D). As on chow diet 
(fig. 5.4C), GR+/- mice had larger left adrenal glands (GR+/+ vs GR+/-; 4.7±0.6 vs 
5.7±0.6mg, p<0.05) than GR+/+ nice fed LF diet (fig. 5.8D). Adrenal morphology 
also differed between genotypes (fig. 5.9). In GR+/- adrenals, columns of endocrine 
cells in the zona fasciculata appeared long, with cells in the columns hypertrophied 
and with homogenous eosinophilic cytoplasm (fig. 5.9B). The zona glomerulosa 
appeared thicker than in GR+/+ mice, with more glomeruli evident containing 
hypertrophied epithelium (fig. 5.9A-B). This appearance suggests stimulation of 
corticosterone and aldosterone producing cells (D. Brownstein, personal 
communication). This adrenal phenotype was also apparent in GR+/- mice fed HF diet 
(fig. 5.9C-D). However, while there were no marked differences in adrenal 
morphology between GR+/- mice fed LF or HF diet, in GR+/+ mice columns of 
endocrine cells in the zona fasciculata appeared longer in HF than in LF fed mice 
(fig. 5.9A and C).  
 
5.3.2.2. Unaltered fat distribution and glucose homeostasis but elevated 
liver triglyceride levels in GR+/- mice. 
 
There were no differences in body weight (fig. 5.10A) or food intake (data not 
shown) between genotypes, on the control LF or HF diet. Fat depot (epididymal, 
inguinal, mesenteric) and muscle (extensor digitorum longus) weights were similar in 
GR+/+ and GR+/- mice (fig. 5.10B) on either diet. GR+/- mice had smaller livers on the 
control diet (GR+/+ vs GR+/-; 1.4±0.09 vs 1.1±0.07g, p<0.05) compared to GR+/+  
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Figure 5.9 Adrenal hypertrophy in GR+/- mice. 
Representative images of haematoxylin & eosin (H&E) stained adrenal sections of 
LF fed (A) GR+/+ and (B) GR+/- mice and  HF fed (C) GR+/+ and (D) GR+/-.mice. ZF; 
zona fasciculate (open arrowheads), ZG; zona glomerulosa (closed arrowheads), 
MED; medulla. n=8-9/group.scale on top of each image at 25 microns.Images 
provided by David Brownstein.  
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Figure 5.10 Unaltered body composition and glucose homeostasis but higher liver 
triglycerides in GR+/- mice following HF.  
Panels show (A) body weights (BW), (B) tissue weights: liver,adipose tissue (L;liver, 
epi; epididymal, ing;  inguinal, mes; mesenteric) and extensor digitorum longus 
(EDL) muscle, (C) liver triglyceride (TAGs) levels and (D) glucose tolerance test 
(GTT) in GR+/+ LF, GR+/- LF, GR+/+ HF and GR+/- HF fed.  Insert showing the area 
under the curve (AUC) per group. For GTT mice were fasted for 6h. Blood was 
collected before and after intraperitoneal injection of glucose (2mg/g body weight) at 
the indicated times. Interactions between genotype and diet were assessed by 2-way 
ANOVA followed by post-hoc Tukeys’ tests for group differences. AUC was 
calculated per animal and the mean±SEM per group was compared by 2-way 
ANOVA.  LF; low fat diet, HF; high fat diet. n=6/group, † p<0.05, ** or †† p<0.01, 
*** p<0.001. 
GTT 




























































Body Weight  



































littermates (fig. 5.10B). HF diet did not affect liver weight in either genotype. There 
was a trend for smaller liver in HF fed GR+/- mice (fig. 5.10B). GR+/- mice appeared  
to have higher hepatic triglyceride levels when fed a HF diet (GR+/+ vs GR+/-; 
14.8±0.7 vs 18.1±0.8μmol/g, p<0.001) compared to GR+/+ mice (fig. 5.10C). Glucose 
tolerance was similar between genotypes on control diet and similarly impaired by 
HF diet (fig. 5.10D). 
 
5.3.2.3. GR+/- mice have elevated blood pressure due to activation of the 
renin-angiotensin-aldosterone system (RAAS).  
 
GR+/- mice had 8mmHg higher systolic blood pressure (GR+/+ vs GR+/-; 102±1.3 vs 
110±1.8mmHg, p<0.01) compared to GR+/+ mice on control diet (fig. 5.11). Blood 
pressure in HF fed mice was higher in both genotypes compared to LF diet   (GR+/+, 
14mmHg increase, p<0.01 and GR+/-, 8mmHg increase, p<0.05).  
 
To dissect the potential mechanism involved in the elevated blood pressure in GR+/- 
mice, systemic or/and tissue (adipose, liver)-specific activation of the renin-
angiotensin system (RAS) was investigated. Increased blood pressure in control LF-
fed GR+/- mice was associated with a 2-fold increase (p<0.05) in plasma renin 
activity compared to GR+/+ mice (fig.5.12A). HF diet did not affect plasma renin 
activity in either genotype, but sustained higher in the GR+/- mice (fig. 5.12A). In LF-
fed mice, plasma angiotensinogen levels were similar in both genotypes but 
increased 3-fold (p<0.01) only in the GR+/- mice after HF feeding (fig. 5.12B). 
Plasma aldosterone levels were also higher in GR+/- mice (fig. 5.12C) on control diet 
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(GR+/+ 20±9 vs GR+/- 132±33pmol/L, p<0.01). Although unaffected by HF diet, 
aldosterone levels remained higher in HF-fed GR+/- mice (fig. 5.12C). Moreover, an 
adipose tissue (epididymal)-specific increase in angiotensinogen mRNA levels (fig. 
5.12D) in GR+/- mice (40% higher than GR+/+ mice, p<0.05), but no change in hepatic 
angiotensinogen mRNA levels was observed (fig. 5.12E). Despite the increased 
blood pressure in both genotypes with HF, it is perhaps surprising that HF diet 
induced a 2.5 and 5 fold reduction (p<0.001) in epididymal angiotensinogen mRNA 
levels in GR+/+ and GR+/- mice, respectively (fig. 5.12D). In contrast, hepatic 
angiotensinogen mRNA levels were increased (20%, p<0.05) only in the GR+/- mice 















Figure 5.11 GR+/- mice have elevated blood pressure. 
Tail cuff plethysmography (performed by Dr Elaine Marshall) was used to measure 
systolic blood pressure (SBP) in GR+/+ LF, GR+/- LF, GR+/+ HF and GR+/- HF fed. 
The effects of genotype and diet interactions were assessed by 2-way ANOVA 
followed by post-hoc Tukeys’ tests for group difference.  n=5/group, * or † p<0.05, 



































Figure 5.12 Activation of the Renin-Angiotensin-Aldosterone System in GR+/- mice.  
Panels show (A) Plasma renin activity, (B) plasma angiotensinogen concentration, 
(C) plasma aldosterone concentration, (D) epididymal fat angiotensinogen (AGT)  
mRNA levels and (E) hepatic AGT mRNA levels in GR+/+ LF, GR+/- LF, GR+/+ HF 
and GR+/- HF fed mice. For plasma measurements, n=5/group. For mRNA levels, 
n=8-9/group. AGT mRNA levels were measured by real-time PCR and β-actin was 
used as an internal control. The ratio of AGT to β-actin mRNA was calculated and 
the mean ± SEM per group was compared by 2-way ANOVA followed by post-hoc 

































A Plasma Angiotensinogen 
GR+/+                  GR+/-
** 











   
















































































5. 4. Discussion  
 
In this chapter I demonstrate that global (central and peripheral) reduction in GR 
density leads to impaired negative feedback inhibition of the HPA axis, unaltered 
adipose tissue mass and distribution, normal glucose homeostasis, higher hepatic 
triglyceride accumulation after HF diet challenge and hypertension, the latter perhaps 
due to systemic activation of the renin-angiotensin-aldosterone system.  
 
An ES cell line, in which a gene-trap cassette had integrated into GR,  was exploited 
to generate GR+/- mice that lack part of the DBD and the entire LBD, to study the 
effects of reduced GR density on HPA axis regulation under basal and after high fat 
diet (HF) challenge. Both male and female GR+/- mice under basal (chow-fed) 
conditions displayed a hyperactive HPA axis phenotype with elevated morning and 
evening corticosterone levels in accordance with previous GR transgenic lines (Pepin 
et al., 1992; Tronche et al, 1998; Cole et al., 1995; Reichardt et al, 1998). However, 
previously described GR+/- mice developed by homologous recombination did not 
show an HPA axis phenotype under basal (non-stress) conditions, but had higher 
corticosterone levels following 30 min restraint stress (Ridder et al., 2005). In the  
model presented here, corticosterone was also higher in male heterozygotes after 10 
min restraint stress in accordance with previous data (Ridder et al., 2005) and 
consistent with their enlarged adrenal glands. These data are consistent with a 
hyperactive HPA axis in male GR+/- mice under basal and acute stress conditions and 
suggest reduced negative feedback regulation as a consequence of global reduction in 
GR density. Indeed, GR expression was ~50-60% decreased in pituitary, PVN and 
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hippocampus of GR+/- mice compared to GR+/+ littermates (chapter 4, section 4.3).   
It is worth noting that plasma corticosterone levels in female mice were higher than 
in male at the peak and following restraint stress, as previously described in rodents 
(Seale et al., 2004; Harizi et al., 2007). Although GR+/- mice displayed higher 
corticosterone levels basally and under acute stress, morning circulating ACTH 
levels were unaltered in both male and female GR+/- mice. Due to limitations (time 
and mice availability), only morning ACTH levels were measured, and although 
unaltered that does not exclude the possibility that evening ACTH might be elevated 
in the GR+/- mice. The ACTH data presented here are consistent with one (Reichardt 
et al., 1998) but in contrast with other GR transgenic models that showed elevated 
ACTH levels (Pepin et al., 1992; Cole et al., 1995; Schmid et al., 1995; Tronche et 
al., 1998). However, caution should be taken when comparing different GR models 
generated by different strategies (especially tissue/cell specific). The GR+/- mice 
presented here should be better compared with the GR+/null (Finotto et al., 1999), 
GR+/hypo (Schmid et al., 1995), GR+/dim (Reichardt et al., 1998) and GR+/antisense (Pepin 
et al., 1992) but unfortunately these data are not available.  
 
Moreover, the effect of chronic HF-feeding, which elevates corticosterone levels and 
thus can be considered as a chronic “low level” stressor, on HPA axis regulation was 
investigated in this model.  HF diets stimulate ACTH production from the pituitary 
gland and increase adrenal capacity to secrete corticosterone (Lawson et al, 1981; 
Tannenbaum et al, 1997; Michel et al, 2004; Lindqvist et al, 2006). For example, 
elevated free fatty acids have direct effects on (a) increasing (in a dose-related 
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manner) ACTH and CORT levels after intralipid emulsion administration in rats 
(Widmaier et al, 1992) and (b) inhibiting ventromedial hypothalamic neuronal firing 
(Oomura Y., 1976) and thus blunting the inhibitory effect that these neurons have on 
HPA axis (Dallman, 1984).   Indeed, that was apparent in GR+/+ mice, in which 
morning plasma levels of corticosterone and ACTH, and adrenal size were increased 
by HF.  However, in GR+/- mice the HF diet had a lesser effect, increasing  morning 
plasma ACTH levels only 13-fold compared to  80-fold icrease in wild type 
littermates. Additionally, HF diet did not further increase (already higher) CORT 
levels and adrenal size in GR+/- mice. It seems as though reduced GR density 
decreases the ability to adapt to the HF diet. The differences between LF and HF 
diets were smaller in GR+/- mice such that the GR+/+ mice seem to “catch up” on HF 
diet.  
 
Having confirmed that GR+/- mice have a dysregulated HPA axis, the primary aim 
was to investigate if reduced GR density and consequently altered  GC sensitivity 
affects body fat distribution, glucose or lipid homeostasis and blood pressure 
regulation during exposure to an ‘obesigenic’ diet.  Global reduction in GR density 
did not affect body weight, fat distribution or glucose homeostasis under basal 
(control low fat diet) or diet-induced obesity (DIO) conditions. GR reduction is 
therefore likely compensated by activation of the HPA axis. Such compensation 
might explain why there are no apparent differences between genotypes in body fat 
distribution or glucose metabolism. The lack of altered glucose homeostasis is not 
surprising since GR inactivation exclusively in hepatocytes showed that GR is 
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essential for glucose homeostasis only under prolonged fasting or streptozytocin-
induced diabetes (Opherk et al., 2004; described in section 1.6.1 & Table 1.1).  
In vitro GCs directly increase hepatic fatty acid (FA) and triglyceride (TG) synthesis 
(Klausner and Heimberg, 1967; Diamant and Shafrir, 1975; Bartlett and Gibbons, 
1988; Brindley, 1988). The effects of GCs on hepatic lipid synthesis in vivo are 
complex. For example, low dose GCs can restore the impaired hepatic de novo fatty 
acid and TG synthesis, secretion and deposition into lipid stores after adrenalectomy 
in rats (Kirk et al., 1976; Mantha et al., 1999) and physiological GC levels promote 
hepatic lipogenesis at least in non-diabetic or not severely stressed rats (Kirk et al., 
1976). Although the peripheral effects of GCs on maintaining lipid production and 
storage are mainly direct, the positive modulation of adipose lipoprotein lipase (LPL; 
the major enzyme catalyses TG hydrolysis and thus FA release) activity might be 
indirect and may be “shared” with insulin’s actions (Ashby and Robinson, 1980; 
Fried et al., 1993). GR+/- mice on LF-diet had smaller livers suggesting that reduced 
GR density could potentially affecting hepatic lipid accumulation and/ or secretion or 
glycogen storage.   Although one might expect that GR+/- mice would have reduced 
hepatic triglyceride levels that might explain their smaller livers, there was no 
difference in liver triglyceride levels under basal conditions (control low fat diet) 
between genotypes. However, the consequences of altered GC status on triglyceride 
metabolism are strongly dependent on diet (Smith & Romsos, 1985; Kang et al., 
1992; Mantha et al., 1999). Corticosterone does not appear to significantly modulate 
triglyceride metabolism when lipid flux is low, ie when animals are maintained on a 
low fat diet (Mantha et al., 2000). In contrast, the impact of glucocorticoids on 
triglyceride metabolism becomes highly significant when animals are fed a HF diet 
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that induces a high lipid flux (Mantha et al., 2000). Support for this notion comes 
from adrenalectomy experiments showing that absence of corticosterone 
significantly reduces hepatic triglyceride accumulation, secretion rate and plasma 
triglycerides in HF fed animals (Mantha et al., 1999). In this experiment, HF diet 
increased hepatic triglyceride accumulation in both genotypes, but the effect was 
more pronounced in GR+/- mice. The enhanced accumulation of hepatic triglycerides 
could be partly explained by the adrenal cortex hyperfunction and the consequently 
elevated circulating corticosterone levels observed in both genotypes on HF diet. 
However, since under basal conditions (LF) the already hypercorticosteronaemic 
GR+/- mice have unaltered hepatic TG levels (compared to GR+/+) it is more likely 
that there is a synergism of GC and insulin actions promoting hepatic TG synthesis 
in both genotypes.  
 
Here, the effect of reduced GR density in the control of blood pressure in mice was 
also investigated. Although the HF diet-dependent increase in blood pressure was 
apparent in both genotypes, only GR+/- mice under basal conditions had elevated 
systolic blood pressure. The hypertensive phenotype in GR+/- mice was associated 
with elevated plasma renin activity and plasma aldosterone concentration as well as 
an adipose tissue specific up-regulation of angiotensinogen (AGT) mRNA 
expression indicating both systemic and local activation of RAAS. Despite this 
induction of the RAAS system components in the GR+/-, there was no genotype-
dependent increase in blood pressure after HF feeding, indicating that a further 
adaptation counteracting the RAAS changes had occured. This is noteworthy since it 
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suggests care should be taken when interpreting tissue specific changes in the RAAS 
system. Thus, whilst angiotensinogen, the circulating substrate for renin, increased 3-
fold in GR+/-, this is presumably the end product of secreted angiotensinogen from 
adipose tissue (where AGT mRNA was more markedly down-regulated in the GR+/- 
mice) and the liver (where there was a slight increase in AGT mRNA levels). One 
interpretation would be that liver AGT makes a larger contribution to circulating 
levels of AGT (Cambell & Habener, 1986; Tamura et al, 1995), nevertheless, even 
with an increased circulating level, the overall net increase in blood pressure is the 
same compared to GR+/+ which show no change in circulating AGT (coincident with 
a smaller reduction in AT and unchanged hepatic AGT mRNA levels). Even given 
the potential for differences in AGT expression and secretion from other organs as 
well as other fat depots, the lack or exaggerated induction of BP in GR+/- suggests 
that an alternate adaptive mechanism might be involved.  
 
Adipose tissue is an important source of AGT (Cambell and Habener, 1986; Cassis et 
al., 1988; Frederic et al., 1992; Engeli et al., 1999) after liver, the major source of 
AGT production (Cambell and Habener, 1986; Tamura et al., 1995). Adipose AGT 
can reach the bloodstream and potentially regulate blood pressure (Massiera et al., 
2001).  Plasma and liver AGT levels were unaltered under basal conditions but 
increased by HF feeding in line with observations that AGT protein concentration in 
plasma parallels mRNA levels in the liver (Lu et al., 2007).  Moreover, adrenal 
histopathology in GR+/- mice suggested stimulation of aldosterone-producing cells in 
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the zona glomerulosa that may contribute to the hypertensive phenotype, with 
elevated circulating aldosterone levels.  
 
Although DIO was associated with up-regulation of adipose AGT expression levels 
(Massiera et al., 2001; Boustany et al., 2004), intriguingly a down-regulation of AGT 
with HF feeding was observed in both genotypes. Another study also failed to show 
an increase in adipose AGT mRNA with obesity in rats (Gabrieli et al., 2001). At 
present is unclear what underlies these discrepancies. Liver cells are targets for 
various hormones that regulate AGT, including the major pertinent metabolic 
hormones insulin and GC. In contrast, adipocytes appear to be responsive only to the 
effects of GCs in the regulation of AGT (Aubert et al., 1997). However, data from in 
vitro studies suggested that insulin may act as a negative regulator of AGT mRNA 
expression in adipose tissue (Aubert et al., 1998; Aihaud, 1999), which would be 
consistent with the observation of a greater down-regulation in the 
hypercorticosteronaemic GR+/- mice. Additionally, in vivo studies showed that mild 
hyperinsulinemia decreased fat AGT expression (Gabriely et al., 2001), and in 
streptozotocin-diabetic rats, hyperinsulineamia induced a down-regulation of renin 
and adipose AGT mRNA levels (Cassis, 1992). It is possible that in the experiments 
reported in the current study, the HF-induced hyperinsulinemia overrided the GC 
effect, thus adipose AGT expression appeared decreased (Aubert et al., 1998). Since 
data on the regulation of AGT by insulin are inconsistent, measurement of plasma 
insulin levels in this study will be informative. Figure 5.13 illustrates the 
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mechanisms that might be involved in the activation of RAS and thus contributing to 
the hypertensive phenotype in GR+/- mice.  
 
Finally, it will be of great interest to distinguish the effects of reduced GR density 
from the possibly confounding effects of increased GC secretion on blood pressure in 
the GR+/- mice. Future adrenalectomy experiments with fixed CORT- replacement 
levels will be informative. Additionally, alterations in the GC clearance rates by A-
ring reductases (etc) in this model will be important to be addressed in the future 
studies. Differences in local (adipose or liver) GC amplification (by altered 11β-
HSD1) in this model can probably be ruled out since GR+/- mice had similar 11β-
HSD1 mRNA levels in adipose and liver to GR+/+ littermates.   
 
In conclusion, mice heterozygous for a null mutation in the GR gene have a 
hyperactive HPA axis with adrenal hypertrophy, elevated hepatic triglyceride levels 
and a novel hypertensive phenotype. Altered tissue GC sensitivity, mediated through 
altered GR density, can differentially result in a variety of phenotypic changes. These 
may not lead to a disease state per se but may explain, in part, an individual’s 
susceptibility to a favourable or unfavourable metabolic and cardiovascular profile as 









5.13 The circulating and adipose-specific activation of the renin-angiotensin system 
(RAS) in GR+/- mice and its potential involvement in their hypertensive phenotype. 
The classical RAS pathway is shaded in yellow. The major source of 
angiotensinogen (AGT) production is the liver. Renin secreted by the kidney, cleaves 
angiotensin I (inactive) from angiotensinogen. Angiotensin I is then converted to 
angiotensin II by the angiotensin converting enzyme (ACE). In GR +/- mice, plasma 
renin activity is elevated. This might lead to subsequent increased angiotensin II 
production which in turn affects downstream systems by inducing (1) 
vasoconstriction in the vasculature and affects blood pressure (BP) or (2) aldosterone 
secretion by the adrenal cortex and thus water and salt retention that might lead to 
increased BP. Alternatively, since GR+/- adrenals appear hypertrophied with signs of 
increased aldosterone producing cells, and indeed elevated plasma aldosterone levels 
which  would be predicted to have a direct effect on the renovasculature and thus  BP 
regulation. Finally, GR+/- mice exhibit increased AGT mRNA levels specifically in 
adipose tissue (3), directly implicating adipose-induced activation of RAS and its 
involvement in the hypertensive phenotype (this is less likely since AGT is 
significantly reduced in HF-fed hypertensive GR+/- and GR+/+ mice) .   
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Pomc-/- mice: A model of HPA axis 








In the previous chapter, the role of reduced GR levels on obesity, metabolic 
parameters and blood pressure was examined using a model of HPA axis 
hyperactivity and GC resistance (GR+/- mice). In this chapter, a model of rodent 
obesity with dysregulated GC action, the Pomc-/- mice, was investigated as a model 
of HPA axis hypoactivity and increased GC sensitivity.   
 
Inactivating mutations of the gene encoding POMC in humans and mice cause 
obesity (Yaswen et al., 1996; Krude et al., 1998; Challis et al., 2004). POMC is the 
polypeptide precursor to a number of bioactive peptides including α-, β- and γ-
melanocyte-stimulating hormone (MSH) – the melanocortins – which, in the 
hypothalamus play critical roles in the regulation of appetite and energy expenditure 
(Schwartz, 2000). Lack of melanocortin signalling in the hypothalamus drives 
hyperphagia and obesity in both humans and mice (reviewed in Coll., 2007) POMC 
is also the precursor to ACTH, sectreted by the anterior pituitary and is essential for 
adrenal gland steroidogenesis (reviewed in Pritchard and White, 2007). Because of 
the lack of ACTH, POMC-deficient humans and mice have adrenal insufficiency and 
low or absent circulating glucocorticoids (Yaswen et al., 1996; Krude et al., 1998; 
Challis et al., 2004).  
 
Pomc-/- mice are unusual because most rodent models of obesity are characterised by 
hypercorticosteronemia, with weight gain normalised following adrenalectomy and 
reinstated by GC replacement (Debons et al., 1982; Freedman et al.,  1986; Sainsbury 
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et al., 1997; Makimura et al., 2000). Additionally, some rodent models of obesity 
have increased levels of 11β-HSD1 selectively in their adipose tissue (Masuzaki et 
al.,  2001; Livingstone et al., 2000) as is found in human obesity (see chapter 7). The 
potentially causative role of higher adipose 11β-HSD1 levels in metabolic disease is 
exemplified by the phenotype of mice with transgenic over-expression of 11β-HSD1 
in adipocytes (aP2-HSD1 mice). aP2-HSD1 mice have  hyperphagia, visceral 
obesity, insulin resistance and hypertension despite unchanged systemic GC levels 
(Masuzaki et al.,  2001; Masuzaki et al.,  2003). Hepatic over-expression of 11β-
HSD1 has no effect on adiposity, but causes hypertension and insulin resistance 
(Paterson et al., 2004). Pomc-/- mice are therefore unusual amongst rodent models in 
that obesity develops in the absence of high circulating or tissue GCs (Challis et al., 
2004). Indeed the obesity and metabolic disease would appear to be entirely 
secondary to central loss of the appetite suppressant melanocortins which tonically 
inhibit food intake (reviewed in Coll, 2007; Lee and Wadlow, 2007; Lam et al., 
2007). However, treatment of adult Pomc-/- mice with corticosterone for 10 days 
exacerbated their hyperphagia and obesity (Coll et al., 2005). CORT treated Pomc-/- 
mice showed a significant increase in weight (38.7+0.6 vs. 34.9+1.1 g, CORT vs. 
vehicle, P<0.05), total fat mass (12.8+0.4 vs. 9.0+0.5, P<0.001) and daily food intake 
(6.4+0.2 vs. 4.9+0.1 g, P<0.001). Plasma leptin levels increased 4-fold and insulin 
levels more than 50-fold in CORT vs vehicle treated Pomc null mice (Coll et al., 
2005). Thus,  glucocorticoid deficiency seen in Pomc null mice ameliorates the 
severe adverse metabolic consequences of the lack of melanocortin peptides (Coll et 
al., 2005). Here I investigated whether altered adipose GR levels or/and GC 
reactivation contributed to the severity of the metabolic abnormalities. 
 216
The effects of GC treatment on obesity and the worsening of the metabolic profile in 
Pomc-/- mice was of considerable interest, one reason being that therapeutic strategies 
aim to directly affect tissue-specific GC action rather than the HPA axis.  Therefore, 
the work presented in this chapter was designed to study the peripheral mechanisms 
involved in GC hypersensitivity in corticosterone treated Pomc-/- mice. It has been   
hypothesised that corticosterone treated Pomc-/- mice would have increased GC 
action in peripheral tissues (liver or/and adipose tissue) and that this would underlie 
their apparent GC-hypersensitivity and exaggerated metabolic syndrome-like 
phenotype. The experimental design of the study is outlined in Figure 6.1.  
 
6.2 Results 
6.2.1 Pomc-/- mice have reduced basal intra-adipose GC action but 
exaggerated GC-amplification responses when CORT treated.  
 
Corticosterone-treated (CORT) Pomc-/- and wild type mice had similar plasma 
CORT levels and hypothalamic CRH mRNA levels (Coll et al. 2005). CORT treated 
Pomc-/- mice showed a significant increase in weight (38.7+0.6 vs. 34.9+1.1 g, 
CORT vs. untreated, P<0.05), total fat mass (12.8+0.4 vs. 9.0+0.5, P<0.001) and 
daily food intake (6.4+0.2 vs. 4.9+0.1 g, P<0.001) (Coll et al. 2006). To examine 
potential mechanisms of CORT hypersensitivity in Pomc-/- mice, 11β-HSD1 and GR 
mRNA levels were measured in epididymal, inguinal and retroperitoneal adipose 
depots. Adipose 11β-HSD1 mRNA expression was lower in all untreated Pomc-/- 
compared to wild type mice (fig. 6.2A,B) and was dramatically increased by CORT 














Figure 6.1 Experimental design. 
Eight week-old male mice (n=5/group) were treated with corticosterone (25μg/ml) in 
their drinking water, a dose that results in similar plasma glucocorticoid levels and 
hypothalamic CRH mRNA levels in Pomc-/- and wild type mice (Coll et al. 2005). 
All mice had ad libitum access to water and chow diet. Systolic blood pressure was 
measured photoelectrically in the tail of restrained conscious mice. Animals were 
killed between 0800 and 0900h by cervical dislocation. Plasma from trunk blood 
samples was used to assay non-esterified fatty acid (NEFA), triglyceride levels renin 
and angiotensinogen concentrations. RNA from liver and adipose tissues (inguinal, 
retroperitoneal and epididymal) was denatured, northern blotted and hybridized to 
32P-labelled cDNA probes for mouse 11β-HSD1, GR, angiotensinogen, 
phosphoenolpyruvate carboxykinase (PEPCK), lipoprotein lipase (LPL) and 18S. 
Specific mRNAs were quantified using a phosphorimager and Aida image analysis 
software and are expressed in arbitrary units (A.U.) relative to 18S. Neutral lipids, 
cholesterol and fatty acids were identified by light microscopy in liver sections 
(30μm) stained with Oil red O and counter-stained with haematoxylin. Hepatic 
triglycerides were extracted and measured spectrophotometrically. For details please 
refer to methods (chapter 2). The corticosterone-replacement experiment, blood 
pressure, plasma NEFA and triglyceride measurements were performed by Tony Coll 
(Cambridge).  
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Figure 6.2 Mediators of GC action in adipose tissue of Pomc-/- mice.  
(A) Representative northern blot showing levels of 11β-HSD1 mRNA and 18S RNA 
in epididymal adipose tissue of Pomc-/- (-/-) and wild type (+/+) mice, either 
untreated or treated for 10 days with corticosterone (cort). (B-C) Quantitation of 
adipose tissue-specific 11β-HSD1 (B), GR (C) in experimental mice. Data are 
presented as % of the value in untreated wild type mice (100%) and are the means ± 
SEM; n=5/group. Data analysed by 2-way ANOVA for the effect of genotype and 
treatment followed by post-hoc Tukeys’ tests for group differences. Significance, 
†P<0.05, **P<0.01 and ***P<0.001.epi; epididymal, ing; inguinal, retro; 
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mice. Adipose expression of GR mRNA was higher in the retroperitoneal fat of 
Pomc-/- mice and was restored to wild type levels after CORT treatment (fig. 6.2C). 
GR mRNA levels did not differ in inguinal and epididymal fat between Pomc-/- and  
wild type mice, and were unaffected by CORT treatment in either genotype (fig. 
6.2C).  
 
To investigate mechanisms downstream of 11β-HSD1/GR by which CORT-
treatment selectively increases fat mass in Pomc-/- mice, adipose levels of mRNA 
encoding lipoprotein lipase (LPL), a GC-regulated gene (Fried et al., 1993), were 
measured. Although LPL mRNA levels were the same in untreated Pomc-/- and wild 
type mice in all depots, adipose LPL expression in Pomc-/- mice was markedly 
increased by CORT-treatment (fig. 6.3A) consistent with increased triglyceride 
uptake, and fat mass in Pomc-/- mice. In wild type mice, CORT-treatment increased 
LPL mRNA only in the inguinal depot, and to a lesser extent than in Pomc-/- mice 
(fig. 6.3A), suggesting adipose depot-dependent regulation of LPL by GCs in non-
obese mice, consistent with previous data in rats (Freedman et al. 1986). 
 
Phosphoenolpyruvate carboxykinase (PEPCK) is essential for gluconeogenesis in 
liver and for glycerol synthesis in adipose tissue (Pilkis & Granner 1992; Reshef et 
al. 2003). PEPCK is a classical GC-target gene which is positively regulated by 
glucocorticoids in hepatocytes and negatively regulated in adipocytes (Sasaki et 
al.1984; Nechushtan et al. 1987). Consistent with this, adipose PEPCK mRNA levels 




Figure 6.3 Effects of CORT-treatment on GC target genes in adipose tissue  
Quantitation of data from northern blots showing levels of mRNA encoding LPL (A) 
and  PEPCK (B) in adipose tissues of Pomc-/-  and wild type  mice, either untreated 
or treated for 10 days with corticosterone (cort). Data are presented as % of the value 
in untreated wild type mice (100%) and are the means ± SEM; n=5/group. Data 
analysed by 2-way ANOVA for the effect of genotype and treatment followed by 
post-hoc Tukeys’ tests for group differences. Significance, *P<0.05, **P<0.01 and 























































   
   












type mice (Fig. 6.3B). Surprisingly, given their GC deficiency, Pomc-/- mice had 
lower levels of PEPCK mRNA in adipose tissue than wild type (Fig. 6.3B). 
However, although CORT treatment decreased PEPCK expression in inguinal and  
retroperitoneal adipose tissue in Pomc-/- mice (significantly lower than in CORT-
treated wild type mice; p=0.01), it had no effect on PEPCK mRNA levels in 
epididymal adipose tissue, suggesting that other regulatory factors dominate PEPCK 
expression in adipose tissue of Pomc-/- mice (Fig. 6.3B).  
 
6.2.2 Pomc-/- mice have unaltered hepatic 11β-HSD1 but higher GR 
mRNA levels. 
Hepatic 11β-HSD1 mRNA levels were similar between the two genotypes (fig. 
6.4A) and unaffected by CORT (fig. 6.4A). Hepatic GR mRNA levels were higher in 
Pomc-/- compared to wild type mice (fig. 6.4B), but again CORT had no effect on GR 
mRNA levels (fig. 6.4B).  Hepatic PEPCK expression was lower in Pomc-/- than in 
wild type mice (fig. 6.4C) and was increased by CORT treatment to levels equivalent 
to untreated wild type mice. In contrast, CORT decreased hepatic PEPCK mRNA 
levels in wild type mice (fig.6.4C). 
 
6.2.3 Pomc-/- mice are dyslipidaemic. 
Pomc-/- mice showed markedly higher circulating triglyceride levels (fig. 6.5A) and 
hepatic lipid accumulation than wild type mice (fig. 6.5B), with 6-fold higher levels 
of hepatic triglyceride (P<0.001) (fig. 6.5C). However, CORT had no effect on 




Figure 6.4 Mediators of GC action in liver of Pomc-/- mice and effects of CORT-
treatment on PEPCK mRNA levels. 
Liver expression of (A) 11β-HSD1, (B) GR and (C) PEPCK mRNA in Pomc-/- (-/-) 
and wild type (+/+) mice, either untreated or treated for 10d with corticosterone 
(cort). Data are presented as % of the value in untreated control mice (100%) and are 
the means ± SEM; n=5/group. Data analysed by 2-way ANOVA for the effect of 
genotype and treatment followed by post-hoc Tukeys’ tests for group differences. 
Significance, †P <0.05, **P<0.01 and †††P<0.001. † and * showing differences 
between genotypes and treatment, respectively. 
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Figure 6.5 Dyslipideamia and fatty liver in Pomc-/- mice. 
(A) Plasma triglyceride (TG) levels in Pomc-/- (-/-) and wild type (+/+) mice, either 
untreated or treated for 10d with corticosterone (cort). (B) Oil Red O staining of 
neutral lipid in liver sections of wild type mice (+/+, left upper panel), CORT-treated 
wild type mice (+/+, left bottom panel), Pomc-/- (-/-, right upper panel) and CORT-
treated Pomc-/- (-/-, right bottom panel). Magnification x40; red=Oil red O, blue 
=haematoxylin (nuclei). (C) hepatic triglyceride content in Pomc-/- (-/-) and wild type 
(+/+) mice, either untreated or treated for 10 days with corticosterone (cort). (D) 
plasma levels of non esterified fatty acids (NEFA) in Pomc-/- (-/-) and wild type (+/+) 
mice, either untreated or treated for 10 days with corticosterone (cort). Data are 
means ± SEM; (n=6/group). Data analysed by 2-way ANOVA for the effect of 
genotype and treatment followed by post-hoc Tukeys’ tests for group differences. 
Significance, ††P<0.01. The data on plasma triglycerides (A) and NEFA (D) have 





















































phenotype (fig. 6.5C). Pomc-/- and wild type mice had similar plasma NEFA levels 
which were unaffected by CORT (fig. 6.5D). 
 
6.2.4 CORT drives hypertension in Pomc-/- mice independently of 
adipose and liver renin-angiotensin system (RAS) activation. 
 
Pomc-/- mice had similar blood pressure to wild type mice (fig. 6.6). CORT markedly 
increased blood pressure only in Pomc-/- mice (fig. 6.6). Since hypertension 
following transgenic expression of 11β-HSD1 in adipose or liver is associated with 
increased levels of angiotensinogen in each of these tissues, respectively (Masuzaki 
et al. 2001; Paterson et al. 2004), it was feasible that a similar mechanism may drive 
CORT-mediated hypertension in Pomc-/- mice. Therefore, key components of the 
renin-angiotensin system (Guyton, 1991) were examined. Pomc-/- mice had higher 
hepatic angiotensinogen mRNA levels than controls (fig. 6.7A). However, CORT did 
not alter hepatic angiotensinogen mRNA levels in either genotype (fig. 6.7A).   
 
Consistent with lower intra-adipose GC action, adipose angiotensinogen mRNA 
levels were lower in Pomc-/- mice in all adipose depots (fig. 6.7B). CORT increased 
angiotensinogen mRNA levels specifically in epididymal adipose tissue of both 
genotypes (2 fold increase; P<0.001) (fig. 6.7B) but had no effect on 
angiotensinogen mRNA levels in inguinal or retroperitoneal adipose tissue of either 
genotype (fig. 6.7B). Plasma angiotensinogen concentrations did not differ with 




Figure 6.6 Corticosterone treatment increases blood pressure in Pomc-/- mice 
Effect of 10d corticosterone treatment (cort) on systolic blood pressure in wild type 
(+/+) and Pomc-/- (-/-) mice. Systolic blood pressure was measured photoelectrically 
in the tail of restrained conscious mice using an IITC model 179 analyser (Woodland 
Hills, California, USA). Prior to recording measurements, all mice underwent 3 
periods of training to accustom them to the procedure. Mice were warmed at 32oC 
for 30 min before taking 10 consecutive readings. The first 5 were discounted and a 
mean value of systolic blood pressure was calculated from the last 5 readings. Five 
mice from each treatment group were measured. All analog recordings were analysed 
by an independent observer who was blinded to the genotype of the mice and any 
treatment they had received. Data are the means ± SEM; Significance; ***P<0.001. 
Data analysed by 2-way ANOVA for the effect of genotype and treatment followed 
by post-hoc Tukeys’ tests for group differences. Data provided by Tony Coll 
(Cambridge). 

















Figure 6.7 Effect of CORT-treatment on the renin-angiotensin system  
Effect of 10d corticosterone treatment (cort) on (A) angiotensinogen (AGT) mRNA 
levels in liver, (B) angiotensinogen (AGT) mRNA in adipose tissue, (C) plasma 
angiotensinogen and (D) plasma renin concentration in wild type (+/+) and Pomc-/-     
(-/-) mice. Epi, epididymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are 
the means ± SEM, and for transcript levels are expressed relative to levels in 
untreated wild type mice (100%); n=5/group. Data analysed by 2-way ANOVA for 
the effect of genotype and treatment followed by post-hoc Tukeys’ tests for group 
differences. Significance; * or †P<0.05. † and * showing differences between 
genotypes and treatment respectively. Note that -/- cort renin level show high 
variability but outliers cannot be excluded since small  number of animals was 
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obesity (Fat mice; Morton et al. 2005), plasma renin concentration was markedly 




Increased GC action specifically in adipose (Masuzaki et al.,  2001) or liver 
(Paterson et al.,  2004) produce distinct metabolic syndromes with hypertension. 
Increased GR sensitivity is also associated with altered fat distribution, hypertension 
and cardiometabolic disease (Buemann et al.,  1997; Rosmond et al.,  2000; Ukkola 
et al.,  2001; Dodson et al.,  2001; van Rossum et al.,  2003). Here, it was 
hypothesized that altered tissue regeneration of active GC and/or peripheral tissue 
sensitivity to GCs underlay, in part, the exaggerated fat accumulation, insulin 
resistance (Coll et al.,  2005) and the hypertension (work presented here) observed in 
Pomc-/- mice with GC replacement.    
 
With fixed circulating GC levels such as that achieved with CORT treatment in the 
current studies, 11β-HSD1 and GR expression levels are the key determinants of GC 
action. Pomc-/- mice had lower adipose but similar hepatic levels of 11β-HSD1 
mRNA levels to wild type mice. CORT-treatment dramatically and more markedly 
increased 11β-HSD1 expression in the adipose tissue of Pomc-/- mice. This was 
accompanied by a marked increase in LPL expression, a GC-inducible gene (Fried et 
al.,  1993), consistent with the exaggerated accumulation of fat in these mice.  
Intriguingly, these data suggest that, at least in adipose tissue, 11β-HSD1 itself is a 
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GC target gene. This finding is consistent with most (Jamieson et al.,  1995; Voice et 
al.,  1996; Hammami & Siteri 1991; Bujalska et al., 1999), but not all (Napolitano et 
al.,  1998) previous reports of GC induction of 11β-HSD1 in a variety of cell types. 
Although not specifically measured here, increased adipose 11β-HSD1 activity is 
predicted to selectively amplify intra-adipose GC concentrations, particularly when 
circulating levels of substrate are high (eg with HPA axis hyperactivity). On the 
other hand, the present data suggest that congenital GC deficiency has little impact 
upon hepatic 11β-HSD1 levels in vivo and hepatic 11β-HSD1 levels are not regulated 
by corticosterone. In contrast, 11β-HSD1 mRNA levels are highly and positively 
regulated by GCs in adipose tissue.  
 
GR levels are another major determinant of cellular GC sensitivity (Vanderbilt et al.,  
1987; Geley et al.,  1996). Small differences in GR mRNA levels can markedly alter 
glucocorticoid responsiveness (Geley et al., 1996; Reichardt et al., 2000). Pomc-/- 
mice had elevated GR mRNA levels in liver and retroperitoneal adipose tissue, 
suggesting increased GC sensitivity selectively in these depots. Following CORT 
replacement in Pomc-/- mice, GR mRNA levels were restored to wild type levels in 
retroperitoneal adipose tissue but not in liver, consistent with tissue- and time-
specific differences in GR autoregulation (Reichardt et al., 2000; Sheppard et al., 
1990; Holmes et al., 1990; Holmes et al., 1995; Holmes et al., 1997; Kalinyak et al. 
1987; Dong et al., 1988).  
 
 229
CORT had no additional effects on the hypertriglyceridaemia and fatty liver of the 
Pomc-/- mice, and did not affect plasma NEFAs, which were normal in Pomc-/- mice. 
The CORT-driven caloric excess in Pomc-/- mice may drive a further increase in the 
flux of triglycerides from the liver, that, coupled with increased adipose fatty acid 
uptake via LPL, maintains the circulating and liver triglyceride levels constant and is 
consistent with increased adipose tissue mass in CORT treated Pomc-/- mice (Coll et 
al., 2005). 
 
Adipose PEPCK is critical for glyceroneogenesis and is thus a key regulator of the 
level of fatty acid re-esterification (reviewed in Reshef et al., 2003). Unexpectedly, 
since GCs reduce adipose PEPCK, GC-deficient Pomc-/- mice had lower levels of 
PEPCK mRNA in all adipose depots. This was further decreased by CORT 
treatment. The lower level of PEPCK mRNA in untreated Pomc-/- mice may be due 
to their higher fed blood glucose levels, thus reducing the need for glyceroneogenesis 
to generate glycerol-phosphate for fatty acid re-esterification (Nechushtan et al., 
1987; Opherk et al., 2004). Pomc-/- mice have lower hepatic expression of PEPCK. 
This may not be due to lack of GC signalling in liver, as mice with a liver-specific 
knock-out of GR have normal levels of PEPCK in liver (Opherk et al., 2004), but 
may be related to the higher circulating levels of insulin in Pomc-/- mice compared to 
wild type (Coll et al., 2005). Insulin dominantly and negatively suppresses hepatic 
PEPCK in the fed state (Pilkis & Granner 1992). In CORT-treated wild type mice, 
the repressive effect of insulin predominated. Indeed, the decreased levels of PEPCK 
in these mice compared to untreated wild type mice may reflect the increase in 
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insulin levels following CORT treatment (Coll et al., 2005). In contrast, hepatic 
PEPCK mRNA levels doubled following CORT treatment in Pomc-/- mice, 
consistent with hepatic insulin resistance and marked hyperinsulinaemia (Coll et al., 
2005).  
 
Blood pressure in Pomc-/- mice is normal despite their hypoadrenal state. This implies 
that secondary mechanisms are invoked to maintain cardiovascular function when 
circulating aldosterone and corticosterone concentrations are chronically reduced 
(Coll et al., 2004). It seems likely that the increased renin activity which observed in 
Pomc-/- mice is part of this adaptive process. However, corticosterone replacement 
did not normalise renin activity and selectively increased blood pressure in Pomc-/- 
mice. This was not attributed to a further activation of the circulating renin-
angiotensin system, since neither renin nor its substrate angiotensinogen were 
increased. Indeed expression of angiotensinogen mRNA in liver and adipose tissues 
did not correlate with blood pressure. It seems likely that corticosterone augmented 
existing mechanisms that were already sustaining vascular function. Apart from 
renin, these secondary processes are likely to involve the hyperinsulinaemic (Sowers 
2004) state of Pomc-/- mice (which is exacerbated by corticosterone treatment) (Coll 
et al., 2005), the sympathetic nervous system (Rascher et al., 1979) (which is thought 
to explain glucocorticoid-induced hypertension in normal mice) or structural 
adaptation of the vasculature (Wallerath et al., 2004).  
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Although Pomc-/- mice represent a mouse model of congenital lack of GCs, it will be 
interesting and more informative to address the effects of GC replacement on blood 
pressure and metabolic parameters in adrenalectomized wild type and Pomc-/- mice 
to avoid a) any possible residual GCs that were undetectable by the corticosterone 
assay and b) the inevitable supraphysiological levels of corticosterone replacement. 
 
In summary, the data presented here show that increased adipose tissue-specific 
sensitivity to GCs in Pomc-/- mice may result in part from exaggerated induction of 
11β-HSD1 in adipose tissue with CORT administration. Whilst acknowledging that 
mRNA changes do not always translate to altered protein (or enzyme activity) levels, 
these data nevertheless suggest that 11β-HSD1 might be a more potent mediator of 
intra-adipose GC action than the GR levels whereas in liver, higher GR levels 
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In the previous 2 chapters, the effects of altered GC sensitivity on obesity and 
parameters of the Metabolic Syndrome were studied in 2 distinct animal models 
(GR+/- and Pomc-/- mice) with altered peripheral GC sensitivity and dysfunctional 
HPA axis. In this chapter alterations in GC action in multiple adipose tissue 
compartments in human obesity are explored.    
 
Exposure to high circulating GC levels, as found in Cushing’s syndrome, causes a 
metabolic disease that resembles features of idiopathic metabolic syndrome including 
pronounced visceral obesity (reviewed in Seckl et al, 2004). However, idiopathic 
obesity is not associated with high circulating GC levels in humans (Marin et al., 
1992). Rather, it appears that intra-cellular regeneration of active GCs by the enzyme 
11β-HSD1 is aberrantly elevated in adipose tissue of obese individuals (reviewed in 
Walker and Andrew, 2006). Visceral (omental) obesity is associated with an 
increased risk for type 2 diabetes, hyperlipidemia and hypertension (Fujioka et al., 
1987; Despres et al., 1989). In contrast, comparable amounts of fat stored 
preferentially in gluteal or femoral depots (lower body obesity) were associated with 
lower risk of morbidity and mortality from metabolic abnormalities (Kennel et al., 
1991). Given the key association of intra-abdominal (visceral) adipose tissue with 
metabolic and cardiovascular risk, it has been hypothesized that increased 11β-HSD1 
in the visceral, rather than subcutaneous, adipose depot causes the adverse metabolic 
consequences of idiopathic obesity and the Metabolic Syndrome  - so called 
‘Cushings disease of the omentum’ (Bujalska et al., 1997).  Data from human studies 
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have engendered some confusion as to whether visceral as well as subcutaneous 11β-
HSD1 is elevated in human obesity (section 1.6.3).   
 
Mechanistically, GCs induce adipose tissue expansion by stimulating preadipocyte 
differentiation (Xu and Bjorntorp, 1990). A key factor in this process, are levels of 
the GRα. In contrast to the plethora of studies (section 1.6.3) of 11β-HSD1 in 
adipose tissue and metabolic parameters, curiously few studies have examined 
associations between GR and such parameters. Higher levels of GR are found in 
omental compared to subcutaneous fat (Rebuffe-Scrive et al., 1990), therefore it 
could be expected that GR levels will have a more pronounced effect on GC action in 
the omental depot. Here, the hypothesis that altered GR, as well as 11β-HSD1 
mRNA levels are associated with obesity in human visceral (omental) and 
subcutaneous (abdominal, thigh, gluteal) adipose tissue was tested.  
  
Specifically the objective of this study was to determine the association between 
11β-HSD1 and GRα mRNA levels in 4 distinct adipose depots and measures of 
obesity and the Metabolic Syndrome. Therefore, adipose tissue biopsies from 
subcutaneous (sc; abdominal, thigh, gluteal) and intra-abdominal (omental) adipose 
depots from 21 women were analysed for 11β-HSD1 and GRα mRNA levels by real 
time PCR. Body composition, fat distribution, fat cell size and blood lipid, glucose 
and insulin levels were correlated with the transcript levels.  
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7.2 Results 
7.2.1 Subject characteristics  
 
Volunteers were recruited to the Mayo Clinic (Rochester, USA) and were Caucasian 
females undergoing tubal ligation surgery, carried out in the follicular phase of the 
menstrual cycle to reduce the risk of pregnancy. The mean age was 35 ± 1 year with 
mean BMI 32.7±1.5 kg/m2 (Table 7.1), indicating an obese group. Median± IQR 
fasting plasma insulin levels were 15.6±19.6 μU/ml and HOMA-IR was 3.3±4.6 
(range 0.42-47). Median fasting plasma glucose levels and mean triglyceride 
concentrations averaged 4.9 ±0.44 mmol/L and 148± 19 mg/dl, respectively (Table 
7.1).  
 
7.2.2 11β-HSD1 mRNA levels are highest in abdominal sc and omental 
adipose tissues whereas GRα mRNA is highest in the omental fat. 
 
11β-HSD1 mRNA levels were greater in abdominal subcutaneous and omental than 
in gluteal or thigh subcutaneous adipose depots (fig 7.1A). 11β-HSD1 mRNA levels 
were positively correlated in the 3 sc depots: abdominal vs thigh; R=0.83, P<0.005 
and abdominal vs gluteal; R=0.86, P<0.005. There were no associations between 
abdominal sc and omental 11β-HSD1 mRNA levels.  GRα mRNA levels were 
highest in omental and lowest in thigh sc adipose tissue (fig 7.1B) but were not 
correlated between any depots. No correlation was found between 11β-HSD1 and 
GRα mRNA levels in any depot (fig 7.1C).  
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Body Fat (%) 
 
 
46 ± 2 (23-56) 
 
 









































Prior to surgery, body composition was assessed by measuring weight, height, body 
fatness (% fat) using dual x-ray absorptiometry (DEXA;DPX-IQ; Lunar Radiation, 
Madison, WI) and abdomial fat distribution using a single sliced computerized 
tomography scan at the L2-3 level. Visceral and subcutaneous adipose tissue areas 
were calculated as previously described (Jensen et al, 1993). Data are presented as 
mean ± SEM. For glucose and insulin, data are presented as median ± IQR. Range of 
values in parenthesis. BMI; body mass index, VAT; visceral adipose tissue, SAT; 
subcutaneous adipose tissue. These data were kindly provided by Prof Michael D 




Figure 7.1 11β-HSD1 and GRα mRNA levels in multiple human adipose tissue 
compartments.  
A) 11β-HSD1 mRNA levels were higher in abdominal and omental compared to 
thigh and gluteal adipose tissues. B) GRα mRNA levels were higher in omental and 
lower in thigh compared to the other adipose tissue compartments. C) 11β-HSD1 and 
GRα mRNA levels are not correlated in omental adipose tissue. Real time PCR 
analysis was performed to measure mRNA levels in multiple adipose compartments. 
Internal control was cyclophilin a. One way ANOVA was used to compare 
differences in mRNA levels between depots. Data are presented as mean ± SEM. 
Pearson correlation was performed to determine an association between 11βHSD1 
and GRα mRNA levels. ** p<0.01 and *** p<0.001. For primer-probe details please 
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7.2.3 Parameters of GC action in the omentum  
7.2.3.1 Obesity is associated with elevated 11β-HSD1 but reduced GRα 
mRNA in omental adipose tissue. 
 
A strong positive association between BMI and omental adipose 11β-HSD1 mRNA 
levels was observed: R=0.570, P<0.01 (fig 7.2A, Table 7.2). Moreover, visceral fat 
area determined by CT (VAT) correlated with increased 11β-HSD1 mRNA levels in 
the omentum (fig 7.2B, Table 7.2).  Omental 11β-HSD1 mRNA levels were 
consistently and positively associated with general adiposity (defined by % of body 
fat; R=0.462, P<0.05) and with subcutaneous/peripheral (SAT) adiposity (Table 7.2). 
In contrast, obesity was associated with decreased GRα mRNA levels in the omental 
depot (R=-0.627, P<0.001) (fig 7.2D, Table 7.2).  Visceral adiposity (fig 7.2E) was 
negatively correlated with omental GRα mRNA levels (VAT; R= - 0.507, P<0.05). 
 
7.2.3.2 Omental fat cell hypertrophy is associated with increased 11β-
HSD1 but reduced GRα transcript levels. 
 
Fat cells were smaller in the omental depot than in subcutaneous adipose tissue 
(omental; 84 ± 4 μm; vs abdominal sc, thigh, gluteal 104 ± 3 μm, 109 ± 3 μm, 106 ± 
2 μm P<0.0001). Omental fat cell size was positively correlated with 11β-HSD1 
mRNA levels (R=0.72, P<0.001) (fig 7.2C, Table 7.2). In contrast, GRα transcript 
levels were negatively correlated with omental fat cell size (fig 7.2F, Table 7.2). In 
order to test for independent effects, multiple regression analyses was performed to 
understand the effects of obesity (BMI) and fat cell size on 11β-HSD1 or GRα 
mRNA levels. Omental fat cell size was strongly and independently correlated with 
11β-HSD1 (standardized β coefficient 1.2; P<0.05), whereas GRα was not associated 
with fat cell size independently of obesity.  
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Figure 7.2 Correlation of 11β-HSD1 and GRα mRNA levels with anthropometric 
parameters and fat cell size in the omental adipose compartment.  
Correlation of (A) BMI with 11βHSD1, (B) Visceral adiposity (VAT) with 11β-
HSD1, (C) Fat cell size with 11βHSD1, (D) BMI with GRα , (E) VAT with GRα and 
(F) Fat cell size with GRα mRNA levels. Pearson correlation between transcript 
levels and anthropometric parameters. Regression lines, R and P values are indicated 
in each graph.  
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Table 7.2 Pearson correlation of 11β-HSD1 and GR mRNA levels in multiple 
adipose tissue depots with body composition, metabolic parameters and fat cell size. 
 
% Body fat was measured using DEXA.VAT and SAT are visceral and subcutaneous 
adipose tissue areas respectively, measured by CT scan. Fat cell sizes (FCS) was 
determined by measuring the mean adipocyte diameter. Plasma insulin and glucose 
values, abdominal fat cell size and 11β-HSD1 mRNA levels in thigh and gluteal 
regions and GR mRNA levels in thigh showed inhomogeneity of variance, therefore 







 11Β-HSD1 MRNA 
 
GRΑ MRNA 
 Abdominal Thigh Gluteal Omental Abdominal Thigh Gluteal Omental 
BMI 0.58* 0.53* 0.54* 0.57** -0.59* -0.24 -0.20 -0.63*** 
% Body fat 0.22 0.41 0.44 0.46* -0.50 -0.24 -0.01 -0.41 
VAT 0.55* 0.73*** 0.71*** 0.64*** -0.30 -0.05 -0.32 -0.51* 
SAT 0.36 0.55** 0.40 0.63*** -0.57 -0.15 -0.13 -0.60*** 
Log fasting 
glucose 
0.20 -0.29 -0.32 -0.18 0.14 -0.41 -0.04 -0.27 
Log fasting 
insulin 
0.13 0.04 0.33 0.31 -0.1 -0.47 0.01 -0.48 
Fasting 
triglycerides 
0.21 0.57** 0.46 0.46 * -0.44 0.01 0.2 -0.50* 
Log FSC 
abdominal 
0.19    -0.80**     
FSC  thigh   0.28     -0.51*   
FSC  
gluteal 
  0.40    0.03  
FSC 
omental 
   0.72***     -0.52** 
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7.2.4 Parameters of GC action in abdominal sc depot 
7.2.4.1 Obesity is associated with increased 11β-HSD1 mRNA levels in 
all sc depots but reduced GRα mRNA in the abdominal sc. 
 
Since reporting on GC action has been largely in the abdominal sc depot, studies 
described in this chapter are extended beyond this to gluteal and thigh in order to test 
whether the expected relationships held in these anatomically and metabolically 
distinct compartments. Positive associations with BMI and 11β-HSD1 mRNA levels 
were detected in all sc adipose compartments examined (eg. abdominal subcutaneous 
adipose: R=0.584, P<0.05) (Table 7.2). Thigh adipose 11β-HSD1 mRNA levels 
correlated positively with SAT and this relationship showed a consistent trend in the 
other depots (Table 7.2). In contrast, abdominal sc GRα mRNA levels were inversely 
correlated with BMI (R=-0.589, P<0.05) (Table 7.2). No significant associations 
were observed between SAT and abdominal sc GRα mRNA levels (fig 7.3B) or GRα 
mRNA levels in any other sc depot (Table 7.2). 
 
7.2.4.2 Abdominal sc hypertrophy is associated with reduced GRα 
mRNA levels. 
 
Although multiple regression analysis with small numbers of abdominal sc biopsies 
should be interpreted cautiously, the data presented here nevertheless indicate the 
following. Surprisingly, in abdominal sc adipose tissue 11β-HSD1 mRNA levels 
were not associated with fat cell size (fig 7.3C). In contrast, GRα transcript levels 
were negatively correlated with fat cell size (fig 7.3D). Multiple regression analysis 
confirmed that GRα mRNA levels were independently and negatively correlated with 
abdominal sc fat cell size (standardized β coefficient -0.014; P<0.05). Although GRα  
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mRNA levels were negatively correlated with fat cell size in the thigh, this 
relationship did not hold when tested by multiple regression analysis.  
 
7.2.5 Associations of depot-specific glucocorticoid action with 
metabolic parameters. 
 
Pearson correlation was used to examine interrelationships between transcript levels 
and metabolic parameters (Table 7.2). Omental and thigh 11β-HSD1 mRNA levels 
were associated with increased plasma triglyceride levels (omental; R=0.46, P<0.05 
and thigh; R=0.57, P<0.01). This effect was not independent of obesity as confirmed 
by multiple linear regression analysis. There were no significant associations 
between fasting glucose, insulin or HOMA-IR and 11β-HSD1 transcript levels. In 
contrast, there was a negative correlation between GRα mRNA levels and plasma 
triglyceride levels selectively in the omental compartment (R=-0.50, P<0.05). 
Moreover, there was a trend for an inverse association between omental GRα mRNA 
levels and fasting plasma insulin levels (R=-0.48, P=0.052). 
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Figure 7.3 Correlation of 11β-HSD1 and GRα transcript levels with peripheral 
adiposity and fat cell size in abdominal sc compartment. 
 Pearson correlation of (A) subcutaneous adipose tissue area (SAT) with 11βHSD1 
mRNA levels, (B) SAT with GRα mRNA levels, (C) Fat cell size (FCS) with 
11βHSD1 mRNA levels and (D) FCS with GRα mRNA levels. Regression lines, R 
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7.3 Discussion  
 
This study examined relationships between two major determinants of tissue GC 
action in multiple adipose tissue depots in lean and obese women. The key findings 
were (i) 11β-HSD1 mRNA is most highly expressed in sc abdominal and omental, 
whereas GRα mRNA is highest in omental adipose tissue; (ii) within individuals, 
there are positive associations between 11β-HSD1 mRNA levels in sc adipose depots 
but not omental fat, whereas GRα mRNA levels do not correlate between depots; (iii) 
between individuals, 11β-HSD1 mRNA levels in all adipose depots including 
omentum are positively associated with BMI and local fat mass, whereas for GRα 
mRNA the main relationships (with BMI, VAT,  triglycerides) were negative 
associations in the omentum; (iv) increased fat cell size strongly associates with 
increased 11β-HSD1 but reduced GRα in the omentum.  
 
Here I extend previous observations form our group (Rask et al., 2002; Lindsay et 
al., 2003; Wake et al., 2004) and others (Paulimyer-Lacroix et al., 2002; Engeli et al., 
2004; Kannisto et al., 2004) on abdominal sc adipose to show a positive relationship 
between BMI and 11β-HSD1 mRNA levels in all 4 adipose compartments examined. 
This implies an upregulation of GC reganarating capacity in multiple adipose tissue 
compartments, including the visceral fat depot. Increased visceral fat is a better 
predictor of metabolic abnormalities compared to upper-body subcutaneous fat 
(Fujioka et al., 1987; Despres et al., 1989), and is independently correlated with 
increased morbidity and mortality (Kuk et al., 2006). In contrast, lower-body obesity 
may even confer a protective effect with respect to metabolic abnormalities (Snijder 
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et al., 2006).  In this cohort, omental 11β-HSD1 mRNA levels were most strongly 
associated with increased general adiposity (% body fat). Kannisto et al., 2004 
previously reported a positive association between % body fat and 11β-HSD1 
mRNA levels in sc fat in obese male and female monozygotic twins. In the present 
study, subcutaneous adipose expression of 11β-HSD1 mRNA did not correlate with 
% body fat. Differences between these studies may be due to the distinct populations 
studied and/or our limited power to detect this interaction since 11β-HSD1 did 
correlate with other markers of generalised obesity such as BMI.  Although in the 
present study 11β-HSD1 activity levels were not measured due to limited sizes of 
biopsies, it is expected, based on previous studies (Lindsay et al., 2003; Wake et al., 
2003), that activity and mRNA levels will be correlated in abdominal sc adipose 
tissue biopsies.  
 
GRα transcript levels were highest in omental (visceral) fat, as previously reported in 
humans (Rebuffe-Scrive et al., 1990) and mice (Masuzaki et al., 2001). The major 
new finding is that in omental, as well as abdominal sc adipose, GRα mRNA levels 
are  inversely associated with adiposity and fat cell size. A previous study has also 
reported lower GRα mRNA levels in sc adipose tissue in morbidly obese women 
(Boullu-Ciocca et al., 2003).  Omental GRα mRNA levels were negatively 
associated with plasma triglyceride and, albeit as a trend, insulin levels. This finding 
is perhaps counterintuitive since GR polymorphisms associated with increased GC 
sensitivity and increased visceral fat accumulation (Trembley et al., 2003). The data 
in the present study suggest that reduction of GR levels to the degree observed in 
 246
obesity, does not sufficiently compensate for the hypertrophy caused by increased 
ligand regeneration (via 11β-HSD1). This notion is supported by data from 
transgenic animal models. Thus, fat-specific 11β-HSD1 overexpressing mice 
(Masuzaki et al., 2001) have increased visceral adiposity and 11βHSD1-deficient 
mice have reduced visceral adiposity (Morton et al., 2004) despite unaltered GR 
levels.  In contrast in humans, this is the first study describing a consistent opposing 
change in 11β-HSD1 and GRα mRNAs in multiple adipose compartments with 
obesity. However, since the two transcripts were not correlated in any depot, 
consistent with previous observations in sc adipose tissue (Kannisto et al., 2004), it 
appears unlikely that GRα and 11β-HSD1 directly regulate each other. Naturally, 
there are clearly limitations with association studies, which do not test causality and 
further direct investigation is needed to elucidate possible mechanisms involved.   
 
The volunteers who participated in this study had normal glucose and triglyceride 
levels but impaired insulin sensitivity. Increased plasma triglycerides were associated 
with increased 11β-HSD1 mRNA levels in both thigh and omental regions but with 
reduced GRα mRNA levels selectively in the omental compartment. Neither 11β-
HSD1 nor GRα mRNA levels were associated with fasting glucose, which is 
consistent with a previous report (Lindsay et al., 2003). However, there appeared to 
be a trend for a negative association of omental and thigh GRα mRNA levels with 
fasting insulin levels that would be interesting to confirm in larger cohorts. 
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Visceral fat adipocytes are more resistant to insulin’s antilipolytic effects compared 
to sc adipocytes (Richelsen et al., 1991). Transgenic mice overexpressing 11β-HSD1 
in fat develop central obesity attributed to adipocyte hypertrophy particularly in the 
mesenteric depot (Masuzaki et al, 2001). To my knowledge, this is the first study that 
addressed the relationship of 11βHSD1 or GRα mRNA levels with regional fat cell 
size in humans. Consistent with previous studies (Ostman et al., 1976; Rebuffe-
Scrive et al., 1990b; Tchernof et al., 2006), abdominal sc adipocytes were larger 
compared to omental, indicating higher fat storage in this depot in women. 
Furthermore, a strong positive correlation between 11β-HSD1 and adipocyte size in 
the omental depot, independent of obesity was apparent.  Despite the negative 
association of GRα mRNA with omental fat cell size, this was not independent of 
obesity. Although 11β−HSD1 was also highest in the abdominal sc depot, there was 
not an association between 11β−HSD1 mRNA levels and abdominal fat cell size, 
despite the strong positive correlation with BMI. This may appear counterintuitive.  
The reasons for this might be either the limited power to detect a possible correlation 
since there were fewer abdominal sc than omental adipose biopsies. Alternatively, 
11β−HSD1 may not be a strong predictor of subcutaneous hypertrophy in this cohort. 
This is supported by the lack of correlation between 11β−HSD1 and fat cell size in 
the thigh and gluteal sc depots.  In contrast to findings in the omental depot, GRα 
mRNA levels were negatively associated with fat cell size in the abdominal sc depot, 
independent of obesity. It would appear that obesity is associated with a down-
regulation of GRα that may limit the hypertrophic effects of GCs in adipose tissue 
(Cigolini and Smith, 1979; Xu and Bjormtrop, 1990; Fried et al., 1993). However, 
the data in the present study suggest that this GR down-regulation cannot entirely 
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counteract increased ligand levels particularly in the omental depot. It will be 
important to determine whether and how altered GR levels can indeed reach a 
functionally limiting state with respect to adipose hypetrophy in obesity. 
 
In conclusion, 11β−HSD1 mRNA is a strong predictor of omental fat hypertrophy 

























8.  Discussion  
 
In this Thesis I investigated the peripheral effects of altered glucocorticoid sensitivity 
and showed that the downstream consequences of either glucocorticoid 
hypersensitivity or resistance are complex and notably involve modulation of blood 
pressure regulation. Specifically, a model of GC resistance, with widespread/globally 
reduced GR density, was generated (GR+/- mice) and phenotyped with respect to 
HPA axis function, glucose, lipid and blood pressure homeostasis. Secondly, a model 
of GC hypersensitivity (POMC-null) was used to study whether altered peripheral 
tissue glucocorticoid reactivation and GR levels contributed to the severity of the 
metabolic abnormalities and blood pressure regulation. The effects of altered GR on 
the HPA axis found in the GR+/- model is in agreement with other published models 
(Pepin et al., 1992; Tronche et al., 1999; Reichardt et al., 1998; Finotto et al., 1999; 
Ridder et al., 2005), whereas, in contrast to earlier reports (Pepin et al., 1992; 
Richard et al., 1993; Cole et al., 1995; Tronche et al., 1998; Tronche et al., 1999; 
Kellendonk et al., 2002 ).Reduced GR density had negligible effects on fat 
distribution and nutrient homeostasis in the GR model studied here in contrast with 
previous observations (Pepin et al., 1992; Kellendonk et al., 2002). Therefore, in the 
following paragraphs I compare and contrast the 2 models (GR+/- and Pomc-/- mice), 
focusing mainly on the pronounced and novel effects that altered GC sensitivity had 
on blood pressure (BP). Finally, alterations in GC sensitivity mediated by alterations 
in peripheral (adipose and liver) 11β-HSD1 and GR expression levels, in the 2 
models and in human obesity are discussed. 
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8.1 Scenario A: Glucocorticoid hypersecretion and reduced GR density 
 
Figure 8.1 illustrates the metabolic and blood pressure effects in the GR+/- mice 
under normal conditions (fig. 8.1A) and after a chronic HF challenge (fig. 8.1B). 
Overall,a‘global’ reduction of GR levels have no effect on body composition or 
metabolic parameters (glucose and lipid homeostasis) under basal or DIO (HF 
feeding) conditions. However, reduction of GR density leads to hypertension. 
Although it is difficult to dissect if the increased BP in GR+/- mice is due to GR 
reduction or increased circulating GC levels per se, it appears to be driven by the 
hyperactive HPA axis. Hypertension develops, in part, through an activation of the 
systemic RAAS components. Possibly, impaired negative feedback leads to elevated 
ACTH levels (although unaltered morning levels, still remains to be tested if evening 
levels are higher in GR+/- mice), adrenal hypertrophy (zona fasciculate) and 
concequently elevated plasma GCs. There are a couple of possibilities that might 
explain the activation of the RAAS system in this model. It could be speculated that 
elevated ACTH could affect the aldosterone producing cells in the zona reticularis 
(ZR) of the adrenal gland (evidence in this model that ZR is hypertrophied) thus 
producing (preliminary data showing increased aldosterone synthase 
immunoreactivity) and secreting increased aldosterone in accordance with previous 
studies (Takeda et al., 1996; Honda et al., 1977; Hautanena et al., 1998). 
Additionally, observations in a ACTH-induced hypertension model showed up-
regulation of renin mRNA expression in the adrenal and elevated plasma aldosterone 
(Chris Kenyon, personal communication).  Alternatively, hypercorticosteroneamia 
could stimulate the non-selective MR in aldosterone target organs such as the kidney 
and could potentially lead to renal sodium retention, blood volume expansion and 
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increased blood pressure (reviewed in Ferrari, 2003). However, this is less likely 
since in a state of MR overstimulation by GC excess, plasma renin is suppressed and 
aldosterone levels are  either normal or decreased (Ferrari, 2003), which does not 
appear to be  the case in the model presented here. The GR+/- mice had increased 
renin (secreted by the kidney) activity, which subsequently cleaves angiotensinogen, 
secreted mainly from the liver (Cambell & Habener, 1986; Tamura et al, 1995) in the 
plasma to form angiotensin I which is further converted to angiotensin II by ACE.  
Consequently, increased angiotensin II levels (although not directly measured here) 
can increase aldosterone secretion directly from the adrenal cortex, indeed the case 
here.  Aldosterone increases blood pressure through direct modulation of vascular 
tone and elevation of blood volume by increasing sodium and water retention in the 
kidney. It can be speculated that the GR+/- mice probably exhibit a renovascular 
hypertension, although further investigation (eg kidney morphology, 11β-HSD2 
activity in the kidney and also see 8.4) is required to confirm it.  Local renin-
angiotensin system (RAS) activation can contribute to altered blood pressure (Engeli 
et al., 2003; Goossens et al., 2007). However, it is unlikely the primary player in the 
hypertension phenotype of GR+/- phenotype because, although adipose 
angiotensionogen (AGT)   mRNA levels appeared to be elevated, liver AGT levels 
(main sourse) were unchanged.  It is possible that local RAS activation contributes to 
the already established hypertension in the GR+/- mice and further exaggerates the 
blood pressure phenotype upon chronic HF feeding, through increased hepatic 
angiotensinogen mRNA expression and, consequently, increased production and 
secretion of angiotensinogen with the downstream consequences mentioned above. 
Hypercorticosteroneamia is also likely a trigger for the hypertension phenotype 
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observed in HF-fed wild type littermates (fig. 8.2). However, in this case there is no 
apparent RAAS activation (neither elevation of plasma renin activity or 
angiotensinogen or aldosterone nor hepatic AGT mRNA leves). A number of 
parameters might contribute to the elevated BP, either direct effects of GCs on for 
example cardiac output and increases in total or regional peripheral resistance 
(Montero and Boscaro, 1992; Whitworth et al., 1995; Kelly et al., 1998) or   
alternatively, in DIO- mediated hypertension it is likely that synergistic effects of 
hypercorticosteroneamia (see above), hyperinsulineamia (Sowers, 2004) and 
hyperleptineamia (as occurs with increased fat mass; Rahmouni et al., 2005) may 
activate the sympathetic nervous system and thus lead to elevated BP (Racher et al., 
1979).   
 
Furthermore, there may be developmental effects programming hypertension in 
GR+/- mice. It has been shown that GC-overexposure in utero reduces nephron 
number and consequently leads to late onset hypertension (Celsi et al., 1998; 
Langley-Evans, 2001; Ortiz et al., 2001; Vehaskari et al., 2001). One could presume 
that the GR+/- mice might be exposed to high GCs  in utero (if GR+/- mums are used 
for breeding). Whether or not they are “protected” from high GC exposure by lower 
GR density is unknown but would be very interesting to address by studies of renal 
structure, nephron number,  11β-HSD2 and MR levels.. 
 
When interpreting the current data, a disadvantage of the GR+/- model needs to be 
considered. The global reduction GR density makes it difficult to dissect the net 
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effects on specific organ/cellular systems. Because global reduction of the receptor 
leads to HPA axis hyperactivity and consequently elevated circulating levels of 
corticosterone, this confounds interpretation of downstream tissue-specific effects 
and should be addressed in the future. Critically, adrenalectomy (adx) experiments 
followed by replacement of CORT to fixed levels will help to dissect the 
confounding responses caused by high systemic CORT levels. Furthermore, it would 
be informative to address whether reduced GR density is compensated by increased 
MR expression (in MR expressing tissues, such as the heart), which will presumably 
be further activated (full receptor occupancy due to lower levels) by elevated CORT 
(if the levels exceed the capacity of MR protecting 11β-HSD2 to inactivate CORT) 
and target aldosrerone sensitive tissues/organs (like kidney) or the heart causing 
renal/cardiac hyperthrophy and consequently affecting BP. However, preliminary 
observations (Michailidou, Brownstein, Chapman, unpublished) in adult male GR+/- 
hearts do not indicate any cardiac hypertrophy. 
 
Another important issue with respect to GC metabolism is the clearance of 
glucocorticoids by hepatic A-ring reductases.  Therefore it will be interesting to 
investigate if GR+/- mice have altered GC-clearance rates by measuring the ratio of 
urinary or fecal glucocorticoid metabolites.   
 
Of course, tissue-specific models of GR knock down (with cre-lox) or 
overexpression (with tissue specific promoters) proved to be informative. As 
discussed in chapter 1, this has illuminated the effects of GR reduction in the liver 
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(Kellendonk et al., 2000; Orpherk et al., 2004) and overexpression in the pancreas 
(Delaunay et al., 1997; Davani et al., 2004). With respect to the effects of altered GR 
on adipose tissue dysregulation, adipose-tissue specific up- and down-regulation GR 
models (recently generated in Edinburgh) will also be informative, although they 
also have their limitations when it comes to relate/translate findings in mice to 
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Figure 8.1 GR+/- mice: a Model of GC-resistance 
A schematic view of the effects of reduced GR density on the HPA axis, metabolic 
parameters and blood pressure homeostasis (A) under basal conditions (low fat diet) 
and (B) after HF feeding. Under basal conditions (A), GR+/- mice, with globally 
reduced GR levels, displayed higher plasma CORT levels, unaltered ACTH levels, 
body weight and glucose homeostasis compared to wild type littermates. GR+/- were 
hypertensive, with elevated renin activity and plasma aldosterone concentration and 
hypertrophic adrenals (zona fasciculate and glomeruloza). The hypertension is 
probably due to activation of RAAS, with elevated ALDO levels predicted to directly 
affect the kidney and cause salt and water retention (however still remains to 
evaluate kidney histology).  The mRNA levels of 11β-HSD1 in liver or adipose 
tissue were unaffected by reduced GR density or hypercorticosteroneamia. After 
chronic HF feeding (B) plasma CORT remained elevated but ACTH increased. 
Although all the phenotyping changes with DIO were observed (obesity, hepatic 
increased TGs, impaired glucose tolerance), they were identical to the wild type mice 
responses (fig. 8.2). The BP was further increased with the systemic RAAS 
components remaining still higher than in the GR+/+ mice but not further increased by 
HF diet. Conversely, an up-regulation of  hepatic AGT mRNA levels was observed 
in HF-fed GR+/- mice possibly further  attributing to the increased BP. BW; body 
weight, CORT; corticosterone, AGT; angiotensinogen mRNA,Agt; plasma 
angiotensinogen concentration, ALDO; aldosterone; AngII; angiotensin II, BP; blood 
pressure ,GTT; glucose tolerance test, TGs; triglycerides, RAS; renin-angiotensin-
aldosterone system, DIO; diet induced obesity,  ? indicates that measurements (eg 
CRH) have not been performed.  
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Figure 8.2 Responses of chronically HF-fed wild type mice.  
Chronic HF feeding increased circulating CORT and ACTH levels and led to 
hypertension but without any alterations in any of the renin-angiotensin-aldosterone 































8.2 Scenario B: Fixed glucocorticoid levels and “normal” GR density 
 
Figure 8.3 illustrates the metabolic and blood pressure effects in the Pomc-/- mice in 
the “absence” of CORT (fig. 8.3A) and after CORT-replacement (fig. 8.3B). Lack of 
all POMC-derived peptides (including ACTH) leads to obesity due to central 
hyperphagia (loss of the appetite suppressing MSH signal), a variety of metabolic 
abnormalities, undetectable plasma CORT but normal BP in Pomc-/- mice (Challis et 
al., 2004; Coll et al., 2005; Michailidou et al., 2007). CORT-replacement augments 
the 
obesity phenotype and the metabolic abnormalities (Coll et al., 2005) and also 
induces hypertension (Michailidou et al., 2007) in Pomc-/- mice. In contrast to 
hypercorticosteroneamic GR+/- mice, the hypertensive phenotype in Pomc-/- mice, 
with supraphysiological GC levels (Coll et al., 2005), cannot be attributed to 
systemic RAAS activation since none of the RAAS components are affected in the 
latter (although insufficient plasma was available for aldosterone assay). Moreover, 
the lack of renal morphological changes (Kenyon, Michailidou, Chapman, 
unpublished observations) in Pomc-/- mice,  that might be explained by low 
aldosterone levels,  rule out a renovascular BP phenotype. Renovascular 
hypertension is typically attributed to RAS activation, with consequently severe 
angiotensin-mediated vasoconstriction, elevated aldosterone release and renal 
ischemia (Bettmann et al., 2004; Arruda et al., 2005; Heo et al., 2007).   Renal 
impairment is prominent when plasma aldosterone levels are increased, as observed 
in aP2-11HSD1 mice (Masuzaki et al., 2003) and Zucker rats (Claphman and Turner, 
1997; Villarreal et al., 1998 ) and is absent when aldosterone is low, as in Pomc-/- 
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(Coll et al., 2004) and Fat mice (Morton et al., 2005). Conversely, in the CORT-
treated wild type mice, it is difficult to evaluate the net circulating CORT levels 
(amount of endogenously produced vs exogenously provided in the drinking water) 
since the mice had intact adrenals.   There are 2 possibilities; circulating CORT is (a) 
reduced after CORT-treatment (due to reduced hypothalamic CRH expression, Coll 
et al., 2005) or (b) unaltered and the exogenous CORT suppressed the HPA axis. In 
any case exogenous CORT treatment in wild type mice did not affect BP or any of 
the systemic RAS components (fig. 8.4).  It seems likely that in Pomc-/- mice 
corticosterone augmented existing mechanisms that were already sustaining vascular 
function. The elavated renin concentration observed in the untreated Pomc-/- mice 
might be due to renal compensation of the very low aldosterone levels in this model. 
Apart from renin, these secondary processes are likely to involve the 
hyperinsulinaemic state (Sowers, 2004) of Pomc-/- mice (which is profoundly 
exacerbated by corticosterone treatment) (Coll et al., 2005), the sympathetic nervous 
system (Rascher et al., 1979) (which is thought to explain GC-induced hypertension 
in normal mice) or structural adaptation or the vasculature (Wallerathetal., 2004). 
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Figure 8.3 POMC-null mice: A model of GC hypersensitivity 
Pomc-null mice responses (A) under basal conditions and (B) after CORT-
replacement. Under basal conditions, Poomc-null mice had undetectable CORT and 
reduced ALDO levels (Coll et al., 2005) and displayed alterations in GC sensitivity 
(reduced adipose 11β-HSD1 but elevated hepatic and retroperitoneal GR levels) but 
unaltered BP compared to wild type mice. After CORT treatment, they developed  
hypertension (together with exaggerated obesity and insulin resistance, Coll et al., 
2005). The BP phenotype in the Pomc-null mice cannot be attributed to systemic 
RAAS activation, since none of the components were elevated.  The cause of the 
elevated BP appears to be complex and possibly the consequence of multi-
parameters dysregulation (eg profound hyperinsulineamia, hypeleptineamia). 
Additionally, Pomc-null mice showed an increased sensitivity to CORT treatment 
with elevated 11β-HSD1 Mrna levels specifically in adipose tissue and up-regulation 










































8.3 Peripheral Interplay: CORT, GR and 11β-HSD1 levels 
 
An interesting finding from the Pomc-/- study was the apparent regulation of 11β-
HSD1 mRNA levels by CORT in adipose tissue but not in liver. The data presented 
in this study provide further evidence that 11β-HSD1 mRNA levels are differentially 
regulated by GCs in adipose and hepatic tissues. In the absence of circulating CORT, 
the GR is up-regulated in both liver and retroperitoneal fat, while 11β-HSD1 is 
specifically down-regulated in adipose in Pomc-/-.  CORT-replacement suggested that 
glucocorticoid regulation of 11β-HSD1 in liver in vivo is minimal, at least at 
“physiological” levels of corticosterone and GR, but that 11β-HSD1 mRNA levels 
are highly regulated by glucocorticoids in adipose tissue (fig. 8.3). This is predicted 
to selectively amplify intra-adipose glucocorticoid concentrations, particularly when 
circulating levels of 11β-HSD1 substrate are high – for example, following HPA 
activation (Harris et al., 2001). In contrast, the elevated CORT levels in GR+/- mice 
with reduced GR levels, did not affect 11β-HSD1 mRNA levels in either liver or 
adipose tissue (fig. 8.1). Moreover, when GR+/- mice develop obesity (DIO 
experiment) they still exhibit high circulating CORT, but 11β-HSD1 mRNA levels 
are significantly down-regulated, as previously published (Morton et al., 2004). More 
interestingly, in a human population (chapter 7), although no cortisol measurements 
are available (but unlikely to be high in indiopathic obesity, see section 1.6.4), there 
are clearly differences in both GR and 11β-HSD1 mRNA expression levels between 
normal weight and obese individuals. Specifically, obese women have significantly 
higher 11β-HSD1 but lower GR mRNA levels in all depots compared to normal 
weight females (fig. 8.5). It seems that there is a fine tuning of GR and 11β-HSD1 
and modulations seem to occur reciprocally to compensate for local GC-
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amplification in peripheral (abdominal sc) but not in visceral (omental) adipose 
tissue (fig. 8.5).  In the latter GR remains equally high as do 11β-HSD1 levels. Thus 
it could be predicted that a series of “abnormalities” such as (a) unfavourable 
deposition of fat in the omentum (because of the anatomical position; drains to the 
portal vein) (b) consequently, elevated 11β-HSD1 levels (positively correlate with 
visceral adipose mass increase) and local amplification of cortisol, and finally (c) 
failure to compensate by reducing the levels of GR, may lead to increased fat 
deposition, adipose insulin resistance (therefore increased portal delivery of free fatty 
acids), altered adipokine expression  and consequent metabolic abnormalities. These, 
observations are very interesting but require further investigation in a larger human 













Figure 8.5 Comparison of adipose GR and 11β-HSD1 levels in normal weight and 
obese females. 
In normal weight (BMI: 24.8±0.9) GR mRNA levels are higher while 11β-HSD1 
mRNA levels are lower compared to obese (BMI: 36.6±1) females. In all depots, 
apart from omental, it seems that elevated 11β-HSD1 mRNA levels and thus local 
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8.4 Future perspectives in the use of GR+/- model  
Overall, the GR+/- model proved to be informative regarding the role of reduced GR 
density on body composition, metabolic parameters and blood pressure homeostasis. 
It is clear that GR haploinsufficiency does not have a permissive effect on the 
development of glucose or lipid abnormalities and does not play an essential role in 
modulating body composition, even when the model is challenged with a chronic HF 
feeding. However, the novel finding of increased blood pressure provides new 
perspectives of the role of GR in the regulation of blood pressure. Future 
experiments could address the net effect (by adx) of reduced GR on, for example, 
salt-induced hypertension.   
 
Additionally, the effects of reduced GR can be studied in a number of systems. For 
example, preliminary data on embryonic heart development (not presented in this 
Thesis) suggest an essential role in a critical “window” (time dependent) of GR in 
cardiac remodelling and will be very exciting to follow up. Furthermore, the 
presence of the LacZ reporter makes it a very useful tool to follow the receptor 
function and regulation in specific cell types (eg of the immune system). 
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Figure A1. Construct pVL318 encodes the GR-ßgal fusion protein (ESKN92). 
pVL318 was constructed by Val Lyons. It is in a  pcDNA3.1 vector (Invitrogen) and 
was assembled using the following plasmids/DNAs: pSV2wrec (Danielsen et al., 
1986), 5’-RACE product from ESKN92 and pGT3 (the gene trap vector).pSV2wrec 
(shown in fig. A3) encodes the WT mouse GR cDNA (accession number X04435) 
and was kindly provided by Mark Danielsen. An EcoRI site is present at the extreme 
5’ end of the GR cDNA in  pSV2wrec (Danielsen et al., 1986). GR cDNA also has a 
unique SalI site within exon 2 (nucleotide 438). During the course of the subcloning, 
sequencing revealed that the 129Ola derived DNA from ESKN92, as well as 
C57BL6/J DNA differed at a single nucleotide in exon 3 from the pSV2wrec 
encoded cDNA (derived from the mouse lymphoma cell line, W7.2). This results in a 
Val437 (in pSV2wrec) to Gly437 (in 129Ola and C57BL6/J) polymorphism. 
Although this polymorphism is reported not to influence the activity of GR (Kasai, 
1990), site-directed mutagenesis was used to change the pSV2wrec sequence to that 
of 129Ola/C57BL6J (generating pSV2wrecG437). The following fragments were 
ligated together to generate an intermediate plasmid (pVL336): pcDNA3.1(-) cut 
with EcoRI and BamHI, a 440bp EcoRI-SalI fragment comprising the 5’ portion of 
mouse GR cDNA from pSV2wrec and an ~1kb SalI (GR exon 2 site)-BamHI (site in 
the linker of the pGT3 vector immediately preceding ß-gal) fragment from the 5’-
RACE PCR product. The pVL336 intermediate plasmid was linearised with XbaI 
(cutting within the pGT3 linker sequence, next to BamHI) and ligated to an XbaI 
fragment from pGT3 encoding the ßgeo cassette. The correct plasmids were 
identified by restriction digests and confirmed by DNA sequencing (Wellcome 



























Figure A2. pVL342 encodes the WT mouse GR 
pVL342 was also constructed by Val Lyons. It is in a  pcDNA3.1 vector (Invitrogen) 
and was assembled using the following plasmids/DNAs: pSV2wrec (Danielsen et al., 
1986) and pGem3 (Promega). An intermediate cloning step in which a 2050bp SalI-
XbaI fragment from pSV2wrecG437 (see legent fig.A1) was subcloned into pGem3. 
This placed a BamHI site immediately 3’ to the XbaI site. The 2060bp SalI-BamHI 
fragment from this intermediate plasmid, together with the 440bp EcoRI-SalI 
fragment from pSV2wrec were ligated into pcDNA3.1(-) cut with EcoRI and 
BamHI. Correctly ligated plasmids were identified by restriction digest and 




































































Figure A5 The pBS-GR129H6.0 plasmid was used for the generation of GR probe in 
FISH (section 2.2.2.3.2.3.2)  
Briefly, the pBS-GR129H6.0 plasmid (gift from H. Reichardt) was digested with 
HindIII in a 25μl digest (5μl DNA, 2.5μl 10xbuffer B, 1μl HindIII and 16.5μl dH2O) 
at 37oC for 2h. The digest was run on a 0.8% low melting point agarose gel and the 
~6kb fragment was cut out, purified and eluted in 24μl  (final concentration 
















APPENDIX B: Sequences  


















































































































B2. 5’-RACE sequence of “trapped” GR 
Sequence in green corresponds to exon 2 of GR, sequence in red corresponds to exon 
3 of GR and blue is the lacZ sequence encoding βgal. The β-geo cassette is spliced 
onto the 3’-end of exon 3. 
 
 
B3. Mouse GR cDNA sequense (accession X04435; length: 2575) 
                      
 
       1  GGAAGTTAAT ATTTGCCAAT GGACTCCAAA GAATCCTTAG CTCCCCCTGG  
 
      51  TAGAGACGAA GTCCCCAGCA GTTTGCTTGG CCGGGGGAGG GGAAGCGTGA  
 
     101  TGGACTTGTA TAAAACCCTG AGGGGTGGAG CTACAGTCAA GGTTTCTGCG  
 
     151  TCTTCACCCT CAGTGGCTGC TGCTTCTCAG GCAGATTCCA AGCAGCAGAG  
 
     201  GATTCTCCTT GATTTTTCAA AAGGCTCAGC AAGCAATGCA CAGCAGCAGC  
 
     251  AGCAGCAGCA GCAGCCGCAG CCAGATTTAT CCAAAGCCGT TTCACTGTCC  
 
     301  ATGGGACTGT ATATGGGAGA GACCGAAACA AAAGTGATGG GGAATGACTT  
 
     351  GGGCTACCCA CAGCAGGGCC AGCTTGGCCT CTCCTCTGGG GAAACAGACT  
 
     401  TTCGGCTTCT GGAAGAAAGC ATTGCAAACC TCAATAGGTC GACCAGCCGT  
 
     451  CCAGAGAATC CCAAGAGTTC AACACCTGCA GCTGGGTGTG CTACCCCGAC  
 
     501  AGAGAAGGAG TTTCCCCAGA CTCACTCTGA TCCATCTTCA GAACAGCAAA  
 
     551  ATAGAAAAAG CCAGCCTGGC ACCAACGGTG GCAGTGTGAA ATTGTATACC  
 
     601  ACAGACCAAA GCACCTTTGA CATCTTGCAG GATTTGGAGT TTTCTGCCGG  
 
     651  GTCCCCAGGT AAAGAGACAA ACGAGAGTCC TTGGAGGTCA GACCTGTTGA  
 
     701  TAGATGAAAA CTTGCTTTCT CCTTTGGCGG GAGAAGATGA TCCATTCCTT  
 
     751  CTGGAAGGGG ACGTGAATGA GGATTGCAAG CCTCTTATTT TACCGGACAC  
 
TCAGCAGCAGGATCAGAAGCCTGTTTTTAATGTCATTCCNCCAATTCCTG                








     801  TAAACCTAAA ATTCAGGATA CTGGAGATAC AATCTTATCA AGCCCCAGCA  
 
     851  GTGTGGCACT GCCCCAAGTG AAAACAGAGA AAGATGATTT CATTGAGCTT  
 
     901  TGCACCCCTG GGGTAATTAA GCAAGAGAAA CTGGGCCCGG TTTATTGCCA  
 
     951  GGCAAGCTTT TCTGGGACAA ATATAATTGG GAATAAAATG TCTGCCATTT  
 
    1001  CTGTTCATGG CGTGAGTACC TCTGGAGGAC AGATGTACCA CTATGACATG  
 
    1051  AATACAGCAT CCCTTTCTCA GCAGCAGGAT CAGAAGCCTG TTTTTAATGT  
 
    1101  CATTCCACCA ATTCCTGTTG GTTCTGAAAA CTGGAATAGG TGCCAAGGGT  
 
    1151  CTGGAGAGGA CAACCTGACT TCCTTGGGGG CTATGAACTT CGCAGGCCGC  
 
    1201  TCAGTGTTTT CTAATGGATA TTCAAGCCCT GGAATGAGAC CAGATGTGAG  
 
    1251  TTCTCCTCCG TCCAGCTCCT CCACAGCAAC GGGACCACCT CCCAAACTCT  
 
    1301  GCCTGGTGTG CTCCGATGAA GCTTCGGTAT GCCATTATGG GGTGCTGACG  
 
    1351  TGTGGAAGCT GTAAAGTCTT CTTTAAAAGA GCAGTGGAAG GACAGCACAA  
 
    1401  TTACCTTTGT GCTGGAAGAA ATGATTGCAT CATTGATAAA ATTCGAAGAA  
 
    1451  AAAACTGTCC AGCATGCCGC TATCGAAAAT GTCTTCAAGC TGGAATGAAC  
 
    1501  CTGGAAGCTC GAAAAACGAA GAAAAAAATT AAAGGAATTC AGCAAGCCAC  
 
    1551  TGCAGGAGTC TCACAAGACA CTTCTGAAAA CGCTAACAAA ACAATAGTTC  
 
    1601  CTGCCGCGCT GCCACAGCTT ACCCCTACCC TGGTGTCACT GCTGGAGGTG  
 
    1651  ATCGAGCCTG AGGTGTTATA TGCAGGATAT GACAGCTCTG TTCCAGACTC  
 
    1701  AGCATGGAGA ATTATGACCA CGCTCAACAT GTTAGGTGGG CGCCAAGTGA  
 
    1751  TTGCCGCAGT GAAATGGGCA AAGGCGATAC CAGGATTCAG AAACTTACAC  
 
    1801  CTGGATGACC AAATGACCCT TCTACAGTAC TCATGGATGT TTCTCATGGC  
 
    1851  ATTTGCCCTG GGTTGGAGAT CATACAGACA AGCAAGTGGA AACCTGCTAT  
 
    1901  GCTTTGCTCC TGATCTGATT ATTAATGAGC AGAGAATGAC TCTACCCTGC  
 
    1951  ATGTATGACC AATGTAAACA CATGCTGTTT ATCTCCACTG AATTACAAAG  
 
    2001  ATTGCAGGTA TCCTATGAAG AGTATCTCTG TATGAAAACC TTACTGCTTC  
 
    2051  TCTCCTCAGT TCCTAAGGAA GGTCTGAAGA GCCAAGAGTT ATTTGATGAG  
 
    2101  ATTCGAATGA CTTATATCAA AGAGCTAGGA AAAGCCATTG TCAAAAGGGA  
 
    2151  AGGAAACTCC AGTCAGAATT GGCAGCGGTT TTATCAACTG ACAAAACTTT  
 
    2201  TGGACTCCAT GCATGATGTG GTTGAAAATC TCCTTAGCTA CTGCTTCCAA  
 
 278
    2251  ACATTTTTGG ATAAGTCCAT GAGTATTGAA TTCCCAGAGA TGTTAGCTGA  
 
    2301  AATCATCACT AATCAGATAC CAAAATACTC AAATGGAAAT ATCAAAAAGC  
 
    2351  TTCTGTTTCA TCAGAAATGA CTGCCTTACT AAGAAAGGCT GCCTTAAAGA  
 
    2401  AAGTTGAATT TATAGCTTTT ACTGTACAAA CTTATCAACT TGTCTTGTAG  
 
    2451  ATGTTTTGTC GTTCTTTTTG TTTGTCTTGT TTGTTTTCTA TACGCACTAC  
 
    2501  ATGTGGTCTC TAGAGGGCCA AGACTTGGCA ACAGAAGCAG ATGAGCCATC  
 









































B4. GR Fasta format (2575 bases)  
                              
GGAAGTTAATATTTGCCAATGGACTCCAAAGAATCCTTAGCTCCCCCTGG 
                               
TAGAGACGAAGTCCCCAGCAGTTTGCTTGGCCGGGGGAGGGGAAGCGTGA 
                               
TGGACTTGTATAAAACCCTGAGGGGTGGAGCTACAGTCAAGGTTTCTGCG 
                               
TCTTCACCCTCAGTGGCTGCTGCTTCTCAGGCAGATTCCAAGCAGCAGAG 
                               
GATTCTCCTTGATTTTTCAAAAGGCTCAGCAAGCAATGCACAGCAGCAGC 
                               
AGCAGCAGCAGCAGCCGCAGCCAGATTTATCCAAAGCCGTTTCACTGTCC 
                               
ATGGGACTGTATATGGGAGAGACCGAAACAAAAGTGATGGGGAATGACTT 
                               
GGGCTACCCACAGCAGGGCCAGCTTGGCCTCTCCTCTGGGGAAACAGACT 
                               
TTCGGCTTCTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGCCGT 
                               
CCAGAGAATCCCAAGAGTTCAACACCTGCAGCTGGGTGTGCTACCCCGAC 
                               
AGAGAAGGAGTTTCCCCAGACTCACTCTGATCCATCTTCAGAACAGCAAA 
                               
ATAGAAAAAGCCAGCCTGGCACCAACGGTGGCAGTGTGAAATTGTATACC 
                               
ACAGACCAAAGCACCTTTGACATCTTGCAGGATTTGGAGTTTTCTGCCGG 
                               
GTCCCCAGGTAAAGAGACAAACGAGAGTCCTTGGAGGTCAGACCTGTTGA 
                               
TAGATGAAAACTTGCTTTCTCCTTTGGCGGGAGAAGATGATCCATTCCTT 
                               
CTGGAAGGGGACGTGAATGAGGATTGCAAGCCTCTTATTTTACCGGACAC 
                               
TAAACCTAAAATTCAGGATACTGGAGATACAATCTTATCAAGCCCCAGCA 
                               
GTGTGGCACTGCCCCAAGTGAAAACAGAGAAAGATGATTTCATTGAGCTT 
                               
TGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCCCGGTTTATTGCCA 
                               
GGCAAGCTTTTCTGGGACAAATATAATTGGGAATAAAATGTCTGCCATTT 
                               
CTGTTCATGGCGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATG 
                               
AATACAGCATCCCTTTCTCAGCAGCAGGATCAGAAGCCTGTTTTTAATGT 
                               
CATTCCACCAATTCCTGTTGGTTCTGAAAACTGGAATAGGTGCCAAGGGT 
                               
CTGGAGAGGACAACCTGACTTCCTTGGGGGCTATGAACTTCGCAGGCCGC 
                               
TCAGTGTTTTCTAATGGATATTCAAGCCCTGGAATGAGACCAGATGTGAG 
                               
TTCTCCTCCGTCCAGCTCCTCCACAGCAACGGGACCACCTCCCAAACTCT 
 280
                               
GCCTGGTGTGCTCCGATGAAGCTTCGGTATGCCATTATGGGGTGCTGACG 
                               
TGTGGAAGCTGTAAAGTCTTCTTTAAAAGAGCAGTGGAAGGACAGCACAA 
                               
TTACCTTTGTGCTGGAAGAAATGATTGCATCATTGATAAAATTCGAAGAA 
                               
AAAACTGTCCAGCATGCCGCTATCGAAAATGTCTTCAAGCTGGAATGAAC 
                               
CTGGAAGCTCGAAAAACGAAGAAAAAAATTAAAGGAATTCAGCAAGCCAC 
                               
TGCAGGAGTCTCACAAGACACTTCTGAAAACGCTAACAAAACAATAGTTC 
                               
CTGCCGCGCTGCCACAGCTTACCCCTACCCTGGTGTCACTGCTGGAGGTG 
                               
ATCGAGCCTGAGGTGTTATATGCAGGATATGACAGCTCTGTTCCAGACTC 
                               
AGCATGGAGAATTATGACCACGCTCAACATGTTAGGTGGGCGCCAAGTGA 
                               
TTGCCGCAGTGAAATGGGCAAAGGCGATACCAGGATTCAGAAACTTACAC 
                               
CTGGATGACCAAATGACCCTTCTACAGTACTCATGGATGTTTCTCATGGC 
                               
ATTTGCCCTGGGTTGGAGATCATACAGACAAGCAAGTGGAAACCTGCTAT 
                               
GCTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGC 
                               
ATGTATGACCAATGTAAACACATGCTGTTTATCTCCACTGAATTACAAAG 
                               
ATTGCAGGTATCCTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTC 
                               
TCTCCTCAGTTCCTAAGGAAGGTCTGAAGAGCCAAGAGTTATTTGATGAG 
                               
ATTCGAATGACTTATATCAAAGAGCTAGGAAAAGCCATTGTCAAAAGGGA 
                               
AGGAAACTCCAGTCAGAATTGGCAGCGGTTTTATCAACTGACAAAACTTT 
                               
TGGACTCCATGCATGATGTGGTTGAAAATCTCCTTAGCTACTGCTTCCAA 
                               
ACATTTTTGGATAAGTCCATGAGTATTGAATTCCCAGAGATGTTAGCTGA 
                               
AATCATCACTAATCAGATACCAAAATACTCAAATGGAAATATCAAAAAGC 
                               
TTCTGTTTCATCAGAAATGACTGCCTTACTAAGAAAGGCTGCCTTAAAGA 
                               
AAGTTGAATTTATAGCTTTTACTGTACAAACTTATCAACTTGTCTTGTAG 
                               
ATGTTTTGTCGTTCTTTTTGTTTGTCTTGTTTGTTTTCTATACGCACTAC 










APPENDIX C: OTHER PRIMERS USED IN THIS THESIS 
 
Table C1: Primer sequences used to identify GR-/- mice (details in section 4.2.2.1) 
Gene Forward (5’-3’) Reverse (5’-3’) 
GR1 GAAGCTTCGGGATGCCATTATGG GGAATGTGAACCCGTCAACACATG 
GR2 GTTTGAAAGAAGATGACTGCAAGG GGGCCACTAATTGATTTTGGATG 
GR3 GTTCTCCATGTCCTTATGCCCAG GCCAGCTTACAGGATAGCCAGTG 
 
 
GR4 GGCATCTGGTTCCCTAGAATTGG GTAACAGTCAGTTCACCAGTTGG   
GR5 TGTTCCAACTGGTGAACTGACTG TGTTACCAACTTCTAGCCACTGG 
En-2 
& 
GR   
Any of the above GR forward primers  CTGGGGTTCGTGTCCTACAACAC 
En-2 
& 
GR   
Any of the above GR forward primers  TCTGTCCTCCAGTCTCCTCCAC 
En-2 
& 
GR   
Any of the above GR forward primers  GAACATCTGAAAAACATACTTTCGG 
En-2 
& 
GR   
Any of the above GR forward primers  GTCCTCTTCACATCCATGCTGAGG 
Combinations of (a) GR forward and reverse primers (described in section 4.2.2 
figures 4.2 and 4.3 (indicating relavant PCR product sizes and (b) GR forward and 
engrailed 2 (en-2) reverse primers were used to identify GR-/- mice. Note that all 



















Appendix D: Addresses of Suppliers 
 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Bucks., HP7 9NA, U.K. 
Beckman Coulter (U.K.) Ltd., Oakley Court, Kingsmead Business Park, London 
Road, High Wycombe, Bucks., HP11 1JU, U.K. 
Berthold Technologies (U.K.) Ltd., The Priory, High Street, Redbourn, Herts., AL3 
7LZ, U.K. 
BD UK Ltd, Between Towns Road, Cowley, Oxford, Oxon., OX4 3LY, U.K. 
Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Avenue, Hemel Hempstead, 
Herts., HP2 7TD, U.K. 
Cambrex Bio Science Wokingham Ltd., 1 Ashville Way, Wokingham, Berks., 
RG41 2PL, U.K. 
Eppendorf AG, Barkhausenweg 1, 22331 Hamburg, Germany 
Greiner Bio-One Ltd., Brunel Way, Stroudwater Business Park, Stonehouse, Glos., 
GL10 3SX, U.K. 
IKA Labortechnik, IKA-Werke GmbH & Co. KG, Janke & Kunkel-Str. 10, D-
79219 Staufen, Germany 
Invitrogen, Ichinnan Business Park, 3 Fountain Drive, Paisley, PA4 9RF, U.K. 
Kendro Laboratory Products Plc., Stortford Hall Park, Bishhop’s Stortford, Herts., 
CM23 5GZ, U.K. 
Nalgene Labware, Unit 1a, Thorn Business Park, Hereford, HR2 6JS, U.K. 
Oswel DNA service, Medical & Biological Sciences Building, University of 
Southampton, Boldrewood, Bassett Crescent East, Southampton, SO16 7PX, UK. 
Promega Ltd., Delta house, Chilworth Research Centre, Southampton, SO1 7NS, 
U.K. 
Qbiogene-Alexis Ltd., P.O. Box 6757, Bingham, Nottingham, NG13 8LS, U.K. 
Quantum Appligene, Parc d’Innovation, BP 72, Illkirch 67402, France 
Roche Diagnostics Ltd., Bell Lane, Lewes, East Sussex, BN7 1LG, U.K. 
Sarstedt Ltd., 68 Boston Road, Beaumont Leys, Leicester, LE4 1AW, U.K. 
Shimadzu Europa U.K., Mill Court, Featherstone Road, Wolverton Mill South, 
Milton Keynes, Bucks., MK12 5RE, U.K. 
Sigma-Aldrich Company Ltd., Fancy Road, Poole, Dorset, BH12 4OH, U.K. 
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Stratagene Europe, Gebouw California, Hogehilweg 15, 1101 CB Amsterdam 
Zuidoost, The Netherlands 
Techne, Duxford, Cambridge, CB2 4P2, U.K. 
Tropix Ltd., 47 Wiggins Avenue, Bedford, MA, U.S.A. 
Worthington Biochemicals, Lorne Laboratories Ltd., 7 Tavistock Estate, Ruscombe 
Business Park, Ruscombe Lane, Twyford, Reading, Berks., RG10 9NJ, U.K. 
VWR International Ltd., Hunter Boulevard, Magna Park, Lutterworth, Leics., 
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(Requests for offprints should be addressed to K E Chapman; Email: karen.chapman@ed.ac.uk)AbstractProopiomelanocortin (POMC)deficiency causes severe obesity
through hyperphagia of hypothalamic origin. However, low
glucocorticoid levels caused by adrenal insufficiency mitigate
against insulin resistance, hyperphagia and fat accretion in
PomcK/K mice. Upon exogenous glucocorticoid replacement,
corticosterone-supplemented (CORT) PomcK/K mice show
exaggerated responses, including excessive fat accumulation,
hyperleptinaemia and insulin resistance. To investigate the
peripheral mechanisms underlying this glucocorticoid hyper-
sensitivity, we examined the expression levels of key
determinants and targets of glucocorticoid action in adipose
tissue and liver. Despite lower basal expression of 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1), which
generates active glucocorticoids within cells, CORT-mediated
induction of 11b-HSD1 mRNA levels was more pronouncedJournal of Endocrinology (2007) 194, 161–170
0022–0795/07/0194–161 q 2007 Society for Endocrinology Printed in Greatin adipose tissues ofPomcK/Kmice. Similarly, CORT treatment
increased lipoprotein lipase mRNA levels in all fat depots in
PomcK/K mice, consistent with exaggerated fat accumulation.
Glucocorticoid receptor (GR) mRNA levels were selectively
elevated in liver and retroperitoneal fat of PomcK/K mice but
were corrected by CORT in the latter depot. In liver, CORT
increased phosphoenolpyruvate carboxykinase mRNA levels
specifically in PomcK/K mice, consistent with their insulin-
resistant phenotype. Furthermore, CORT induced hyperten-
sion in PomcK/Kmice, independently of adipose or liver renin–
angiotensin system activation. These data suggest that CORT-
inducible 11b-HSD1expression in fat contributes to the adverse
cardiometabolic effects of CORT in POMC deficiency,
whereas higher GR levels may be more important in liver.
Journal of Endocrinology (2007) 194, 161–170Introduction
Glucocorticoids exert pleiotrophic effects on metabolism and
energy partitioning. Centrally, they increase food intake and
reduce energy expenditure, whilst peripherally, they promote
insulin resistance, fat accumulation (Dallman et al. 1993,
Kellendonk et al. 2002) and hypertension (Saruta 1996,
Whitworth et al. 2001). Polymorphisms in the human
glucocorticoid receptor NR3c1 gene (GR) are associated
with glucocorticoid hypersensitivity, visceral obesity, hyper-
tension and increased cardiovascular disease risk (Buemann
et al. 1997, Rosmond et al. 2000, Dobson et al. 2001, Ukkola
et al. 2001a,b, van Rossum et al. 2003). Many rodent models
of obesity are characterised by hypercorticosteronaemia, with
weight gain normalised following adrenalectomy and
reinstated by glucocorticoid replacement (Debons
et al.1982, Freedman et al. 1986, Sainsbury et al.1997,
Makimura et al. 2000). Although plasma glucocorticoid levels
are normal in human idiopathic obesity (Flier 2004), it hasbeen proposed that intra-adipose glucocorticoid action is
selectively increased, through increased adipose expression of
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1), the
intracellular enzyme that regenerates active glucocorticoids
from intrinsically inert 11-keto-glucocorticoids (Kotelevtsev
et al. 1997, Jamieson et al. 2000, Andrew et al. 2002).
Obese humans (Rask et al. 2001, Paulmyer-Lacroix et al.
2002, Lindsay et al. 2003, Kannisto et al. 2004) and some
rodent models of obesity (Livingstone et al. 2000, Masuzaki
et al. 2001) have selectively increased adipose levels of 11b-
HSD1 and transgenic overexpression of 11b-HSD1 in
adipocytes causes hyperphagia, obesity, insulin resistance
and hypertension despite unchanged systemic glucocorticoid
levels (Masuzaki et al. 2001, 2003). Hepatic overexpression of
11b-HSD1 has no effect on adiposity, but causes hypertension
and insulin resistance (Paterson et al. 2004). Conversely, mice
deficient in 11b-HSD1 are insulin sensitised and resist the
adverse metabolic effects of a high-fat diet (Kotelevtsev et al.
1997, Morton et al. 2001, 2004).DOI: 10.1677/JOE-07-0090
Britain Online version via http://www.endocrinology-journals.org
Z MICHAILIDOU and others . Glucocorticoid action in Pomc null mice162Proopiomelanocortin (POMC) is a polypeptide precursor
which undergoes extensive post-translational modification to
yield a range of smaller, biological active peptides.These include
a-, b- and g-melanocyte-stimulating hormone and adreno-
corticotrophic hormone (ACTH), collectively known as
melanocortins. Inactivating mutations of the POMC gene in
humans and mice result in a complex phenotype. Loss of
melanocortin signalling within the hypothalamus causes
hyperphagia and obesity (Krude et al. 1998, Yaswen
et al.1999, Challis et al. 2004). Further, a failure to produce
ACTHwithin the anterior pituitary causes adrenal insufficiency
with low or absent circulating glucocorticoids (Krude et al.
1998, Yaswen et al.1999, Challis et al. 2004). PomcK/Kmice are
therefore unusual amongst rodent models in that obesity
develops in the absenceof circulatingglucocorticoids.However,
glucocorticoid treatment exacerbates hyperphagia and obesity
in adult PomcK/K mice and induces severe insulin resistance,
hyperleptinaemia and diabetes (Coll et al. 2005).
We have tested the hypothesis that increased glucocorticoid
action in peripheral tissues of glucocorticoid-treated PomcK/K
mice contributes to their apparent glucocorticoid hypersensi-
tivity and exaggeratedmetabolic syndrome-like phenotype.We
further demonstrate that glucocorticoid replacement induces
hypertension in PomcK/K mice, independently of renin–
angiotensin system (RAS) activation.Materials and Methods
Animals and CORT replacement
ThegenerationofPomcK/Kmiceon a129/SvEvbackgroundhas
been described previously (Challis et al. 2004). All mice were
housed in standard conditions on a 12 h light:12 h darkness cycle
(lights on 0070 h) with ad libitum access towater and chow (4.5%
fat diet, Special Diet Services, Witham, UK). Eight-week-old
male mice (nZ5 per group) were treated with corticosterone
(25 mg/ml) in their drinking water, a dose that results in similar
plasma glucocorticoid levels and hypothalamic corticotrophin
releasing hormone (CRH)mRNA levels in PomcK/K and wild-
type mice (Coll et al. 2005). All animal protocols used in these
studieswere approvedunder the auspices of theUKHomeOffice
Animals (Scientific Procedures) Act 1986.Blood pressure measurement
Systolic bloodpressurewasmeasured photoelectrically in the tail
of restrained conscious mice using an IITC model 179 analyser
(WoodlandHills, CA, USA). Prior to recordingmeasurements,Figure 1 Mediators of GC action in adipose tissue of PomcK/K mice an
northern blot showing levels of 11b-HSD1 mRNA and 18S RNA in ep
mice, either untreated or treated for 10 days with corticosterone (cort). (
LPL (D) and PEPCK (E) mRNA levels in experimental mice. Epi, epidid
presented as percentage of the value in untreated wild-type mice (100
0.05, **P!0.01 and ***P!0.001.
Journal of Endocrinology (2007) 194, 161–170all mice underwent three periods of training to accustom them
to the procedure.Micewerewarmed at 32 8C for 30 min before
taking ten consecutive readings. The first five were discounted
and a mean value of systolic blood pressure was calculated from
the last five readings. Fivemice from each treatment groupwere
measured. All analogue recordings were analysed by an
independent observer who was blinded to the genotype of the
mice and any treatment they had received.Plasma hormone and lipid measurements
Animals were killed between 0800 and 0900 h by cervical
dislocation. Trunk blood samples were collected into EDTA-
coated tubes (Sarstedt, Leicester, UK), centrifuged at 6000 g for
10 min and plasma stored at K80 8C until required for assay.
Non-esterified fatty acid (NEFA) and triglyceride levels were
determined by commercial kits (NEFA, Roche Diagnostics;
triglyceride, Dade Behring, Marburg, Germany). Plasma renin
and angiotensinogen concentrations were determined as
previously described (Morton et al. 2005).Tissue morphology and hepatic triglyceride levels
Neutral lipids, cholesterol and fatty acidswere identified by light
microscopy at 40! magnification in cryostat liver sections
(30 mm) stainedwith oil redO (Sigma) and counter stainedwith
haematoxylin as previously described (Morton et al. 2005).
Hepatic triglycerides were extracted by homogenisation in
isopropanol (ten volumes) and then incubated at 37 8C for
45 min and measured spectrophotometrically in supernatants
(3000 g for 10 min) using reagent TR224221 (Alpha Labora-
tories, Eastleigh, Hampshire, UK).RNA extraction and northern blot analysis
Pieces of liver and adipose tissues (inguinal, retroperitoneal and
epididymal) were rapidly frozen in dry ice, stored atK80 8C and
then homogenised inTrizol reagent (Invitrogen). TotalRNAwas
purified using a binding matrix (RNaid Plus kit, BIO 101;
Anachem,UK) and eluted in diethylpyrocarbonate-treatedwater
containing 400 U/ml RNasin (Promega) and 10 mmol/l
dithiothreitol. RNA (5–10 mg) was blotted and hybridised to
32P-labelled cDNA probes for mouse 11b-HSD1, GR,
angiotensinogen, phosphoenolpyruvate carboxykinase
(PEPCK), lipoprotein lipase (LPL) and 18S as previously
described (Morton et al. 2005). SpecificmRNAswere quantified
using a phosphorimager (Fuji BAS FLA 2000, Raytek, Sheffield,d effects of CORT treatment on GC target genes. (A) Representative
ididymal adipose tissue of PomcK/K (K/K) and wild-type (C/C)
B–E) Quantitation of adipose tissue-specific 11b-HSD1 (B), GR (C),
ymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are
%) and are the meansGS.E.M.; nZ5 per group. Significance *P!
www.endocrinology-journals.org
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Z MICHAILIDOU and others . Glucocorticoid action in Pomc null mice164UK) and Aida image analysis software (Raytek) and are expressed
in arbitrary units relative to 18S RNA.Statistical analyses
The effects of genotype and corticosterone interactions were
assessed by two-way ANOVA followed by post hoc Tukey’s
tests for group differences. Significance was set at P!0.05.
Values are meansGS.E.M.Results
PomcK/K mice have reduced intra-adipose GC action but
exaggerated CORT-mediated GC amplification
Corticosterone-treated PomcK/K and wild-type mice had
similar plasma corticosterone levels and hypothalamic CRH
mRNA levels (Coll et al. 2005). To examine potential
mechanisms of corticosterone hypersensitivity in PomcK/K
mice, 11b-HSD1 and GR mRNA levels were measured in
epididymal, inguinal and retroperitoneal adipose depots.
Adipose 11b-HSD1 mRNA expression was lower in all
untreated PomcK/K compared with wild-type mice (Fig. 1A)
and was dramatically increased by corticosterone in both
genotypes (Fig. 1A), with larger increases (two- to four-fold
greater) in PomcK/K mice.
Adipose expression of GR mRNA was higher in the
retroperitoneal fat of PomcK/K mice and restored to wild-
type levels by corticosterone treatment (Fig. 1B). GR mRNA
levels did not differ in inguinal and epididymal fat between
PomcK/K and wild-type mice, and were unaffected by
corticosterone treatment in either genotype (Fig. 1B).
To investigate mechanisms downstream of 11b-HSD1/GR
by which corticosterone treatment selectively increases fat mass
in PomcK/K mice, adipose levels of mRNA encoding LPL, a
glucocorticoid-regulated gene (Fried et al. 1993), were
measured. Although LPL mRNA levels were the same in
untreated PomcK/K and wild-type mice in all depots, adipose
LPL expression in PomcK/K mice was markedly increased by
corticosterone treatment (Fig. 1C) consistent with increased
triglyceride uptake, and fatmass inPomcK/Kmice. Inwild-type
mice, corticosterone treatment increased LPL mRNA only in
the inguinal depot, and to a lesser extent than in PomcK/Kmice
(Fig. 1C), suggesting adipose depot-dependent regulation of
LPL by glucocorticoids in non-obese mice, consistent with
previous data in rats (Freedman et al. 1986).
PEPCK is an enzyme essential for gluconeogenesis in liver
and glycerol synthesis in adipose tissue (Pilkis & Granner
1992, Reshef et al. 2003). PEPCK is a classical glucocorticoid
target gene which is positively regulated by glucocorticoids in
hepatocytes and negatively regulated in adipocytes (Sasaki
et al.1984, Nechushtan et al. 1987). Consistent with this,
adipose PEPCK mRNA levels were decreased in epididymal
and retroperitoneal fat by corticosterone treatment in wild-
type mice (Fig. 1D). Surprisingly, given their glucocorticoidJournal of Endocrinology (2007) 194, 161–170deficiency, PomcK/K mice had lower levels of PEPCK
mRNA in adipose tissue than in wild-type (Fig. 1D).
However, although corticosterone treatment in PomcK/K
mice decreased PEPCK expression in inguinal and retro-
peritoneal adipose tissue (significantly lower than in
corticosterone-treated wild-type mice; PZ0.01), it had no
effect on PEPCK mRNA levels in epididymal adipose tissue,
suggesting that other regulatory factors dominate PEPCK
expression in adipose tissue of PomcK/K mice (Fig. 1D).PomcK/K mice are dyslipidaemic, and have unaltered hepatic
11b-HSD1 but higher GR mRNA levels
Hepatic 11b-HSD1 mRNA levels were similar between the
two genotypes (Fig. 2A) and unaffected by corticosterone
(Fig. 2A). Hepatic GRmRNA levels were higher in PomcK/K
compared with wild-type mice (Fig. 2B), but again
corticosterone had no effect on GR mRNA levels (Fig. 2B).
Hepatic PEPCK expression was lower in PomcK/K than in
wild-type mice (Fig. 2C) and was increased by corticosterone
treatment to levels equivalent to untreated wild-type mice. In
contrast, corticosterone decreased hepatic PEPCK mRNA
levels in wild-type mice (Fig. 2C).
PomcK/K mice showed markedly higher circulating trigly-
ceride levels (Fig. 3A) and hepatic lipid accumulation thanwild-
type mice (Fig. 3B), with sixfold higher levels of hepatic
triglyceride (P!0.001; Fig. 3C). However, corticosterone had
no effect on plasma triglyceride levels in either genotype
(Fig. 3A), nor did it worsen the liver phenotype (Fig. 3C).
PomcK/K and wild-type mice had similar plasma NEFA levels
which were unaffected by corticosterone (Fig. 3D).CORT drives hypertension in PomcK/K mice independently of
adipose and liver RAS activation
PomcK/K mice had similar blood pressure to wild-type mice
(Fig. 4A). Corticosterone markedly increased blood pressure
only inPomcK/Kmice (Fig. 4A). Since hypertension following
transgenic expression of 11b-HSD1 in adipose or liver is
associated with increased levels of angiotensinogen in each of
these tissues respectively (Masuzaki et al. 2001, Paterson et al.
2004), we hypothesised that a similar mechanism may drive
corticosterone-mediated hypertension in PomcK/K mice. We
therefore examined key components of the RAS (Guyton
1991). PomcK/K mice had higher hepatic angiotensinogen
mRNA levels than controls (Fig. 4B). However, corticoster-
one did not alter hepatic angiotensinogen mRNA levels in
either genotype (Fig. 4B). Consistent with lower intra-adipose
GC action, adipose angiotensinogenmRNA levels were lower
in PomcK/K mice in all adipose depots (Fig. 4C). Corticos-
terone increased angiotensinogen mRNA levels specifically in
epididymal adipose tissue of both genotypes (twofold increase;
P!0.001; Fig. 4C) but had no effect on angiotensinogen
mRNA levels in inguinal or retroperitoneal adipose tissue of
either genotype (Fig. 4C). Plasma angiotensinogenwww.endocrinology-journals.org
Figure 2 Mediators of GC action in the liver of PomcK/K mice and
effects of CORT treatment on GC target genes. Liver mRNA
expression of (A) 11b-HSD1, (B) GR and (C) PEPCK in PomcK/K
(K/K) and wild-type (C/C) mice, either untreated or treated for
10 days with corticosterone (cort). Data are presented as
percentages of the value in untreated control mice (100%) and are
the meansGS.E.M.; nZ5 per group. Significance *P!0.05, **P!
0.01 and ***P!0.001.
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www.endocrinology-journals.orgconcentrations did not differ with genotype or corticosterone
(Fig. 4D). As has been found in another model of
glucocorticoid-deficient obesity (Morton et al. 2005), plasma
renin concentration was markedly higher in PomcK/K mice
(Fig. 4E) but this was unaffected by corticosterone (Fig. 4E).Discussion
Increased glucocorticoid action specifically in adipose
(Masuzaki et al. 2001) or liver (Paterson et al. 2004) produces
distinct metabolic syndromes with hypertension. Increased
GR sensitivity is also associated with altered fat distribution,
hypertension and cardiometabolic disease (Buemann et al.
1997, Rosmond et al. 2000, Dobson et al. 2001, Ukkola et al.
2001a,b, van Rossum et al. 2003). We hypothesised that
altered tissue regeneration of active glucocorticoid and/or
peripheral tissue sensitivity to GCs might explain in part the
exaggerated fat accumulation, insulin resistance (Coll et al.
2005) and the hypertension observed in PomcK/K mice with
glucocorticoid replacement.
With fixed circulating glucocorticoid levels, 11b-HSD1
and GR expression levels are the key determinants of GC
action. PomcK/K mice had lower adipose but similar hepatic
levels of 11b-HSD1 mRNA levels to wild-type mice.
Corticosterone treatment dramatically and more markedly
increased 11b-HSD1 in the adipose tissue of PomcK/K mice.
This was accompanied by a marked increase in the expression
of the glucocorticoid-inducible (Fried et al. 1993) gene LPL,
which is consistent with the exaggerated accumulation of fat
in these mice. Intriguingly, these data suggest that, at least in
adipose tissue, 11b-HSD1 itself is a glucocorticoid target
gene. This finding is consistent with most (Hammami &
Siteri 1991, Jamieson et al. 1995, Voice et al. 1996, Bujalska
et al. 1999), but not all (Napolitano et al. 1998) previous
reports of glucocorticoid induction of 11b-HSD1 in a variety
of cell types. Although not specifically measured here,
increased adipose 11b-HSD1 activity is predicted to
selectively amplify intra-adipose glucocorticoid concen-
trations, particularly when circulating levels of substrate are
high. On the other hand, our data suggest that congenital
glucocorticoid deficiency has little impact upon hepatic 11b-
HSD1 levels in vivo and is not regulated by corticosterone. In
contrast, 11b-HSD1 mRNA levels are highly and positively
regulated by glucocorticoids in adipose tissue.
GR levels are another major determinant of cellular
glucocorticoid sensitivity (Vanderbilt et al. 1987, Geley et al.
1996). Small differences in GR mRNA levels can markedly
alter glucocorticoid responsiveness (Geley et al. 1996,
Reichardt et al. 2000). PomcK/K mice had elevated GR
mRNA levels in liver and retroperitoneal adipose tissue,
suggesting increased glucocorticoid sensitivity selectively in
these depots. Following corticosterone replacement in
PomcK/K mice, GR mRNA levels were restored to wild-
type levels in retroperitoneal adipose tissue but not in liver,
consistent with tissue- and time-specific differences in GRJournal of Endocrinology (2007) 194, 161–170
Figure 3 Dyslipidaemia and fatty liver in PomcK/K mice. (A) Plasma triglyceride levels in PomcK/K (K/K)
and wild-type (C/C) mice, either untreated or treated for 10 days with corticosterone (cort). (B) Oil Red O
staining of neutral lipid in liver sections of wild-type mice (C/C, left upper panel), CORT-treated wild-type
mice (C/C, left bottom panel), PomcK/K (K/K, right upper panel) and CORT-treated PomcK/K (K/K, right
bottom panel). Magnification is 40!; red, oil red O; blue, haematoxylin (nuclei). (C) Hepatic triglyceride
content in PomcK/K (K/K) and wild-type (C/C) mice, either untreated or treated for 10 days with
corticosterone (cort). (D) Plasma levels of non-esterified fatty acids (NEFA) in PomcK/K (K/K) and wild-type
(C/C) mice, either untreated or treated for 10 days with corticosterone (cort). Data are meansGS.E.M.; (nZ6
per group). Significance ***P!0.001.
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Sheppard et al. 1990, Holmes et al., 1995, 1997, Reichardt
et al. 2000).
Corticosterone had no additional effects on the hyper-
triglyceridaemia and fatty liver of the PomcK/K mice, and did
not affect plasma NEFAs, which were normal in PomcK/K
mice. The corticosterone-driven caloric excess in PomcK/K
mice may drive a further increase in the flux of triglycerides
from the liver, that, coupled with increased adipose uptake via
LPL, maintains the circulating and liver triglyceride levels
constant and is consistent with increased adipose tissue mass in
corticosterone-treated PomcK/K mice (Coll et al. 2005).
Adipose PEPCK is critical for glyceroneogenesis and is thus
a key regulator of the level of fatty acid re-esterification
(reviewed in Reshef et al. 2003). Unexpectedly, since
glucocorticoids reduce adipose PEPCK, glucocorticoid-Journal of Endocrinology (2007) 194, 161–170deficient PomcK/K mice had lower levels of PEPCK
mRNA in all adipose depots. This was further decreased by
corticosterone treatment. The lower level of PEPCK mRNA
in untreated PomcK/K mice may be due to their higher fed
blood glucose levels (Nechushtan et al. 1987, Opherk et al.
2004), thus reducing the need for glyceroneogenesis to
generate glycerol phosphate for fatty acid re-esterification.
PomcK/K mice have lower hepatic expression of PEPCK.
This may not be due to the lack of glucocorticoid signalling in
liver, as mice with a liver-specific knockout of GR have
normal levels of PEPCK in liver (Opherk et al. 2004), but may
be related to the higher circulating levels of insulin in
PomcK/K mice compared with wild-type (Coll et al. 2005).
Insulin dominantly and negatively suppresses hepatic PEPCK
in the fed state (Pilkis & Granner 1992). In corticosterone-
treated wild-type mice, the repressive effect of insulinwww.endocrinology-journals.org
Figure 4 Corticosterone treatment increases blood pressure in PomcK/K mice: effect of CORT treatment on
the Renin-angiotensin system. Effect of 10 days corticosterone treatment (cort) on (A) systolic blood pressure,
(B) renin concentration, (C) plasma angiotensinogen, (D) angiotensinogen (Agt) mRNA in adipose tissue (AT),
and (E) angiotensinogen (Agt) mRNA levels in liver in wild-type (C/C) and PomcK/K (K/K) mice. Epi,
epididymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are meansGS.E.M., and for transcript levels
are expressed relative to levels in untreated wild-type mice (100%); nZ5 per group. Significance *P!0.05,
**P!0.01 and ***P!0.001.
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these mice compared with untreated wild-type mice may
reflect the increase in insulin levels following corticosterone
(Coll et al. 2005). In contrast, hepatic PEPCK mRNA levels
doubled following corticosterone treatment in PomcK/K
mice, consistent with hepatic insulin resistance and marked
hyperinsulinaemia (Coll et al. 2005).
Blood pressure in PomcK/K mice is normal despite their
hypoadrenal state. This implies that secondary mechanisms
are invoked to maintain cardiovascular function when
circulating aldosterone and corticosterone concentrations
are chronically reduced (Coll et al. 2004). It seems likely
that the increased renin activity which we have observed in
PomcK/K mice is part of this adaptive process. However,
corticosterone replacement did not normalise renin activity
and selectively increased blood pressure in PomcK/K mice.
This was not attributed to a further activation of the
circulating RAS, since neither renin nor its substrate
angiotensinogen was increased. Indeed, the expression of
angiotensinogen mRNA in liver and adipose tissues did not
correlate with blood pressure. It seems likely that corticos-
terone augmented existing mechanisms that were already
sustaining vascular function. Apart from renin, these
secondary processes are likely to involve the hyper-
insulinaemic (Sowers 2004) state of PomcK/K mice (which
is exacerbated by corticosterone treatment; Coll et al. 2005),
the sympathetic nervous system (Rascher et al. 1979; which is
thought to explain glucocorticoid-induced hypertension in
normal mice) or structural adaptation of the vasculature
(Wallerath et al. 2004).
In summary, we show that increased adipose tissue-specific
sensitivity to glucocorticoids in PomcK/K mice may result in
part from exaggerated induction of 11b-HSD1 in adipose
tissue with corticosterone administration. Whilst acknowl-
edging that mRNA changes do not always translate to altered
protein (or enzyme activity) levels, these data nevertheless
suggest that 11b-HSD1 might be a more potent mediator of
intra-adipose GC action than the GR levels, whereas in liver,
higher GR levels contribute to the diabetogenic phenotype of
the PomcK/K mice.Acknowledgements
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Objectives: In ideopathic obesity, there is evidence that
enhanced cortisol regeneration within abdominal subcuta-
neous adipose tissue may contribute to adiposity and met-
abolic disease. Whether the cortisol regenerating enzyme,
11-hydroxysteroid dehydrogenase type 1 (11HSD1), or
glucocorticoid receptor (GR) levels are altered in other
adipose depots remains uncertain. Our objective was to
determine the association between 11HSD1 and GR
mRNA levels in four distinct adipose depots and measures
of obesity and the metabolic syndrome.
Research Methods and Procedures: Adipose tissue biop-
sies were collected from subcutaneous (abdominal, thigh,
gluteal) and intra-abdominal (omental) adipose depots from
21 women. 11HSD1 and GR mRNA levels were mea-
sured by real-time polymerase chain reaction. Body com-
position, fat distribution, fat cell size, and blood lipid,
glucose, and insulin levels were measured.
Results: 11HSD1 mRNA was highest in abdominal sub-
cutaneous (p  0.001) and omental (p  0.001) depots and
was positively correlated with BMI and visceral adiposity in
all depots. Omental 11HSD1 correlated with percent body
fat (R  0.462, p  0.05), fat cell size (R  0.72, p 
0.001), and plasma triglycerides (R  0.46, p  0.05).
Conversely, GR mRNA was highest in omental fat (p 
0.001). GR mRNA was negatively correlated with BMI in
the abdominal subcutaneous (R  0.589, p  0.05) and
omental depots (R  0.627, p  0.05). Omental GR
mRNA was inversely associated with visceral adiposity
(R  0.507, p  0.05), fat cell size (R  0.52, p 
0.01), and triglycerides (R  0.50, p  0.05).
Discussion: Obesity was associated with elevated
11HSD1 mRNA in all adipose compartments. GR
mRNA is reduced in the omental depot with obesity. The
novel correlation of 11HSD1 with omental fat cell size,
independent of obesity, suggests that intracellular cortisol
regeneration is a strong predictor of hypertrophy in the
omentum.
Key words: abdominal obesity, omental, adipose tissue,
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Introduction
Visceral obesity is associated with an increased risk for
type 2 diabetes, hyperlipidemia, and hypertension (the met-
abolic syndrome) (1,2). In contrast, comparable amounts of
fat stored preferentially in gluteal or femoral depots (lower
body obesity) showed lower risk of morbidity and mortality
from metabolic abnormalities (3). Exposure to high circu-
lating glucocorticoid (GC)1 levels, as found in Cushing’s
syndrome, causes a metabolic disease that resembles fea-
tures of idiopathic metabolic syndrome including pro-
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nounced visceral obesity (4). However, idiopathic obesity is
not associated with high circulating GC levels (4). Rather, it
seems that intracellular generation of active from inactive
GCs by the enzyme 11-hydroxysteroid dehydrogenase
type 1 (11HSD1) is aberrantly elevated in adipose tissue of
obese individuals (4). Thus, we and others have shown that
11HSD1 mRNA and activity are elevated in abdominal
subcutaneous adipose tissue from obese compared with
non-obese individuals (5–10) and in adipose depots in mo-
nogenic obesity in rodents (11,12). In vivo microdialysis
confirmed increased abdominal subcutaneous adipose re-
generation of cortisol from cortisone in human obesity (13).
Given the key association of intra-abdominal (visceral) ad-
ipose tissue in metabolic and cardiovascular risk, it has been
hypothesized that increased 11HSD1 in the visceral, rather
than subcutaneous, adipose depot causes the adverse meta-
bolic consequences of idiopathic obesity and the metabolic
syndrome (14). This hypothesis has been supported by the
observation that transgenic mice overexpressing 11HSD1
in adipose tissue develop visceral obesity and the phenotype
of the metabolic syndrome (12,15). Conversely, global
11HSD1 knockout mice are protected from the metabolic
consequences of dietary obesity, at least in part, through
adipose tissue insulin sensitization and fat redistribution
away from the visceral depot (16,17). However, Tomlinson
et al. (18) reported a negative association between omental
11HSD1 activity and BMI in primary omental human
adipocytes cultured in vitro, although there was no correla-
tion in whole adipose biopsies. A further study could not
detect increased portal vein cortisol (19) or increased
splanchnic cortisol production rates (20) in obesity, suggest-
ing that if cortisol generation is indeed elevated in visceral
fat, it is further metabolized or is not released at higher rates
from adipocytes. Together, these data have engendered
some confusion as to whether visceral and subcutaneous
11HSD1 is elevated in human obesity. Mechanistically,
GCs induce adipose tissue expansion by stimulating pre-
adipocyte differentiation (21) and lipoprotein lipase-medi-
ated triglyceride accumulation (22,23). A key factor in this
process is tissue levels of the intracellular glucocorticoid
receptor  (GR). In contrast to the plethora of studies
(5–10,14) of 11HSD1 in adipose tissue and metabolic
syndrome, curiously few studies have examined associa-
tions between GR and such parameters. Genetic studies
strongly support the role of the GC receptor in determining
body composition and fat distribution (24,25). Higher levels
of GR found in omental compared with subcutaneous fat
(26) would further be expected to have a more pronounced
effect on GC action in the omental depot. However, our
previous study showed no correlation between adipose tis-
sue GR mRNA in abdominal subcutaneous adipose tissue
and obesity (10), whereas Kannisto et al. (9) reported an
inverse correlation between subcutaneous adipose GR
mRNA and BMI. Here we hypothesized that high adipose
11HSD1, but not GR, mRNA levels predicts obesity in
visceral and subcutaneous fat depots in women.
Research Methods and Procedures
Subjects
Informed, written consent was obtained from 21 women
undergoing elective, laparoscopic tubal ligation surgery; the
study was approved by the Mayo Clinic Institutional Re-
view Board. Tubal ligation surgery was done routinely in
the follicular phase of the menstrual cycle to eliminate the
risk of pregnancy. Before surgery, body composition was
assessed by measuring weight, height, body fatness (% fat)
using DXA (DPX-IQ; Lunar Radiation, Madison, WI), and
abdominal fat distribution using a single sliced computer-
ized tomography scan at the L2–L3 level (27,28). Visceral
and subcutaneous adipose tissue areas were calculated as
previously described (28). Although 8 of 21 subjects were
taking oral contraceptives, there was no effect on our vari-
ables by Student’s t test, and the data were pooled.
Blood Assays. Fasting plasma triglycerides, glucose, and
insulin levels were assayed as previously described (29).
Homeostasis model of assessment insulin resistance index
(HOMA-IR) was calculated by the following equation: fast-
ing insulin (U/mL)  fasting glucose (mM)/22.5 (30).
Adipose Tissue Biopsies. Subcutaneous fat from abdom-
inal (n  13), thigh (n  16), and gluteal (n  18) regions
were collected just before surgery and omental (n  21)
adipose biopsies were obtained intraoperatively. The tissue
was washed to remove blood and snap frozen in liquid
nitrogen and stored at 80 °C. Biopsies were homogenized
in 1 to 2 mL Trizol (Gibco BRL, Paisley, United Kingdom).
RNA was extracted using RNAid binding matrix
(Anachem, Luton, UK) and eluted in diethylpyrocarbonate-
treated water, containing 10 mM dithiothreitoland 400
U/mL RNasin (Promega, Southampton, UK). Total RNA
was quantified using a spectrophotometer at A260.
RNA integrity was verified by agarose gel electrophore-
sis. Oligo dT-primed cDNA was synthesized from 0.5 g of
RNA samples using the Promega Reverse Transcription
System (Promega, Madison, WI). GR and 11HSD1
mRNA levels were quantified by real-time polymerase
chain reaction primer-probe sets using the ABI PRISM
7700/7900 Sequence Detection System (Applied Biosystems,




TAMRA-3 (probe); GR, 5-CATTGTCAAGAGGGAA-
GGAAACTC-3 (forward), 5-ATTTTCAACCACTTCAT-
GCATAGAA-3 (reverse), and 5-6-FAM-TTGTCAGT-
TGATAAAACCGCTGCCAGTTCT-TAMRA-3 (probe).
Levels of GR or 11HSD1 mRNA are reported relative to
human cyclophilin A RNA (Applied Biosystems, Cheshire,
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United Kingdom) as previously optimized (10) and are
expressed in arbitrary units. Standard curves for primer-
probe sets and real-time polymerase chain reaction analysis
were performed as previously described (10). Fat cell size
(mean diameter of mature adipocytes in micrometers) was
determined using the AdCount (Biomedical Imaging Re-
source, Rochester, MN) approach as previously described
(31).
Statistical Analysis
Repeated-measures ANOVA followed by Tukey post hoc
test were performed to determine differences in transcript
levels in paired adipose compartments. Pearson correlation
was performed to examine the relationships between anthro-
pometric and metabolic parameters with 11HSD1 or GR
mRNA levels in different fat depots according to a priori
hypotheses to minimize multiple interdependent variables.
Multiple linear regression was performed to test whether
relationships between fat cell sizes or triglycerides with
transcript levels are independent of obesity. Data were
tested for normality and were normalized by log transfor-
mation where appropriate.
Data are means  standard error unless otherwise stated.
Differences were considered significant at p  0.05. All
statistical analyses were performed using Sigma Stat 3.1
software (Systat Software Inc., San Jose, CA).
Results
Subject Characteristics
Volunteers were white women 35  1 years of age with
a mean BMI of 32.7  1.5 kg/m2 (Table 1), indicating an
obese group. Their median  interquartile range fasting
insulin was 15.6  19.6 U/mL, and HOMA-IR as 3.3 
4.6 (range, 0.42 to 47). Median fasting glucose and mean
triglyceride concentrations averaged 4.9  0.44 mM and
148  19 mg/dL, respectively (Table 1).
Comparison of 11HSD1 and GR mRNA Levels in
Multiple Fat Depots
11HSD1 mRNA levels were greater in subcutaneous
abdominal and omental adipose tissues than in other sub-
cutaneous tissues (gluteal, thigh; Figure 1A). 11HSD1
mRNA levels were positively correlated in the three subcu-
taneous depots: abdominal subcutaneous vs. thigh (R 
0.83, p  0.005) and abdominal vs. gluteal (R  0.86, p 
0.005). There were no associations between abdominal sub-
cutaneous and omental 11HSD1 mRNA levels. GR
mRNA expression levels were highest in omental and low-
est in thigh subcutaneous adipose tissue (Figure 1B) but
were not correlated between any compartments. No corre-
lation was found between 11HSD1 and GR mRNA lev-
els in any depot (data not shown).
Association of Obesity with Elevated 11HSD1 but
Reduced GR mRNA in Omental Fat
A strong positive association between BMI and omental
adipose 11HSD1 mRNA levels was observed (R  0.570;
Figure 2A; Table 2; p  0.01). Moreover, visceral fat tissue
[visceral adipose tissue (VAT)] area by computed tomog-
raphy was correlated with increased 11HSD1 mRNA lev-
els in the omentum (Figure 2B; Table 2). Omental
11HSD1 mRNA levels were consistently and positively
associated with general adiposity (as defined by percent of
body fat; R  0.462, p  0.05) and with subcutaneous/
peripheral adiposity (Table 2). In contrast, obesity was associ-
ated with decreased GR mRNA levels in the omental depot
(R  0.627, p  0.001; Figure 2D; Table 2). Visceral
adiposity (Figure 2E) was negatively correlated with omental
GR mRNA levels (VAT; R  0.507, p  0.05).
Association of Omental Fat Cell Hypertrophy with
Increased 11HSD1 but Reduced GR
Fat cells were smaller in the omental depot than in
subcutaneous adipose tissue (SAT) (omental, 84  4 m;
vs. abdominal subcutaneous, thigh, gluteal, 104  3, 109 
3, and 106  2 m, respectively; p  0.0001). Omental fat
cell size was positively correlated (R  0.72, p  0.001)
with 11HSD1 mRNA levels (Figure 2C; Table 2). In
contrast, GR transcript levels were negatively correlated
with omental fat cell size (Figure 2F; Table 2). To test for
independent effects, multiple regression analyses were per-
formed to understand the effects of obesity (BMI) and fat
cell size on 11HSD1 or GR mRNA. Omental fat cell size
Table 1. Anthropometric and metabolic characteris-
tics of study participants
Women (n  21)
Anthropometry
Age (yrs) 35.3  1.4 (20 to 44)
BMI (kg/m2) 32.7  1.5 (20 to 42)
Body fat (%) 46  2 (23 to 56)
VAT area (cm2) 96  16.3 (23 to 236)
SAT area (cm2) 326  35 (59 to 577)
VAT/SAT 0.28  0.03 (0.11 to 0.64)
Plasma biochemistry
Fasting glucose (mM) 4.9  0.44 (4.1 to 7.0)
Fasting insulin (U/mL) 16.5  3.5 (2.2 to 64.3)
Fasting triglyceride (mg/dL) 146.7  18.7 (38 to 278)
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
Data are presented as mean  standard error. For glucose, data are
presented as median  interquartile range. Range values in
parentheses.
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was strongly and independently correlated with 11HSD1
(standardized  coefficient, 1.2; p  0.05), whereas GR
was not associated with fat cell size independently of obe-
sity.
Association of Obesity with Increased 11HSD1 mRNA
Levels in Subcutaneous Depots but Reduced GR
mRNA in the Abdominal Subcutaneous Fat
Because reporting on glucocorticoid action has been
largely in the abdominal subcutaneous depot, we extended
our subcutaneous depots to gluteal and thigh to test whether
the expected relationships held in these distinct compart-
ments. Positive associations with BMI and 11HSD1
mRNA levels were detected in all subcutaneous adipose
compartments examined (e.g., abdominal subcutaneous ad-
ipose: R  0.584, p  0.05; Table 2). Thigh adipose
11HSD1 mRNA correlated positively with SAT, and this
relationship showed a consistent trend in the other depots
(Table 2). In contrast, abdominal subcutaneous GR mRNA
levels were inversely correlated with BMI (R  0.589,
p  0.05; Table 2). No significant associations were ob-
served between SAT and abdominal subcutaneous GR
mRNA levels (Figure 3B) or GR mRNA levels in any
other subcutaneous depots (Table 2).
Abdominal Subcutaneous Hypertrophy is Associated
with Reduced GR mRNA Levels
Although multiple regression analysis with small num-
bers of abdominal subcutaneous biopsies should be inter-
preted cautiously, our data nevertheless indicate the follow-
ing. Surprisingly, in subcutaneous abdominal adipose
tissue, 11HSD1 mRNA levels were not associated with fat
cell size (Figure 3C). In contrast, abdominal subcutaneous
GR transcript levels were negatively correlated with fat
cell size (Figure 3D). Multiple regression analysis con-
firmed that GR mRNA levels were independently and
negatively correlated with abdominal subcutaneous fat cell
size (standardized  coefficient, 0.014; p  0.05). Al-
though GR levels were negatively correlated with fat cell
size in the thigh, this relationship did not hold when tested
by multiple regression analysis.
Associations of Depot-specific Glucocorticoid Action
with Metabolic Parameters
Pearson correlation was used to examine interrelation-
ships between transcript levels and metabolic parameters
(Table 2). Higher omental and thigh 11HSD1 levels were
associated with increased triglycerides levels (omental: R 
0.46, p  0.05; thigh: R  0.57, p  0.01). This effect was
not independent of obesity as confirmed by multiple linear
regression analysis. There were no significant associations
between fasting glucose, insulin, or HOMA-IR and
11HSD1 transcript levels. In contrast, there was a negative
correlation between GR mRNA levels and plasma triglyc-
erides levels selectively in the omental compartment (R 
0.50, p  0.05). Moreover, there was a trend for inverse
associations between omental GR and fasting plasma in-
sulin levels (R  0.48, p  0.052).
Discussion
This study examined relationships between two major
determinants of tissue glucocorticoid action in multiple
adipose tissue depots in lean and obese women. The key
findings were 1) 11HSD1 mRNA is most highly expressed
in subcutaneous abdominal and omental tissues, whereas
GR mRNA is highest in omental adipose tissue; 2) within
individuals, there are positive associations between
11HSD1 mRNA levels in subcutaneous adipose depots but
not omental fat, whereas GR mRNA levels do not corre-
late between depots; 3) between individuals, 11HSD1
mRNA levels in all adipose depots, including omentum, are
Figure 1: 11HSD1 and GR mRNA levels in multiple adipose tissue compartments in women. (A) 11HSD1 mRNA levels were higher
in abdominal and omental compared with thigh and gluteal adipose tissues. (B) GR mRNA levels were higher in omental and lower in
thigh compared with the other adipose tissue compartments. Data are presented as mean  standard error.
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positively associated with BMI and local fat mass, whereas
for GR mRNA the main relationships were negative asso-
ciations in the omentum; 4) increased fat cell size strongly
associates with increased 11HSD1 but reduced GR in the
omentum.
Here we extend our (4,6,8,10) and others (5,7,9) previous
observations on abdominal subcutaneous adipose to show a
positive relationship between BMI and 11HSD1 mRNA
levels in all four adipose compartments examined. This
implies an up-regulation of glucocorticoid production in
multiple adipose tissue compartments, including the vis-
ceral fat depot. Increased visceral fat is a better predictor of
metabolic abnormalities compared with upper-body subcu-
taneous fat (1,2) and is independently correlated with in-
creased morbidity and mortality (32). In contrast, lower-
body obesity may even show a protective effect with respect
to metabolic abnormalities (33). In our cohort, omental
11HSD1 mRNA levels were also most strongly associated
with increased general adiposity (% body fat). Kannisto et
al. (9) previously reported a positive association between
percent body fat and 11HSD1 mRNA levels in subcuta-
neous in obese male and female monozygotic twins. In our
Figure 2: Correlation of 11HSD1 and GR transcript levels with anthropometric parameters and fat cell size in the omental adipose
compartment. Correlation of (A) BMI with 11HSD1, (B) VAT with 11-HSD1, (C) fat cell size with 11HSD1, (D) BMI with GR
mRNA levels, (E) VAT with GR mRNA levels, and (F) fat cell size with GR mRNA levels. Regression lines and R and p values are
indicated in each graph. NS, non-significant correlation.
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study, subcutaneous adipose expression of 11HSD1
mRNA did not correlate with percent body fat. Differences
between these studies may be caused by the distinct popu-
lations studied and/or our limited power to detect this in-
teraction because 11HSD1 did correlate with other mark-
ers of generalized obesity such as BMI. Although in this
study we did not measure 11HSD1 activity levels because
of limited sizes of biopsies, we expect, from previous stud-
ies (7,10), that activity and mRNA levels are correlated in
abdominal subcutaneous adipose tissue biopsies.
GR transcript levels were highest in omental (visceral)
fat, as previously reported in humans (26) and mice (12).
The major new finding is that in omental and abdominal
subcutaneous adipose, GR is inversely associated with
adiposity and fat cell size. A previous study also reported
lower GR mRNA levels in subcutaneous adipose tissue in
severely obese women (34). Moreover, omental GR
mRNA levels were negatively associated with plasma tri-
glyceride and, albeit as a trend, insulin levels. This finding
is perhaps counterintuitive because GR polymorphisms
causing increased glucocorticoid sensitivity lead to in-
creased visceral fat accumulation (25). Our data suggest that
reduction of GR levels to the degree we observe in obesity
does not sufficiently compensate for the hypertrophy caused
by increased ligand regeneration (i.e., 11HSD1). This no-
tion is supported by data from transgenic animal models.
Thus, fat-specific 11HSD1 overexpressing mice (12) have
increased visceral adiposity, and 11HSD1 null mice have
reduced visceral adiposity (16), despite unaltered GR levels.
In contrast in humans, to our knowledge, this is the first
study describing a consistent opposing change in 11HSD1
and GR mRNA in multiple adipose compartments with
obesity. However, because the two transcripts were not
correlated in any depot, consistent with previous observa-
tions in subcutaneous adipose tissue (9), it seems unlikely
that GR and 11HSD1 directly regulate each other. Nat-
urally, there are clearly limitations with association studies,
which do not test causality, and further direct study is
needed to elucidate possible mechanisms involved.
The volunteers who participated in our study had normal
glucose and triglyceride levels but impaired insulin sensi-
tivity. Increased plasma triglycerides were associated with
increased 11HSD1 in both thigh and omental regions but
with reduced GR mRNA levels selectively in the omental
compartment. Neither 11HSD1 nor GR mRNA levels
were associated with fasting glucose, which is consistent
with our previous report (7). However, there seemed to be a
Table 2. Pearson correlation (R) of 11HSD1 and GR mRNA levels in multiple adipose tissue depots with
body composition, metabolic parameters, and fat cell sizes








BMI 0.58* 0.53* 0.54* 0.57† 0.59* 0.24 0.20 0.63‡
Percent body fat 0.22 0.41 0.44 0.46* 0.50 0.24 0.01 0.41
VAT 0.55* 0.73‡ 0.71‡ 0.64‡ 0.30 0.05 0.32 0.51*
SAT 0.36 0.55† 0.40 0.63‡ 0.57 0.15 0.13 0.60‡
Log fasting glucose 0.20 0.29 0.32 0.18 0.14 0.41 0.04 0.27
Fasting insulin 0.1 0.09 0.26 0.33 0.38 0.12 0.01 0.41
Fasting triglycerides 0.21 0.57† 0.46 0.46* 0.44 0.01 0.2 0.50*
Log FCS abdominal 0.19 0.80†
FCS thigh 0.28 0.51*
FCS gluteal 0.40 0.03
FCS omental 0.72‡ 0.52†
11 HSD1, 11-hydroxysteroid dehydrogenase type 1; GR, glucocorticoid receptor ; VAT, visceral adipose tissue; SAT, subcutaneous
adipose tissue; FSC, fat cell size. Percent body fat was measured using DXA. VAT and SAT were measured by computed tomography scan.
FCS was determined by measuring the mean adipocyte diameter. Plasma glucose values, abdominal FCS, and 11HSD1 mRNA levels in
thigh and gluteal regions and GR mRNA levels in thigh showed inhomogeneity of variance and were log-transformed before analysis.
* p  0.05.
† p  0.01.
‡ p  0.001.
Glucocorticoid Action in Fat Depots, Michailidou et al.
1160 OBESITY Vol. 15 No. 5 May 2007
trend for a negative association of omental and thigh GR
mRNA with fasting insulin levels that would be interesting
to confirm in larger cohorts.
Visceral fat adipocytes are more resistant to insulin’s
anti-lipolytic effects compared with subcutaneous adipo-
cytes (35). Transgenic mice overexpressing 11HSD1 in fat
develop central obesity attributed to adipocyte hypertrophy,
particularly in the mesenteric depot (12). To our knowledge,
this is the first study that addressed the relationship of
11HSD1 or GR mRNA levels with regional fat cell size.
Consistent with previous studies (36–38), we found larger
adipocytes in the abdominal subcutaneous compared with
omental depot, indicating higher fat storage in this depot in
women. We showed a strong positive correlation between
11HSD1 and adipocyte size in the omental depot, inde-
pendent of obesity. Despite the negative association of GR
mRNA with omental fat cell size, this was not independent
of obesity. Although 11HSD1 was equally high in the
abdominal subcutaneous and omental depot, we did not find
an association between 11HSD1 mRNA levels and ab-
dominal fat cell size, despite the strong positive correlation
with BMI. This may seem counterintuitive. The reasons for
this might be our limited power to detect a possible corre-
lation because we had fewer abdominal subcutaneous com-
pared with omental depot biopsies. Alternatively, 11HSD1
is not a strong predictor of subcutaneous hypertrophy in our
cohort. This is supported by the lack of correlation between
11HSD1 and fat cell size in the thigh and gluteal depots.
In contrast to findings in the omental depot, GR mRNA
was negatively associated with fat cell size in the abdominal
subcutaneous depot, independent of obesity. It would seem
that obesity is associated with a down-regulation of GR
that is expected to limit the hypertrophic effects of GCs in
adipose tissue (21–23). However, our data suggest that this
GR down-regulation cannot entirely counteract increased
ligand levels, particularly in the omental depot. It will be
important to determine whether and how altered GR levels
can indeed reach a functionally limiting state with respect to
adipose hypertrophy in obesity.
In conclusion, 11HSD1 mRNA is a strong predictor of
omental fat hypertrophy, whereas GR mRNA is negatively
associated with obesity.
Figure 3: Correlation of 11HSD1 and GR transcript levels with peripheral adiposity and fat cell size in abdominal subcutaneous
compartment. Correlation of (A) SAT with 11HSD1 mRNA levels, (B) SAT with GR mRNA levels, (C) fat cell size (FCS) with
11HSD1 mRNA levels, and (D) FCS with GR mRNA levels. Regression lines and R and p values are indicated in each graph. NS,
non-significant correlation.
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